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ABSTRACT 
Tetrahydroxanthones are a large class of natural products that contain a partially 
reduced xanthone moiety. These compounds exist in both monomeric and dimeric forms 
in nature. A concise retro-biomimetic synthetic approach to monomeric 
tetrahydroxanthone natural products has been developed. The key transformation 
involves vinylogous addition of siloxyfurans to benzopyryliums to access chromone 
lactone precursors which is followed by late-stage Dieckmann cyclization to the 
tetrahydroxanthone core. Application of this methodology led to efficient syntheses of 
blennolides B, C, and its stereoisomer epi-blennolide C.  
Synthetic efforts towards dimeric tetrahydroxanthones, including 2,2’-biaryl 
dimer secalonic acid D, have been pursued as well. We developed an efficient kinetic 
resolution using homobenzotetramisole (HBTM) catalysis to obtain enantiopure 
tetrahydroxanthones. The development of a mild, copper-mediated dimerization of 
stannyl tetrahydroxanthones also allowed access to enantiopure 2,2’-linked dimeric 
tetrahydroxanthones including secalonic acids A and D.  
 vii
After successful syntheses of secalonic acids A and D, we also applied the 
methodologies developed towards a synthesis of the axially chiral dimer rugulotrosin A. 
An enantiopure monomer was prepared in gram-scale by applying our previously 
developed methodology. The atropselective synthesis of rugulotrosin A was achieved via 
a one-pot Sukuzi dimerization with chiral palladium precatalyst. A rationale for point-to-
axial chirality transfer observed in the key dimerization step has been developed. This 
key transformation led to the successful 7-step syntheses of rugulotrosin A, its 
enantiomer, and the atropisomer. 
Finally, we further exploited the kinetic resolution using homobenzotetramisole 
catalysts which successfully led to a unified strategy for syntheses of both the 2,4’-linked 
and 4’,4’-linked secalonic acid derivatives.  The isomerization properties of 2,2’-linked, 
2,4’-linked, and 4,4’-linked secalonic acids was also studied in an effort to understand the 
“shapeshifting” properties of the dimeric tetrahydroxanthone family.   
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Chapter 1 
 
Tetrahydroxanthone Natural Products and  
Select Previous Synthetic Studies 
 
1.1 Introduction 
 The diverse chemical structure and unique bioactivities of fungal secondary 
metabolites 1  have drawn widespread attentions from scientific community, and have 
encouraged studies regarding isolation, chemical synthesis, and biological evaluation of 
natural products and derivatives. Among these exciting discoveries, tetrahydroxanthone 
natural products, a class of compounds which belong to the mycotoxins, have shown 
interesting biological activities and intriguing structural frameworks. In this introductory 
chapter, the fascinating chemical structures, biological activities, and studies toward the 
syntheses of tetrahydroxanthone natural products will be described. 
 
1.2 Structure Identification and Biological Activities of 
Tetrahydroxanthone Natural Products 
1.2.1 General Structure of the Tetrahydroxanthone Natural Products 
Xanthones or 9H-xanthen-9-ones comprise an important class of oxygenated, 
bioactive heterocycles with diverse pharmacological activities. 2  Xanthones are often 
isolated as fully aromatized molecules or can be partially aromatized as exemplified by 
2 
tetrahydroxanthones (Figure 1.1). Tetrahydroxanthones are a class of mycotoxins 3 
bearing both monomeric and dimeric frameworks. In 2008, the monomeric 
tetrahydroxanthone natural products blennolides A (1) and B (2) (Figure 1.2) were 
isolated from Blennoria sp.4  Blennolide A (1) has an anti configuration between the 
methyl ester and the adjacent secondary alcohol, while blennolide B (2) has a syn 
configuration between these two functional groups. Compounds 1 and 2 have an 
additional methyl group that is anti to the methyl ester in the C-ring, while blennolide C 
(3) lacks this additional alkyl group. The relative stereochemistry of blennolide A (1) was 
established by X-ray single crystallography, and the absolute stereochemistry was 
determined by comparing experimentally measured CD spectra with those calculated by 
the TDDFT (Time-dependent density functional theory) method.5 The stereochemistry of 
blennolide B (2) was assigned based on key NOE’s between H-5 and H-7a (cf. Figure 
1.2). The corresponding dimeric tetrahydroxanthones of blennolide A and B, secalonic 
acids B (4) and D (5), were first isolated and characterized in the 1960s.6 They were 
initially assigned as 4,4’-linked dimers, but this assignment was later corrected to be a 
Figure 1.1 Xanthone and Tetrahydroxanthone 
 
 
3 
2,2’-linkage by chemical degradation,7 NMR,8 and X-ray crystallographic studies.9 From 
the X-ray structure of secalonic acid D (5) (Figure 1.3), the 2,2’-linkage was 
ambiguously confirmed and the dihedral angle between the two aryl was about 30°. The 
dihydro-2H-xanthone framework is also found in blennolide C (3) and other related 
natural products. In addition, dimeric forms of epi-blennolide C are found in nature: 
rugulotrosin A (6)10 has a 2,2’ chiral biaryl linkage and the congener rugulotrosin B (7) 
has a 2,4’ linkage. The tetrahydroxanthone core may be further rearranged into a 
chromanone structure as found in paecilin B (8).11 Dimeric chromone lactone natural 
products including gonytolide A (9) have also been isolated and characterized.12 The 
absolute stereochemistry and axially chirality were verified by X-ray crystal structure 
analysis. Besides numerous isolated homodimers, heterodimers also exists, such as the 
Figure 1.2 Tetrahydroxanthones and Related Natural Products 
 
4 
tetrahydroxanthone/chromone lactone 4,4’-linked heterodimer such as gonytolide D 
(10).13 
 
1.2.2 Biological Activities of Tetrahydroxanthone Natural Products  
      Blennolide A (1), B (2) and secalonic acid B (4) were tested and found to exhibit 
antifungal and anti-algal properties.3 Secalonic acids have shown diverse biological 
properties. These compounds were isolated from Penicillium species that exist on freshly 
harvested corn and wheat.14 Secalonic acid B exhibited antimicrobial activity against both 
gram-positive and gram-negative bacteria.3 Additionally, secalonic acid B (4) was shown 
to have antitumor activity and its diastereomer secalonic acid D (5) shows potent 
cytotoxicity to HL60/K562 cells by down-regulation of the oncogenic transcription factor 
c-Myc.15 Compound 5 has been reported to inhibit DNA topoisomerase I (IC50 = 0.16 µM) 
and to have strong cytotoxicity to KB cells with IC50 < 1 µg/mL. Secalonic acid D (5) 
was found to be an inhibitor of cyclic AMP-dependent protein kinase (cAK) 16  and 
calmodulin17 which both are Ca2+-dependent enzymes. Moreover, secalonic acids D (5) 
Figure 1.3 X-ray Structure of Secalonic acid D 
 
 
5 
and B (4), have been shown to exhibit antibacterial, cytostatic, and anti-HIV properties.18 
The enantiomer of 5, secalonic acid A (not shown, ent-5), has antitumor properties and 
has also been shown to reduce colchicine toxicity in rat cortical neurons.19 
        Rugulotrosins A and B both display significant antibacterial activity.8 Gonytolide A 
(9) showed promoting activites on Drosphila innate immune response. The compound 
also increased TNF-α-stimulated production of IL-8 in human umbilical vein endothelial 
cells.10 However, the monomer of gonytolide A and gonytolide D (10) lacked this 
bioactivity, highlighting the importance of the biaryl linkage of the two chromanone 
moieties.11 
 
1.3 Biosynthesis of the Tetrahydroxanthone Natural Products 
       Tetrahydroxanthone natural products share the same polyketide biosynthetic pathway 
of related xanthone and phenolic natural products as was proposed in 1961.20 In 1978, the 
Vining group further verified the polyketide biosynthesis of secalonic acid A (ent-5), the 
Scheme 1.1 Biosynthesis of Secalonic Acid A 
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enantiomer of secalonic acid D (5), by 13C-labeled sodium acetate feeding 
experiments. 21 , 22  The investigators proposed that the octaketide 11 is precursor to 
anthraquinone 12, which could undergo further enzymatic cleavage/oxidation to 
benzophenone 13 (Scheme 1.1). A subsequent oxa-Michael addition, reduction, and 
additional hydroxylation would give rise to tetrahydroxanthone product ent-2. 
Biosynthetic details of the key dimerization step for the synthesis of secalonic acid A 
(ent-5) remain undetermined.    
     
       The biosynthetic pathway of xanthones described by König and co-workers23 showed 
that the anthraquinone emorin 14 could yield two different benzophenone intermediates 
13 (pathway a) and 15 (pathway b) via an asymmetric oxidative cleavage (Scheme 1.2). 
The intermediate 13 would convert to tetrahydroxanthone, where the methyl group is on 
the C-ring (e.g. blennolide A 1). In a similar manner, benzophenone 15 could generate 
tetrahydroxanthone with the methyl group on the A-ring (e.g. blennolide C 3). 
 
 
Scheme 1.2 Biosyntheses of Diverse Tetrahydroxanthones 
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1. 4 Rearrangement of Tetrahydroxanthone Natural Products 
       There have been more than 100 tetrahydroxanthone natural products isolated thus far, 
and this number continues to grow. The main reason for the chemical diversity is that the 
family contains both chromone lactones and tetrahydroxanthones (diasteromers, 
enantiomers) as monomeric units.  Moreover, for the dimeric tetrahydroxanthones, the 
biaryl linkage can also vary (2,2’, 2,4’ and 4,4’). Intriguingly, this biaryl linkage in 
tetrahydroxanthone dimers can interconvert under certain conditions. For example, 2,2’-
linked secalonic acids were found to covert to 2,4’- and 4,4’- linked structures in polar 
solvents (Figure 1.4).24 The 2,2’-linked secalonic acid A (ent-5) was found to convert to 
Figure 1.4 Equilibrium between 2,2’, 2,4’ and 4,4’ Secalonic acid A 
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a mixture of 2,2’-linked ent-5, 2,4’-linked 16, and 4,4’-linked compounds 17 when 
heated to 40 °C in pyridine for 4 days. In a similar manner, the 2,4’-linked dimer 
secalonic acid A or the 4,4’-linked compound secalonic acid could also be converted to 
the same mixture under basic conditions. 
 
  Another interesting class of tetrahydroxanthones known as parnafugins, inhibitors of 
the enzyme polyadenosine polymerase (PAP), were isolated by investigators of Merck.25 
Parnafugins were found to consist of four isomers: A1 (18), A2 (19), B1 (20), and B2 (21) 
in a 4:1:5:1 ratio in DMSO at room temperature, respectively. Even when one isomer was 
separated in pure form, it was converted to the mixture with the same ratio in 10-20 hours 
at room temperature (Scheme 1.3). The rationale of the equilibrium could be attributed to 
Scheme 1.3 Equilibrium between the Parnafugins 
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the retro-oxa-Michael/oxa-Michael reaction of the enol moiety (Scheme 1.3). 
Parnafungin A1 (18) could lead to the open acetophenone 22 through retro-Michael 
reaction. The syn-configuration between the methyl ester and the alcohol found in 
parnafungin A1 (18) and the anti-configuration found in parnafungin A2 (19) would be 
generated by the oxa-Michael reaction of the 3-hydroxyl. Additionally, 22 could covert to 
23 by rotation and was further cyclized to parafungins B1 (20) and B2 (21). Interestingly, 
the authors determined that the linear, syn isomer parnafungin A1 (18) binds 
preferentially to PAP in comparison to other isomers through the application of affinity-
selection/mass spectrometry (AS-MS).26 
 In addition to the equilibrium of diastereomers and linkage isomers, 
tetrahydroxanthones can also rearrange to the corresponding chromone-lactone 
molecules. For example, xanthoquinodin A1 (24) is a tetrahydroxanthone/anthraquinone 
Scheme 1.4 Retro-Dieckmann Reaction for Xanthoquinodin A1 
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heterodimer.27,28 Upon thermolysis of 24 in methanol, different diastereomers and linkage 
isomers attributed to the retro-Michael/Michael reaction were obtained. Additionally, the 
chromone lactone xanthoquinodin A3 (27) was also isolated from this reaction (Scheme 
1.4). The authors proposed that the enol moiety could tautomerize to diketone structure 
25. Subsequently the secondary alcohol could attack the ketone and form the O-bridged 
lactone 26. After a retro-Dieckmann reaction, chromone lactone 27 has been generated 
from the tetrahydroxanthone core. It is important to note that 27 cannot rearrange to 
tetrahydroxanthone 24 under the same thermal conditions. 
 
1.5 Previous Synthetic Approaches to Tetrahydroxanthones and Related 
Natural Products 
      Although ergochrysin was first isolated in 1912 by Freeborn, 29  the structure of 
secalonic acids and ergochrysin were correctly determined in the 1970s. Since that time, 
the promising biological data quickly drew attention from scientific community. The first 
synthesis effort was reported in 1973 by Franck and coworkers,30 who also isolated the 
secalonic acids/ergochromes. However, there were no reports of the syntheses of 
tetrahydroxanthones for more than two decades. In 1997, a model study for the synthesis 
of tetrahydroxanthones was established. 31  This triggered additional synthetic efforts 
toward this family of natural products. In the following sections, we will highlight a 
number of synthetic efforts toward and total syntheses of tetrahydroxanthone and related 
structures which will be categorized based on the synthetic methodology and strategy 
employed. 
11 
1.5.1 Biomimetic Approach to Tetrahydroxanthones 
     In 1973, Franck and coworkers reported the first synthesis of the core of 
tetrahydoxanthone structure des-carboxyl hemisecalonic acid 31.30 They synthesized the 
advanced benzophenone intermediate 28 (Scheme 1.5), which was treated with FeCl3 to 
generate para-quinone 29.  Addition of Na2CO3 triggered an oxa-Michael reaction. The 
ketone of the dearomatized xanthone 30 was then reduced with NaBH4 to obtain 31 with 
syn stereochemistry between the methyl and hydroxyl. Finally, Pd/C-catalyzed 
hydrogenation led to the tetrahydroxanthone core 31 with the same relative 
stereochemistry as found in blennolide B (2). 
 
1.5.2 Domino Oxa-Michael Addition/Aldol Approach to 
Tetrahydroxanthones 
      In 2004, Bräse and colleagues demonstrated that salicylic aldehyde and 2-
cyclohexen-1-one under basic conditions could rapidly generate the tetrahydroxanthone 
core. 32  The mechanism was regarded as a domino oxa-Michael addition/aldol 
Scheme 1.5 Franck’s Synthesis of Tetrahydroxanthone 
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condensation. Using this methodology, the Bräse group reported the first total synthesis 
of tetrahydroxanthone natural product diversonol (32), in 1996.33  The synthesis began 
with the key domino oxa-Michael addition/aldol condensation between 33 and 34 
(Scheme 1.6). After sonication for 7 days, tricyclic adduct 35 was obtained in 61 % yield. 
Next, the protected derivative 36 was treated with tetrabutylammonium tribromide to 
introduce the benzylic alcohol 37. Tricyclic bromide 37 underwent elimination and 
further oxidation of benzylic position to afford dihydroxanthone 38. Base on Gabbutt’s 
model study,29 the sequential key methyl conjugate addition worked smoothly to form 
single diastereomer 39 in 52 % yield. After removal of remaining aryl bromide, 40 was 
treated with magnesium monoperoxophthalate to achieve diastereoselective 
hydroxylation at C8a. Diversonol (32) was abtained after deprotection of 41 and 
diastereoselective reduction of the unconjugated carbonyl function.  
     Using the same intermediate 38, Bräse and coworkers performed conjugate addition of 
lithiated trimethylorthomethanetrithioate to access addition product 43 in 20 % yield 
(Scheme 1.6).34 After dehalogenation and hydrolysis to methyl ester 45, blennolide C (5) 
was obtained in 23 % yield after BBr3 deprotection. Using the domino oxa-Michael 
addition/aldol condensation strategy, the Bräse group constructed other 
tetrahydroxanthones and related analogues.35,36,37 
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Scheme 1.6 Bräse’s Total Syntheses of Diversonol and Blennolide C 
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1.5.3 Oxa-Michael Addition Approach to Tetrahydroxanthones 
  In 2008, Nicolaou and Li reported a unified strategy to construct tetrahydroxanthones 
using a late-stage oxa-Michael reaction.38 Using this route, they synthesized blennolide C 
(3) and diversonol (32). They also finished the syntheses and structural revision of α- and 
β- diversonolic esters. The synthetic sequence involves base-mediated coupling between 
vinyl bromide 46 and aldehyde 47 which was followed by oxidation to generate 
acetophenone 48 (Scheme 1.7). The resulting substrate was treated with HF·py and then 
Pd(0)/tributyltin hydride to provide intermediate 49 which underwent subsequent in situ 
oxa-Michael cyclization to epi-blennolide C (50) and blennolide C (3) in 2:1 dr. Both 
structures were verified by X-ray crystal analysis. 
Scheme 1.7 Nicolaou’s Total Syntheses of Blennolide C/Diversonol 
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    In order to access diversonol (32), the methyl-substituted intermediate 51 was 
prepared in a similar manner. Tetrahydroxanthone 52 was obtained after deprotection. 
Following the procedure developed by Bräse and coworkers, diversonol (32) was 
synthesized after hydroxylation and selective reduction. 
 
1.5.4 Dieckmann Condensation Approach to Tetrahydroxanthones 
     In 2008, the Tietze group developed an asymmetric synthesis of the 
tetrahydroxanthone core of 4-dehydroxydiversonol utilizing intramolecular Dieckmann 
condensation.39 Using palladium-catalyzed domino reactions, the investigators prepared 
the enantiorich chromanone 53 which was treated with TiCl4 and base to generate 
tetrahydroxanthone 54 (Scheme 1.8). By applying this strategy, (-)-diversonol (32) was 
successfully synthesized in 2013.40 
    Recently, Tietze and coworks also successfully prepared (-)-blennolide A through a Ti-
mediated Dieckmann reaction.41 They synthesized an E/Z mixture of the alkene 55 in six 
steps from resorcin (Scheme 1.9). In the presence of (R,R)-Bn-BOXAX ligand and 
Pd(TFA)2, the cyclized product 56 was obtained in 82 % yield and in 86 % ee. After 
asymmetric dihydroxylation and separation of diastereomers, the secondary alcohol of 
anti-57 was TBS-protected to afford 58. Next, a sequence involving oxidation, 
Scheme 1.8 Tietze’s Dieckmann Condensation 
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olefination, and diastereoselective cuprate conjugate addition transformed 58 to 
intermediate 60. The key substrate 62 was obtained after debenzylation and three 
sequential oxidations. The titanium enolate chemistry worked smoothly on substrate 62 
which led to tetrahydroxanthone 63. The final natural product blennolide A (-)-1 was 
accomplished after triethylamine trihydrofluoride desilylation and BBr3 demethylation. 
 
 
Scheme 1.9 Tietze’s Synthesis of blennolide A 
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  In 2011, the Bräse group also reported the asymmetric total synthesis of diversonol 
(32) and lachnone C.42 Using Jorgensen’s catalyst 65, salicylic aldehyde 33 and prenal 64 
were condensed to access tricyclic lactol 66 in 67 % yield (83 % ee) (Scheme 1.10). 
After elimination and dihydroxylation, the desired diastereomer 64 was treated with a 
Scheme 1.10 Bräse’s Asymmetric Synthesis of Diversonol 
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Wittig reagent to yield alkene 70. Chromene lactone intermediate 74 was synthesized 
from 70 in four steps. Chromene lactone was further reduced by hydrogenation, and 
oxidized to chromone lactone 75 in two steps. Using the cyclization methodology 
developed by our lab (vide infra), tetrahydroxanthone 77 was prepared by treatment of 75 
with NaOMe/THF. Finally, 77 was transformed to diversonol (32) after deprotection, 
hydroxylation, and reduction. 
 
1.5.5 Other Synthetic Studies for Related Tetrahydroxanthones 
  Nidulalin A (83) is dihydroxanthone natural product which lacks an enol at the C8 
position in comparison to blennolide C (3).43 The total synthesis of nidulalin A (83) was 
accomplished in 2009 by Hosokawa and coworkers.44 Benzophenone 78 was treated with 
Pb(OAc)4 to generate the dearomatized xanthone 79 in 39 % yield (Scheme 1.11). After 
two sequential reductions, 81 was further reduced by LiAlH4 and silyl-protected to afford 
82 with an anti-configuration. The oxidation and deprotection was achieved in a one-pot 
reaction by treatment of SeO2. 
Scheme 1.11 Total Synthesis of Nidulalin A 
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           Recently, the Sudhakar group reported an enantioselective synthesis of 
chromone lactone natural products. 45  They performed a Ti-mediate enolate coupling 
between acylated orcinol 84 and butenolide ketone 85/85a (Scheme 1.12). The resulting 
mixture of 86 and 87 was treated with SOCl2 and pyridine and heated at 110 oC to 
provide the thermodynamic product, chromone lactone 88 known as gonytolide C, in 
18:1 dr. The authors proposed that the preference for diasteromer 88 was due to retro-
oxa-Michael/oxa-Michael reaction through the intermediate 90. Investigator further 
considered that gonytolide C (88) was the thermodynamic product, which led to a higher 
dr at higher reaction temperatures. 
 
 
 
Scheme 1.12 Total Synthesis of (+)-Gonytolides C 
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1.6 Conclusion 
    In summary, general structural features and selective biological activities of 
tetrahydroxanthone natural products have been described in this chapter. A number of 
synthetic efforts towards tetrahydroxanthone and related compounds have been reported, 
and their key transformations have been discussed. Tetrahydroxanthones contain diverse, 
interesting, and challenging structural motifs and intriguing biological properties. In this 
thesis, I will describe our efforts toward a rapid and efficient route to construct chromone 
lactone and tetrahydroxanthone structures. Our successful methodology led to the 
synthesis of monomeric tetrahydroxanthones (Chapter 2), 2,2’-linked dimeric 
tetrahydroxanthones (Chapter 3), axially chiral dimeric tetrahydroxanthones (Chapter 4), 
and dimeric tetrahydroxanthones bearing diverse linkages (Chapter 5). 
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Chapter 2 
 
Vinylogous Addition of Siloxyfurans to Benzopyryliums: A Concise 
Approach to the Tetrahydroxanthone Natural Products 
 
2.1 Introduction to Monomeric Tetrahydroxanthones and Related 
Natural Products 
       Most tetrahydroxanthone natural products have been isolated in dimeric form. 
However, numerous monomeric tetrahydroxanthone natural products have also been 
isolated. For example, blennolide A-C4 (1-3) are tetrahydroxanthones containing a methyl 
ester group on the C10a position (Figure 2.1). This group also could be a methyl as 
Figure 2.1 Monomeric Tetrahydroxanthones and Related Natural Products 
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found in the natural product leptosphaerin G (91),46 a compound which has the same 
relative stereochemistry in comparison to the congener blennolide B (2). Besides the 
tetrahydroxanthone core, chromone lactone structures are also widely observed in nature 
and include paecilin B (8), gonytolide C (88), and lachnone C (92).47  Moreover, enolized 
oxepine lactones have also appeared in natural products such as conioxepinol D (93)48 
and brocaenol A (94),49,50 compounds which are structurally related to blennolides C (3) 
and A (1), respectively. 
 
2.2 Retrosynthetic Analysis for Tetrahydroxanthone Natural Products 
Biosynthetically, the blennolides appear to be derived from a sequence involving 
oxidation of benzophenone ester 95, oxa-Michael addition, and reduction to dihydro-2H-
xanthenone 96 (Figure 2.2, (a)).21,22  The chromone lactone structure 97 found in paecilin 
Figure 2.2 Biosynthetic Pathway vs. “Retrobiomimetic” Synthesis 
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B (8) appears to be derived from hydrolysis/lactonization of the tetrahydroxanthone 
framework 96. We envisioned that precursor 99 may be obtained by vinylogous addition 
of siloxyfurans 51  to activated benzopyrylium salts 98. 52  Conjugate reduction of 
butenolide 99 should afford chromone lactone 97. The last step in the sequence entails a 
“retrobiomimetic” transformation53 in which tetrahydroxanthones 96 may be produced by 
Dieckmann cyclization of chromone lactones 97.     
 
2.3 Synthetic Studies towards Vinylogous Addition of Siloxyfurans 
Based on our retrosynthetic plan, we initiated our study by treating the readily 
available 5-hydroxychromone 100 54  or the methyl-protected chromone 101 with a 
number of Lewis acids in an effort to promote vinylogous addition of 2-trimethylsilyloxy 
furan (Scheme 2.1). Unfortunately, in initial experiments we did not observe substantial 
adduct formation. For example, use of Sc(OTf)3 as  catalyst provided only ~3% 
conversion to the desired vinylogous addition product. In addition to metal Lewis acid 
promoters, photo-excitation and strong Brønsted acids were also investigated for this 
reaction. The desired vinylogous addition products were not observed or were observed 
in trace amounts. 
Scheme 2.1 Attempted Lewis Acid-Promoted Vinylogous Addition 
 
 
26 
In light of the high reactivity of 4-siloxy-1-benzopyrylium salts towards carbon 
nucleophiles,52 we focused our efforts on silyl triflate activation of chromone 100/101. In 
1991, Akiba and coworkers demonstrated that the simple chromone 102 could efficiently 
be transformed to benzopyrylium species 103 by treatment with TMSOTf (Scheme 2.2 
(a)). The generated benzopyryliums could be attacked by nucleophiles, such as silyl enol 
ethers, to yield addition products 104 or further deprotected products 105. For example, 
benzopyrylium 106 was reacted with silyl ketene acetal 107 in dichloromethane at room 
temperature to afford the addition product 108 in 96 % yield. However, after searching 
for literature examples regarding chromone addition, we found that if groups other than a 
Scheme 2.2 Single Silyl Triflate Activation 
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hydrogen are present at the C2 position, the addition became less efficient. 
 In our experiments, we treated the methyl protected chromone 101 with TBSOTf at 
40 °C which led to production of a yellow solution (Scheme 2.2 (b)). We believed that 
benzopyrylium 109 was formed, which has further confirmed by 1H NMR analysis. We 
then added trimethylsiloxyfuran to the benzopyrylium 109 solution at various 
temperatures. Interestingly, we found that at -78 °C, the dr of butenolide products 110 
and 111 was 3:1, but was 1:3 at -30 oC, and 1:6  at 0 oC.  
After the success in addition of trimethylsiloxyfuran to the methyl-protected 
chromone 101, we anticipated that this transformation could be achieved using the 
Scheme 2.3 Dialkylsilyl Ditriflate Promoted Vinylogous Addition 
 
 
Figure 2.3 Xray Structure of 113 
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unprotected chromone 100. In particular, we reasoned that dialkylsilyl ditriflate reagents, 
generally used to protect diols as silylenes, 55  may directly afford activated 
siloxybenzopyrylium species.  In the event, treatment of chromone ester 100 with 
diisopropyl silyl ditriflate in the presence of 2,6-lutidine led to clean formation of 
Scheme 2.4 Mechanism Study of Benzopyrylium 112 
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benzopyrylium 112 (Scheme 2.3). Treatment of 112 with 2-trimethylsiloxy furan at -78 
°C cleanly led to formation of chromone butenolide 113 (dr = 15:1) after desilylation 
with Et3N·3HF. Crystallization of 113 facilitated X-ray crystal structure analysis of the 
major diastereomer (Figure 2.3). Finally, conjugate reduction of butenolide 113 with 
nickel boride56 provided chromone lactone 114. 
The intermediates for the benzopyrylium chemistry were monitored using 1H NMR 
analysis. The 3-H for chromone 100 has a 7.02 ppm shift in CD2Cl2 (Scheme 2.4, (1)). 
After forming benzopyrylium 112, this proton was shifted downfield to 7.97 ppm due to 
electron deficiency (Scheme 2.4, (2)). This peak was subsequently shifted upfield to 4.95 
ppm, the typical alkene proton region, after trimethylsiloxyfuran was added (Scheme 2.4, 
(3)). 
      We also evaluated the effect of time and temperature for vinylogous additions 
(Table 2.1). Increased reaction temperatures led to reduced diastereoselectivities in 
additions to 112 and diastereomer 116 was major diastereomer at higher temperature, 
similar to to protected chromone 101 (cf. entries 1 and 2). Conducting the reaction at 0 °C 
for 0.5 h (entry 3) led to a 3:1 mixture of 113:116 which supports epimerization at higher 
temperatures and longer reaction times (vide infra). Similar results were obtained for 
vinylogous additions to chromone 117 leading to adducts 118 and 119 (entries 5 and 6). 
Addition of 4-methyl-2-trimethylsiloxyfuran to 100 (entry 7) led to reduced 
diastereoselectivities (2:1) in comparison to 2-trimethylsiloxyfuran (dr = 15:1, cf. 
Scheme 2.3).  
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    Based on our experimental data, we propose the mechanism for vinylogous addition 
shown in Scheme 2.5. Initial vinylogous addition of 2-trimethylsiloxyfuran to 100 at -78 
°C leads to the kinetic adduct 122 which may lose TMSOTf to afford silylene 115, a 
precursor to chromone 113. At higher temperature, thermodynamic equilibration of 122 
to 124 may occur by butenolide enolization 57  through silylated intermediate 123. 
Computational studies indicate that adduct 125 is approximately 1 kcal/mol more stable 
than its diastereomer 115. 
 
 
Table 2.1 Evaluation of Time and Temperature 
 
 
 
entr
y 
R1 R2 temp  
(oC) 
time 
(h) 
yield    
(%)a 
ratiob 
1 H H -30 3 95 3: 1 (113: 116) 
2 H H 0 3 90 1: 2 (113: 116) 
3 H H 0 0.5 91 3: 1 (113: 116) 
4 H H 40 3 64 1: 2 (113: 116) 
5 Me H -78 1 96 20: 1(118: 119) 
6 Me H 0 3 97 1: 2 (118: 119) 
7 H Me -78 1 89 2: 1 (120: 121) 
8 H Me 0 3 85 1: 2 (120: 121) 
 
a Yield determined based on crude 1H-NMR analysis using 1,3,5-trimethoxybenzene as internal standard. 
b Ratio determined based on crude 1H-NMR analysis. 
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The equilibration process was further confirmed by 1H NMR studies. 
Trimethylsiloxyfuran was added to a solution of the benzopyrylium in CD2Cl2 -78 °C.  
After 1 h, the crude reaction mixture showed 115 and 125 in a 2:1 ratio (Scheme 2.6).  
The crude mixture was monitored by 1H NMR analysis at room temperature every 10 
min. After 30 minutes, the diasteromeric ratio of 115 and 125 was 1:2, which matched the 
diastereomer ratio of reactions performed at 0 °C.  
Scheme 2.5 Proposed Mechanism for Vinylogous Addition 
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   In order to understand the observed regio- and diastereoselectivity, and in 
collaboration with Dr. Richard Johnson at UNH we employed DFT methods to model the 
reaction of benzopyrylium 112 with 2-trimethylsiloxy furan. FMO analyses showed that 
C2 of 112 and C5 of the siloxyfuran should be the most reactive sites (Figure 2.4). 
Thirteen candidate transition state structures were generated by conformational variation 
Scheme 2.6 1H NMR Studies of Isomerization 
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about the nascent C2-C5 bond and were optimized at the B3LYP/6-31G(d) level of 
theory. Similar transition states have been proposed for vinylogous Mukaiyama aldol 
reactions. The de Lera group reported a vinylogous Mukaiyama aldol between aldehyde 
126 and trimethylsiloxyfuran.58 After analysis of all possible transition states, they found 
that the Diels-Alder-like assembly 127 was the lowest energy for the addition product 
128 (Figure 2.5). In our studies, the lowest energy Re-Si (or Si-Re) structure (TS-A in 
Figure 26)  which leads to the observed major product bears striking resemblance to an 
asynchronous endo [4+2] transition state; other TS candidates of like stereochemistry 
were greater than 4.3 kcal/mol higher in energy. The most favorable Re-Re (or Si-Si) TS 
Figure 2.4 Composite Surfaces of the B3LYP/6-31G(d) LUMO of 112 and HOMO of 2-
Trimethylsiloxyfuran. Mapped onto an electron density isosurface using Spartan ‘08.  Reactive sites are 
shown in blue. 
 
 
Figure 2.5 Literature Transition State of Vinylogous Mukaiyama Aldol  
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structure (TS-B in Figure 2.6) is 2.68 kcal/mol above TS-A, consistent with the 
stereochemistry observed for the minor, kinetic product. With 4-methyl-2-trimethylsiloxy 
furan (cf. Table 2.1, entry 7), TS structures similar to TS-A would be disfavored by steric 
factors, thus explaining the loss of diastereoselectivity. 
2.4 Synthetic Studies towards Dieckmann Cyclization 
     Having achieved the synthesis of chromone lactone structures, we next turned our 
attention to Dieckmann-type cyclizations (Scheme 2.7).59 Treatment of 114 with NaOMe 
in MeOH led exclusively to the ring-opened hydroxy ester 129. Gratifyingly, we found 
that treatment of 114 with NaOMe in THF60 led to observable precipitation to a presumed 
dianion intermediate and formation of dihydro-2H-xanthenones 130 and 131 after 
aqueous workup. After evaluating several bases (e.g. LiHMDS, DBU) and acids (e.g. 
TMSOTf, TFA), NaH was found to be superior to NaOMe to afford 130/131 in 67 % 
Figure 2.6 Lowest Energy Transition State Structures for Re-Si (TS-A) and Re-Re (TS-B) Addition in the 
Reaction of 112 and 2-Trimethylsiloxyfuran 
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yield (dr = 20:1 by 1H NMR). In order to evaluate the cyclization on the diastereomer of 
132, we subjected a mixture of butenolides 116 and 113 (2:1) to conjugate reduction 
(NiB2) which afforded 132 and 114 in a 2:1 ratio. Subsequent Dieckmann cyclization 
(NaH/THF) afforded 131 and 130 in a 1:2 ratio. These studies support a mechanism for 
equilibration to favor the syn-hydroxy configuration in 130 as shown in Scheme 2.8. 
Enolate 133 derived from 114 may condense with the lactone to form tetrahedral 
intermediate 134 (Scheme 2.9). After ring-opening, the resulting dianion 135 (a precursor 
to 130) may equilibrate by retro-Michael addition to 136 which may be followed by oxa-
Michael addition to provide diastereomer 137 and then 131 after workup.  
Scheme 2.7 Dieckmann Cyclization 
 
 
Scheme 2.8 Syntheses of anti-Configuration Tetrahydroxanthone 
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After completion of the model studies, we synthesized both epi-blennolide C (Scheme 
2.10) and blennolide C (Scheme 2.11) from butenolides 118 and 119. Conjugate 
reduction of 118 and 119 (20: 1) using NiB2 led to chromone lactones 138 (dr = 20: 1). 
Dieckmann cyclization of 138 using NaH/THF led to production of epi-blennolide C 50. 
Similar transformations were used to obtain blennolide C (3) from a 2: 1 mixture of 119: 
118 via lactone 139 (Scheme 2.11). The spectroscopic properties of synthetic 3 and epi-
blennolide C 50 were in complete agreement with previously published data.38 
Scheme 2.10 Synthesis of (±)-epi-Blennolide C 
 
 
Scheme 2.9 Equilibration of Dieckmann products 
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     The natural product blennolide B (2) has a syn, anti stereochemistry of ester, 
hydroxyl, and methyl groups on the dihydro-2H-xanthenone core. Based on our model 
studies and the hypothesis that butenolide reduction should occur anti to the 5-
substituent,62 we initiated our synthesis using a 2:1 mixture of butenolides 120 and 121 
(Table 2.1, Entry 7). In this case, nickel boride chemoselectively reduced the butenolide 
to afford a mixture of four chromone lactone diastereomers. Interestingly, when 
Scheme 2.11 Synthesis of (±)-Blennolide C 
 
 
Scheme 2.12 Synthesis of (±)-Blennolide B 
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Rh/Al2O3 was used for conjugate reduction,61 we obtained 140 as a single diastereomer as 
well as the separable, overreduced hydroxyl chromone lactones 141 and 142. Alcohols 
141 and 142 could be reoxidized to lactones 140 and 144, respectively, using the Bobbitt 
reagent 143 (50 wt% on SiO2).62 Other oxidants such as PCC and MnO2 were found to be 
unsuccessful. The stereochemistry of 140 and 144 was confirmed by X-ray analysis 
(Figure 2.7). The NMR data for chromone lactones 140 and 144 were not in agreement 
with data reported for paecilin B (Figure 2.1) indicating that 8 is possibly a diastereomer 
of both 140 and 144. Interestingly, Tietze and coworkers later synthesized two other 
diastereomers63 which also did not match paecilin B data. This indicates that the structure 
of paecilin B may require reassignment. Treatment of 140 with NaH in THF afforded 
blennolide B (2) whose spectroscopic properties were identical to reported data. 
Interestingly, cyclization of chromone lactone 144 (NaH) also led to the isolation of 
blennolide B (73 %) with negligible amounts of diastereomer 145 observed in the crude 
1H NMR spectrum. This further supports the isomerization process shown in Scheme 
2.12 which likely occurs due to unfavorable repulsion between the ester and methyl 
groups in diastereomer 145. 
Figure 2.7 X-ray Structures of 140 and 144 
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2.5 Synthetic Studies Toward Related Analogues 
    Besides the trimethylsiloxyfuran as the nucleophile for the addition to 
benzopyrylium, we are also interested in other nucleophiles that would enable us to 
construct spiro-chromanone structures. We found that copper acetylide could successfully 
add to chromone ester 146 (Scheme 2.13). The resulting alkyne 147 was cyclized to 
spiro-chromanone 148 using AuCl3 catalysis. Interestingly, the methyl ester failed to 
perform in a similar Au (III)-catalyzed cyclization. 
We noticed that epi-blennolide C 50 and blennolide B (2) had a syn-configuration 
between the methyl ester and secondary alcohol. Thus, we anticipated that these 
tetrahydroxanthones could form interesting analogues containing a β-lactone moiety.64  
Tetrahydroxanthone 50 was treated with BBr3 to tetrahydroxanthone acid 149 with 84 % 
yield (Scheme 2.14). Following Corey’s procedure,65 the tetrahydroxanthone β-lactone 
150 was smoothly synthesized. The β-lactone moiety was further confirmed by the 
presence of a peak around 1830 cm-1 in IR spectrum, typical for a β-lactone carbonyl 
C=O stretch. 
Scheme 2.13 Synthesis of Spiro Chromanone 
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Besides blennolide B (2) and blennolide C (3), another important monomer in this 
family as well as a major fragment of numerous dimeric natural products is blennolide A 
(1). Our synthetic plan of blennolide A (1) began with the thermodynamic butenolide 116 
(Scheme 2.15). Conjugate methylation should occur on the less hindered face to afford 
chromone lactone 151 which could be transformed to blennolide A through Dieckmann 
cyclization. However, several different conjugate methylation conditions (e.g. Me2CuLi, 
ZnMe2, AlMe3) using different solvents and temperatures were investigated, all leading 
to decomposition. However, the additive TMSCl could stabilize the copper methylation 
product, and could be utilized for the synthesis of blennolide A in future studies. 
 
 
 
Scheme 2.14 Synthesis of a Tetrahydroxanthone β-lactone  
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2.6 Conclusion 
In conclusion, we have developed a concise approach to tetrahydroxanthones 
employing vinylogous addition of siloxyfurans to benzopyryliums as a key step. The 
regio- and diastereoselectivity of vinylogous additions was probed using computational 
studies which suggest involvement of a Diels-Alder-like transition state. Using this 
methodology, the natural products (±)-blennolides B and C were synthesized in a 
maximum of 4 steps from readily available 5-hydroxychromones. The rapid approach to 
construct tetrahydroxanthone core provided us with the opportunity to further investigate 
syntheses of dimeric tetrahydroxanthone natural products which is described in detail in 
chapter 3.  
 
2.7 Experimental Section 
General Information: 1H NMR spectra were recorded at 400 MHz at ambient 
temperature with CDCl3 (Cambridge Isotope Laboratories, Inc.) as the solvent unless 
otherwise stated. 13C NMR spectra were recorded at 100.0 MHz at ambient temperature 
with CDCl3 as the solvent unless otherwise stated. Chemical shifts are reported in parts 
per million relative to CDCl3 (1H, δ 7.26; 13C, δ 77.0). Data for 1H NMR are reported 
as follows: chemical shift, integration, multiplicity (app = apparent, br = broad, par obsc 
= partially obscure, ovrlp = overlapping, s = singlet, d = doublet, t = triplet, q = quartet, m 
= multiplet) and coupling constants. All 13C NMR spectra were recorded with complete 
proton decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
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Chemical Instrumentation Center using a Waters Q-TOF mass spectrometer. Melting 
points were recorded on a Mel-temp (Laboratory Devices). Analytical thin layer 
chromatography was performed using 0.25 mm silica gel 60-F plates. Flash 
chromatography was performed using 200-400 mesh silica gel (Sorbent Technologies, 
Inc.). Preparative TLC was conducted with glass backed 1000μm silica gel 60-F plates 
(Silicycle, Inc.) Yields refer to chromatographically and spectroscopically pure 
compounds, unless otherwise stated.  All other reactions were carried out in oven-dried 
glassware under an argon atmosphere unless otherwise noted. The ArthurTM Suite 
Reaction Planner (Symyx Technologies, Inc.) was used for experimental procedure 
planning. HPLC grade tetrahydrofuran, methylene chloride, diethyl ether and hexanes 
were purchased from Fisher and VWR and were purified and dried by passing through a 
PURE SOLV® solvent purification system (Innovative Technology, Inc.). Methanol was 
purchased from Fisher and used without further purification. 5 % Rhodium on alumina 
and nickel (Ⅱ) chloride hexahydrate were purchased from Strem Chemicals. All other 
chemicals and reagents were used as received from Sigma-Aldrich. Oxoammonium salt 
144 (50 wt% on SiO2) was prepared according to the literature procedure. CD2Cl2 (1H, δ 
5.32) was purchased from Cambridge Isotope Laboratories, Inc. 
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Chromone 100: 2, 6-Dihydroxyacetophenone (1.5 g, 9.9 mmol) and dimethyl oxalate 
(5.8 g, 49.3 mmol, 5 equiv) were dissolved in 100 mL MeOH/MeONa solution (freshly 
prepared by dissolving Na (1.1 g, 49.3 mmol, 5 equiv) in 100 mL of MeOH), and the 
reaction was heated to reflux overnight. The reaction was cooled, solvent removed in 
vacuo, and 100 mL H2O was added. A yellow precipitate was formed immediately upon 
acidification with conc. HCl. The resulting solid was collected by vacuum filtration and 
dissolved in 50 mL of MeOH. An additional 10 mL of conc. HCl was added again, and 
the solution was refluxed at 85 °C for 2 h. The aqueous phase was extracted three times 
with EtOAc. The combined organic phase was washed with brine, dried over sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was purified by column 
chromatography (hexanes/EtOAc = 8: 1) which afforded 100 (1.05 g, 48 %) as a bright 
yellow solid. NMR, IR, and MS spectra were found to be identical with previously 
published data. 
 
 
Chromone butenolide 113: To a flame-dried flask under argon containing chromone 
100 (150 mg, 0.68 mmol) and 2, 6-lutidine (87 µL, 0.75 mmol) was added 10 mL of 
anhydrous CH2Cl2 followed by diisopropylsilyl bis(trifluoromethanesulfonate) (221 µL, 
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0.75 mmol) dropwise. The resulting solution was stirred at rt for 30 min during which 
time a dark red solution was observed. The solution was cooled to -78 oC and 2-
trimethylsiloxyfuran (146 µL, 0.89 mmol) was added dropwise. The mixture was stirred 
at -78 oC for 1 h at which time 320 µL of Et3N·3HF was added dropwise. The reaction 
was stirred for an additional 30 min and was quenched at -78 oC with 10 mL of saturated 
NH4Cl solution. The mixture was extracted three times with EtOAc and the combined 
extracts washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. 
The crude residue was analyzed by 1H NMR analysis to be a 15: 1 mixture of 
diastereomers. Compound 113 was found to decompose on silica gel. However, the 
gummy solid was dissolved in THF and slowly evaporated which led to crystallization 
from solution. Subsequently, the crystals were washed with MeOH to afford colorless 
crystals of chromone butenolide 113 (192 mg, 93 %) (Single diastereomer by 1H NMR 
analysis). Rf = 0.34 (hexanes/EtOAc = 1: 1); mp 157-159 °C (THF); IR (thin film): νmax 
3104, 3022, 2958, 1791, 1759, 1651, 1628, 1463, 761 cm-1; 1H NMR (CDCl3, 400 MHz): 
δ 11.43 (s, 1H), 7.51 (dd, J = 5.8, 1.4 Hz, 1H), 7.38 (t, J = 8.3 Hz, 1H), 6.55 (d, J = 8.4 
Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 6.34 (dd, J = 5.8, 2.0 Hz, 1H), 5.38 (s, 1H), 3.78 (s, 
3H), 3.26 (d, J = 17.1 Hz, 1H), 3.16 (d, J = 17.1 Hz, 1H); 13C NMR (CDCl3, 100 MHz) : 
δ 194.2, 170.9, 168.5, 161.8, 158.4, 150.7, 138.8, 124.2, 110.8, 107.4(1), 107.3(6), 83.0, 
82.3, 53.9, 39.5; HRMS ESI (m/z): [M+H] + calcd for C15H13O7, 305.0661; found, 
305.0660.  
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Chromone lactone 114: Butenolide chromone 113 (40 mg, 0.13 mmol) and nickel 
chloride hexahydrate (34.3 mg, 0.14 mmol, 1.1 equiv) were dissolved in THF/MeOH (3: 
1, 4 mL). After cooling to 0 oC, NaBH4 (10.5 mg, 0.28 mmol, 2.1 equiv) was added in 
one portion. After 10 min, the reaction was quenched with saturated NH4Cl and extracted 
twice with 20 mL of EtOAc. The combined organic phase was washed twice with brine, 
dried over sodium sulfate, filtered, and concentrated. The crude product was purified by 
silica gel chromatography (hexanes/EtOAc = 3: 1) to afford chromone lactone 114 (34.8 
mg, 86 %) as a colorless gum. Rf = 0.31 (hexanes/EtOAc = 1: 1); mp 131-133 °C 
(CH2Cl2); IR (thin film): νmax 3024, 2965, 1792, 1757, 1652, 1629, 1464, 762 cm-1; 1H 
NMR (CDCl3, 500 MHz): δ 11.45 (s, 1H), 7.40 (t, J = 8.3 Hz, 1H), 6.55 (dd, J = 8.4, 0.9 
Hz, 1H), 6.51 (dd, J = 8.2, 0.9 Hz, 1H), 4.78 (dd, J = 8.6, 4.3 Hz, 1H), 3.74 (s, 3H), 3.48 
(d, J = 17.3 Hz, 1H), 3.10 (d, J = 17.3 Hz, 1H), 2.81 (m, 1H), 2.58 (m, 1H), 2.51 (m, 1H), 
2.34 (m, 1H); 13C NMR (CDCl3, 100 MHz) : δ 194.8, 175.9, 169.0, 161.8, 159.1, 138.8, 
110.5, 107.4(5), 107.4(3), 84.6, 79.7, 53.7, 40.5, 27.8, 21.7; HRMS ESI (m/z): [M+H] + 
calcd for C15H15O7, 307.0818; found, 307.0814. 
 
Hydroxy ester 129: Chromone lactone 114 (35.8 mg, 0.117 mmol) was dissolved in 6 
mL of MeOH, and NaOMe (15.8 mg, 0.292 mmol, 2.5 equiv) was added in one portion. 
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After stirring for one hour, the reaction was quenched with aqueous 2M HCl, and was 
extracted with EtOAc (10 mL×2). The combined organic phase was washed with brine, 
dried over sodium sulfate, filtered, and concentrated. The crude mixture was purified by 
silica gel chromatography (hexanes/EtOAc = 3: 1 or CH2Cl2/EtOAc = 20: 1) to afford 
hydroxy ester 129 (34.6 mg, 88 %) as a colorless oil. Rf = 0.34 (hexanes/EtOAc = 1: 1); 
0.30 (CH2Cl2/EtOAc = 20: 1); IR (thin film): νmax 3472, 2955, 1732, 1646, 1627, 1462, 
1356, 1226, 1203, 1174, 1056, 731 cm-1; 1H NMR (CDCl3, 500 MHz): δ 11.54 (s, 1H), 
7.39 (t, J = 8.3 Hz, 1H), 6.54 (dd, J = 8.3, 0.9 Hz, 1H), 6.53 (dd, J = 8.3, 0.9 Hz, 1H), 
3.94 (ddd, J = 10.6, 8.0, 2.5 Hz, 1H), 3.71 (s, 6H), 3.36 (d, J = 17.3 Hz, 1H), 3.11 (d, J = 
17.3 Hz, 1H), 2.68 (d, J = 8.0 Hz, 1H), 2.60 (t, J = 6.6 Hz, 2H), 2.01 (m, 1H), 1.88 (m, 
1H) ; 13C NMR (CDCl3, 100 MHz) : δ 195.9, 174.3, 170.2, 161.8, 159.5, 138.6, 110.2, 
107.6, 107.5, 86.0, 74.1, 53.2, 51.9, 40.3, 30.5, 26.0; HRMS ESI (m/z): [M+H] + calcd 
for C16H19O8, 339.1080; found, 339.1094. 
 
 
Tetrahydroxanthone 130: Chromone lactone 114 (40 mg, 0.13 mmol) and NaH (13.1 
mg, 0.33 mmol, 2.5 equiv) were placed into a flask under a N2 atmosphere. 4 mL of THF 
was next added into the flask which was warmed up to 60 oC and stirred for 16 h. After 
cooling to room temperature, the reaction was quenched with aqueous 2M HCl and 
extracted twice with 10 mL of EtOAc. The organic phase was combined, washed with 
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brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by 
column chromatography (CH2Cl2/EtOAc = 20: 1) afforded product 130 (26.9 mg, 67 %) 
as a white powder. Rf = 0.30 (hexanes/EtOAc = 1: 1); 0.30 (CH2Cl2/EtOAc = 10: 1); mp 
179-181 °C (CH2Cl2); IR (thin film): νmax 3499, 3014, 2954, 2894, 1736, 1612, 1585, 
1465, 1355, 1297, 1217, 1053, 815, 752 cm-1; 1H NMR (CDCl3, 500 MHz): δ 13.95 (s, 
1H), 11.22 (s, 1H), 7.36 (t, J = 8.3 Hz, 1H), 6.55 (dd, J = 8.3, 0.9 Hz, 1H), 6.54 (dd, J = 
8.3, 0.9 Hz, 1H), 4.32 (ddd, J = 12.4, 5.0, 2.6 Hz, 1H), 3.70 (s, 3H), 2.85 (d, J = 2.7 Hz, 
1H), 2.67 (m, 2H), 2.19 (m, 1H), 2.09 (m, 1H) ; 13C NMR (CDCl3, 100 MHz) : δ 187.0, 
178.3, 170.1, 162.0, 158.7, 138.0, 110.7, 107.9, 107.0, 101.4, 84.4, 71.9, 53.2, 27.6, 23.8; 
HRMS ESI (m/z): [M+H] + calcd for C15H15O7, 307.0818 ; found, 307.0822.   
 
 
 
 
 
 
 
 
Tetrahydroxanthones 130 and 131: To a flame-dried flask under argon containing 
compound 100 (150 mg, 0.68 mmol) and 2,6-lutidine (87 µL, 0.75 mmol, 1.1 equiv) was 
added 10 mL  of anhydrous CH2Cl2 followed by diisopropylsilyl 
bis(trifluoromethanesulfonate) (221 µL, 0.75 mmol, 1.1 equiv) dropwise. The resulting 
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solution was stirred at rt for 30 min during which time a dark red solution was formed. 
The solution was cooled to 0 oC and 2-trimethylsiloxyfuran (146 µL, 0.89 mmol, 1.3 
equiv) was added dropwise. The mixture was stirred at 0 oC for 3 h at which time 320 µL 
of Et3N·3HF was added dropwise. The reaction was stirred for 30 min and was quenched 
with 10 mL of saturated NH4Cl solution at 0 oC. After warming to rt, the reaction mixture 
was extracted three times with 20 mL EtOAc. The combined extracts were washed with 
brine, dried over sodium sulfate, filtered, and concentrated in vacuo.  
The crude product was directly dissolved in a solution of THF/MeOH (3: 1, 8 mL) and 
nickel chloride hexahydrate (178 mg, 0.75 mmol, 1.1 equiv) was added to the solution. 
After cooling the reaction mixture to 0 oC, NaBH4 (54 mg, 1.43 mmol, 2.1 equiv) was 
added in one portion. After stirring for 10 min, the reaction was quenched with saturated 
NH4Cl, extracted with EtOAc (20 mL×2), washed with brine, and dried over sodium 
sulfate, filtered, and concentrated. The crude product was purified by silica gel 
chromatography (hexanes/EtOAc = 3: 1) to afford a mixture (154.2 mg, 74 %) of two 
diastereomers, 132 and 114 (2: 1 ratio by 1H NMR analysis). 
The mixture of compounds 132 and 114 (130 mg, 0.43 mmol) and NaH (42.4 mg, 1.06 
mmol, 2.5 equiv) were placed into a flask under a N2 atmosphere. 8 mL of THF was next 
added into the flask which was warmed up to 60 oC and stirred for 16 h. After cooling to 
room temperature, 2M HCl was used to quench the reaction which was extracted twice 
with 20 mL EtOAc. The organic phase was combined, washed with brine, and dried over 
sodium sulfate. Purification by column chromatography (hexanes/EtOAc= 3: 1) afforded 
tetrahydroxanthone 131 (30.6 mg, 24 %) as a white powder as well as a mixture of 
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starting material and tetrahydroxanthone 130. The mixture was further separated by 
column chromatography (CH2Cl2/EtOAc = 20: 1) to afford tetrahydroxanthone 130 (52.6 
mg, 41 %) as a white powder. Tetrahydroxanthone 131: Rf = 0.34 (hexanes/EtOAc = 1: 
1); 0.51 (CH2Cl2/EtOAc = 20: 1); mp 158-159 °C; IR (thin film): νmax 3505, 2953, 1737, 
1613, 1583, 1465, 1360, 1236, 1059, 1021, 731 cm-1; 1H NMR (CDCl3, 500 MHz): δ 
14.07 (s, 1H), 11.33 (s, 1H), 7.32 (t, J = 8.3 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 6.49 (d, J 
= 8.2 Hz, 1H), 4.33 (d, J = 1.4 Hz, 1H), 3.68 (s, 3H), 2.83 (ddd, J =19.2, 11.3, 7.2 Hz, 
1H), 2.75 (s, 1H), 2.40 (dd, J = 19.3, 6.8 Hz, 1H), 2.14 (m, 1H), 1.95 (m, 1H); 13C NMR 
(CDCl3, 100 MHz) : δ 187.3, 179.8, 171.1, 162.0, 157.7, 137.6, 111.2, 107.8, 107.0, 
100.3, 83.8, 66.9, 53.4, 24.4, 23.0; HRMS ESI (m/z): [M+H] + calcd for C15H15O7, 
307.0818; found, 307.0805.   
 
 
Chromone lactone 138: To a flame-dried flask under argon containing chromone 117 
(150 mg, 0.64 mmol) and 2,6-lutidine (82 µL, 0.70 mmol, 1.1 equiv) was added 10 mL of 
anhydrous CH2Cl2 followed by diisopropylsilyl bis(trifluoromethanesulfonate) (208 µL, 
0.70 mmol, 1.1 equiv) dropwise. The resulting solution was stirred at rt for 30 min during 
which time a dark red solution was formed. The solution mixture was cooled to -78 oC 
and 2-trimethylsiloxyfuran (137 µL, 0.83 mmol, 1.3 equiv) was added dropwise. The 
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mixture was stirred at -78 oC for 1 h at which time 320 µL of Et3N·3HF was added 
dropwise. The reaction was stirred for an additional 30 min and was quenched with 10 
mL of saturated NH4Cl solution at -78 oC and warmed to room temperature. The mixture 
was extracted three times with 20 mL EtOAc and the combined extracts were washed 
with brine, dried over sodium sulfate, filtered, and concentrated in vacuo.  
The crude product was directly dissolved in THF/MeOH (3: 1, 8 mL) and nickel chloride 
hexahydrate (168 mg, 0.70 mmol, 1.1 equiv) was added to the solution. After cooling the 
solution to 0 oC, NaBH4 (51 mg, 1.35 mmol, 2.1 equiv) was added in one portion. After 
stirring for 10 min, the reaction was quenched with saturated NH4Cl, extracted with 
EtOAc (20 mL×2), washed with brine, dried over sodium sulfate, filtered, and 
concentrated. The crude product was purified by silica gel chromatography 
(hexanes/EtOAc = 3: 1) to afford chromone lactone 138 (143 mg, 70 %) as a colorless 
gum. Rf = 0.42 (hexanes/EtOAc = 2: 3); 0.64 (CH2Cl2/EtOAc = 20: 1); mp 176-178 °C 
(CH2Cl2); IR (thin film): νmax 2958, 1785, 1754, 1648, 1572, 1456, 1367, 1202, 1164, 838, 
733 cm-1; 1H NMR (CDCl3, 500 MHz): δ 11.39 (s, 1H), 6.34 (s, 2H), 4.75 (dd, J = 8.5, 
4.2 Hz, 1H), 3.72 (s, 3H), 3.42 (d, J = 17.2 Hz, 1H), 3.04 (d, J = 17.3 Hz, 1H), 2.78 (m, 
1H), 2.55 (m, 1H), 2.47 (m, 1H), 2.32 (m, 1H), 2.28 (s, 3H) ; 13C NMR (CDCl3, 100 
MHz) : δ 194.0, 176.0, 169.0, 161.6, 158.8, 151.1, 110.9, 108.2, 105.4, 84.5, 79.6, 53.6, 
40.2, 27.7, 22.5, 21.6; HRMS ESI (m/z): [M+H] + calcd for C16H17O7, 321.0974; found, 
321.0974. 
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Epi-blennolide C 50: Chromone lactone 138 (30 mg, 0.09 mmol) and NaH (9.4 mg, 0.23 
mmol, 2.5 equiv) were placed into a flask under a N2 atmosphere. 4 mL of THF was next 
added to the flask which was warmed up to 60 oC and stirred for 16 h. After cooling to 
room temperature, 2M HCl aqueous solution was used to quench the reaction which was 
further extracted twice with 10 mL of EtOAc. The organic phase was combined, washed 
with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by 
silica gel column chromatography (CH2Cl2/EtOAc = 20: 1) afforded tetrahydroxanthone 
50 (21.7 mg, 72 %) as a white powder. Rf = 0.41 (hexanes/EtOAc = 2: 3); 0.30 
(CH2Cl2/EtOAc = 20: 1); mp 212-213 °C (CH2Cl2); IR (thin film): νmax 3475, 2958, 1719, 
1617, 1585, 1461, 1356, 1265, 1201, 1068, 860, 835 cm-1; 1H NMR (CDCl3, 500 MHz): 
δ 13.91 (s, 1H), 11.17 (s, 1H), 6.40 (d, J = 0.6 Hz, 1H), 6.36 (d, J = 0.7 Hz, 1H), 4.31 (dd, 
J = 12.2, 4.5 Hz, 1H), 3.71 (s, 3H), 2.79 (s, 1H), 2.66 (m, 2H), 2.30 (s, 3H), 2.19 (m, 1H), 
2.09 (m, 1H) ; 13C NMR (CDCl3, 125 MHz) : δ 186.6, 177.6, 170.1, 161.9, 158.5, 150.4, 
111.3, 108.7, 104.9, 101.2, 84.4, 71.9, 53.2, 27.5, 23.8, 22.6; HRMS ESI (m/z):  
[M+H]+ calcd for C16H17O7, 321.0974 ; found, 321.0959.   
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Blennolide C (3) and epi-blennolide C 50: To a flame-dried flask under argon 
containing chromone 117 (150 mg, 0.64 mmol) and 2,6-lutidine (82 µL, 0.70 mmol, 1.1 
equiv) was added 10 mL of anhydrous CH2Cl2 followed by diisopropylsilyl 
bis(trifluoromethanesulfonate) (208 µL, 0.70 mmol, 1.1 equiv) dropwise. The resulting 
solution was stirred at rt for 30 min during which time a dark red solution was formed. 
The solution was cooled to 0 oC and 2-trimethylsiloxyfuran (137 µL, 0.83 mmol, 1.3 
equiv) was added dropwise. The reaction mixture was stirred at 0 oC for 3 h at which time 
320 µL of Et3N·3HF was added dropwise. The reaction was stirred for an additional 30 
min and was quenched at 0 oC with 10 mL of saturated NH4Cl solution. After warming to 
rt, the reaction mixture was extracted three times with 20 mL of EtOAc. The combined 
extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo.  
The crude product was directly dissolved in THF/MeOH (3: 1, 8 mL), and nickel chloride 
hexahydrate (168 mg, 0.70 mmol, 1.1 equiv) was added to the solution. After cooling the 
reaction mixture to 0 oC, NaBH4 (51 mg, 1.35 mmol, 2.1 equiv) was added in one portion. 
After stirring for 10 min, the reaction was quenched with saturated NH4Cl, extracted with 
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EtOAc (20 mL×2), washed with brine, dried over sodium sulfate, filtered, and 
concentrated. The crude product was purified by silica gel chromatography 
(hexanes/EtOAc = 3: 1) afford a mixture (124.2 mg, 61 %) of two diastereomers 139 and 
138 (2: 1 ratio by 1H NMR analysis). 
The mixture of lactone compounds 139 and 138 (30 mg, 0.09 mmol) and NaH (9.37 mg, 
0.23 mmol, 2.5 equiv) were placed into a flask under a N2 atmosphere. 4 mL of THF was 
also added to the flask which was warmed up to 60 oC and stirred for 16 h. After cooling 
to room temperature, 2M HCl was used to quench the reaction which was extracted twice 
with 10 mL of EtOAc. The organic phase was combined, washed with brine, dried over 
sodium sulfate, filtered, and concentrated. Purification by column chromatography 
(hexanes/EtOAc = 3: 1) afforded blennolide C (3) (11.1 mg, 37 %) as a white powder as 
well as a mixture of starting material and epi-blennolide C 50. The latter mixture was 
further separated by column chromatography (CH2Cl2/EtOAc= 20: 1) to afford epi-
blennolide C 50 (9.0 mg, 30 %) as a white powder. Blennolide C (3): Rf = 0.51 
(hexanes/EtOAc = 2: 3); 0.42 (CH2Cl2/EtOAc = 20: 1); mp 182-184 °C (CH2Cl2); IR 
(thin film): νmax 3497, 2953, 1737, 1613, 1579, 1462, 1364, 1237, 1203, 879, 836, 730 
cm-1; 1H NMR (CDCl3, 500 MHz): δ 14.03 (s, 1H), 11.26 (s, 1H), 6.36 (s, 1H), 6.33 (s, 
1H), 4.31 (m, 1H), 3.69 (s, 3H), 2.82 (ddd, J = 19.2, 11.6, 7.2 Hz, 1H), 2.74 (s, H), 2.38 
(ddd, J = 19.2, 6.8, 1.0 Hz, 1H), 2.28 (s, 3H), 2.14 (m, 1H), 1.95 (m, 1H); 13C NMR 
(CDCl3, 125 MHz) : δ 186.9, 179.1, 171.2, 161.8, 157.5, 149.9, 111.7, 108.7, 104.8, 
100.1, 83.8, 66.9, 53.4, 24.3, 23.0, 22.4; HRMS ESI (m/z): [M+H] + calcd for C16H17O7, 
321.0974; found, 321.0966.   
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Chromone Lactone 140: To a flame-dried flask under argon containing chromone 
lactone 100 (150 mg, 0.68 mmol) and 2,6-lutidine (87 µL, 0.75 mmol, 1.1 equiv) was 
added 10 mL of anhydrous CH2Cl2 followed by diisopropylsilyl 
bis(trifluoromethanesulfonate) (221 µL, 0.75 mmol, 1.1 equiv) dropwise. The resulting 
solution was stirred at rt for 30 min during which time a dark red solution was formed. 
The solution was cooled to -78 oC and 4-methyl-2-trimethylsiloxyfuran (150.8 mg, 0.89 
mmol, 1.3 equiv) was added dropwise. The mixture was stirred at -78 oC for 1 h at which 
time 320 of µL Et3N·3HF was added dropwise. The reaction was stirred for an additional 
30 min, was quenched with 10 mL of saturated NH4Cl solution at -78 oC, and warmed to 
room temperature. The mixture was extracted 3× 20 mL EtOAc and the combined 
extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo.  
The crude product was directly dissolved in 8 mL of MeOH. Rh/Al2O3 (5 wt% on 
alumina) (10 mol %, 140 mg, 0.068 mmol, 0.1 equiv) was added to the solution. 
Subsequently, atmosphere was changed to hydrogen and the reaction was stirred at rt for 
12 h. The reaction vessel was purged with nitrogen, filtered through Celite to remove the 
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catalyst, and the solvent removed in vacuo. Purification by silica gel column 
chromatography (hexanes/EtOAc = 3: 1) afforded chromone lactone 140 (81.6 mg, 37 %) 
as a colorless gum. Rf = 0.30 (hexanes/EtOAc = 1: 1); 0.62 (CH2Cl2/EtOAc = 10: 1); mp 
147-149 °C (CH2Cl2/MeOH = 1: 1); IR (thin film): νmax 3624, 2956, 1790, 1757, 1647, 
1627, 1461, 1227, 1160, 1017, 759 cm-1; 1H NMR (CDCl3, 500 MHz): δ 11.38 (s, 1H), 
7.40 (t, J = 8.3 Hz, 1H), 6.54 (dd, J = 8.4, 0.9 Hz, 1H), 6.46 (dd, J = 8.2, 0.9 Hz, 1H), 
4.84 (d, J = 7.9 Hz, 1H), 3.73 (s, 3H), 3.65 (d, J = 17.4 Hz, 1H), 2.98 (m, 1H), 2.89 (d, J 
= 17.4 Hz, 1H), 2.60 (dd, J = 11.0, 2.0 Hz, 2H), 1.25 (d, J = 7.1 Hz, 3H) ; 13C NMR 
(CDCl3, 100 MHz) : δ 194.5, 175.5, 169.6, 161.7, 159.3, 138.7, 110.3, 107.3, 107.1, 84.5, 
82.0, 53.3, 41.4, 35.8, 33.5, 13.4; HRMS ES I (m/z): [M+H]+ calcd for C16H17O7, 
321.0974 ; found, 321.0989. Further purification using silica gel chromatography 
(hexane/EtOAc = 1: 1) afforded the overreduced compounds 141 (44 mg, 20 %) and 142 
(56.8 mg, 26 %). 
 
Chromone Lactone 140: Compound 141 (44 mg, 0.14 mmol, 1.0 equiv) was added into 
flame-dried flask with 3 mL CH2Cl2 which was followed by addition of oxoammonium 
salt 143 (50 wt% on SiO2, 123 mg, 0.21 mmol, 1.5 equiv). The reaction was stirred for 12 
h, filtered, and concentrated. Purification by column chromatography (hexanes/EtOAc = 
3: 1) afforded chromone lactone 140 (29.8 mg, 68 %) as a colorless gum.  
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Chromone Lactone 144: Compound 142 (56.8 mg, 0.18 mmol, 1.0 equiv) was added 
into flame-dried flask with 3 mL CH2Cl2 which was followed by addition of 
oxoammonium salt 143 (50 wt% on SiO2, 159 mg, 0.27 mmol, 1.5 equiv). The reaction 
was stirred for 12 h, filtered, and concentrated. Purification by column chromatography 
(hexanes/EtOAc = 3: 1) afforded chromone lactone 144 (38.8 mg, 69 %) as a colorless 
gum. Rf = 0.30 (hexanes/EtOAc = 1: 1); mp 173-174 °C (CH2Cl2); IR (thin film): νmax 
2957, 1788, 1760, 1648, 1628, 1463, 1229, 1160, 1056, 732 cm-1; 1H NMR (CDCl3, 500 
MHz): δ 11.44 (s, 1H), 7.41 (t, J = 8.3 Hz, 1H), 6.55 (dd, J = 8.3, 0.8 Hz, 1H), 6.54 (dd, J 
= 8.2, 0.9 Hz, 1H), 4.79 (d, J = 6.8 Hz, 1H), 3.73 (s, 3H), 3.25 (d, J = 17.3 Hz, 1H), 3.18 
(d, J = 17.3 Hz, 1H), 2.96 (m, 1H), 2.69 (dd, J = 17.3, 8.3 Hz, 1H), 2.46 (dd, J = 17.3, 7.9 
Hz, 1H), 1.32 (d, J = 7.2 Hz, 3H) ; 13C NMR (CDCl3, 125 MHz) : δ 193.9, 174.8, 169.0, 
161.9, 158.8, 139.0, 110.5, 107.5(9), 107.5(7), 84.3, 82.7, 53.6, 39.8, 36.7, 33.4, 14.8; 
HRMS ESI (m/z): [M+H] + calcd for C16H17O7, 321.0974 ; found, 321.0981.                    
Selected NOE’s for chromone lactone 144:  
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Blennolide B (2): Chromone lactone 140 (59 mg, 0.18 mmol, 1.0 equiv) and NaH (18.4 
mg, 0.46 mmol, 2.5 equiv) were placed into a flask under a N2 atmosphere. 5 mL of THF 
was next added into the flask which was warmed up to 60 oC and stirred for 16 h. After 
cooling to rt, 2M aqueous HCl solution was used to quench the reaction which was 
further extracted twice with 10 mL of EtOAc. The organic phase was combined, washed 
with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by 
column chromatography (CH2Cl2/EtOAc = 20: 1) afforded blennolide B (2) (44.6 mg, 
76 %) as a pale yellow solid. Rf = 0.35 (CH2Cl2/EtOAc = 10: 1); mp 192-193 °C 
(CH2Cl2); IR (thin film): νmax 3471, 3024, 2958, 1740, 1619, 1584, 1465, 1222, 1058, 764 
cm-1; 1H NMR (CDCl3, 500 MHz): δ 13.80 (s, 1H), 11.23 (s, 1H), 7.36 (t, J = 8.3 Hz, 
1H), 6.55 (dd, J = 8.4, 0.8 Hz, 1H), 6.53 (dd, J = 8.2, 0.8 Hz, 1H), 3.92 (dd, J = 11.2, 2.1 
Hz, 1H), 3.69 (s, 3H), 2.77 (d, J = 2.4 Hz, 1H), 2.73 (dd, J = 19.1, 6.2 Hz, 1H), 2.42 (m, 
1H), 2.30 (dd, J = 19.1, 6.2 Hz, 1H), 1.17 (d, J = 6.5 Hz, 3H) ; 13C NMR (CDCl3, 125 
MHz) : δ 187.0, 177.5, 170.3, 162.0, 158.8, 138.0, 110.7, 107.9, 107.0, 101.6, 84.7, 77.0, 
53.2, 36.2, 29.2, 18.0; HRMS ESI (m/z): [M+H] + calcd for C16H17O7, 321.0974 ; found, 
321.0971.   
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Blennolide B (2): Chromone lactone 145 (20.5 mg, 0.064 mmol, 1.0 equiv) and NaH (6.4 
mg, 0.16 mmol, 2.5 equiv) were placed into a flask under a N2 atmosphere. 2 mL of THF 
was also added into the flask which was warmed up to 60 oC and stirred for 16 h. After 
cooling to rt, 2M HCl aqueous solution was used to quench the reaction which was 
further extracted twice with 10 mL of EtOAc. The organic phase was combined, washed 
with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by 
column chromatography (CH2Cl2/EtOAc = 20: 1) afford blennolide B 2 (14.9 mg, 73 %) 
as a pale yellow solid. The ratio of blennolide B (2) to 145 was found to be 20: 1 by 1H 
NMR analysis using this procedure. 
 
 
Spiro-Chromanone 148: Chromone 147 (50 mg, 0.13 mmol, 1.0 equiv) and AuCl3 (2.4 
mg, 0.007 mmol, 0.05 equiv) were placed into a flask under a N2 atmosphere. 1 mL of 
acetone was also added into the flask and stirred at rt for 1h. The solution was then 
concentrated in vacuo. Purification by column chromatography (hexanes/EtOAc = 4: 1) 
afford spiro-chromanone 148 (34 mg, 81 %) as a white solid. 1H NMR (CDCl3, 400 
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MHz): δ 11.46 (s, 1H), 7.63 (m, 2H), 7.45 (m, 3H), 6.43 (s, 1H), 6.29 (s, 1H), 6.07 (s, 
1H), 3.30 (d, J = 17.2 Hz, 1H), 2.96 (d, J = 17.2 Hz, 1H), 2.30 (s, 3H).  
 
O
OH O OH
Me
HO2C OH
3 equiv BOPCl
3 equiv Et3N
CH2Cl2, 0 C to rt, 1 h
40 %
O
OH O OH
Me
OO
149 150  
Tetrahydroxanthone β-lactone 150: Tetrahydroxanthone acid 149 (20 mg, 0.065 mmol, 
1.0 equiv) and BOPCl (50.0 mg, 0.20 mmol, 3 equiv) were placed into a flask under a N2 
atmosphere. 1 mL of CH2Cl2 was also added into the flask which was cooled down to 0 
oC and followed by adding Et3N (20.1 mg, 14 µL, 0.20 mmol, 3 equiv). After warming 
up to rt and stirred for 1 h, water was added to quench the reaction which was further 
extracted twice with 2 mL of EtOAc. The organic phase was combined, washed with 
brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by 
column chromatography (hexanes/EtOAc = 2: 1) afford β-lactone 150 (7.8 mg, 40 %) as 
a pale yellow solid. Rf = 0.70 (hexanes/EtOAc = 1: 1); IR (thin film): νmax 1832, 1645, 
1612, 1582, 1367, 1204, 846 cm-1; 1H NMR (CDCl3, 400 MHz): δ 14.13 (s, 1H), 11.16 (s, 
1H), 6.42 (s, 1H), 6.33 (s, 1H), 5.06 (s, 1H), 2.55 (m, 2H), 2.43 (d, J = 2.0 Hz, 1H), 2.30 
(s, 3H), 1.91 (m, 1H); 13C NMR (CDCl3, 100 MHz) : δ 186.3, 177.5, 165.7, 162.1, 156.6, 
151.1, 112.1, 108.4, 104.0, 96.4, 86.8, 77.5, 24.0, 22.6, 21.0; HRMS ESI (m/z):  
[M+H]+ calcd for C15H13O6, 289.0712 ; found, 289.0717.   
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2.8 NMR Data Comparisons for the Blennolides 
 
A) 1H NMR spectrum of synthetic blennolide C in comparison with literature data:  
 
 
 
 
 
Position 
δ (JH-H in Hz) 
Natural Product Isolation4 
( 500 MHz, CDCl3) 
Synthetic (Nicolaou)38 
( 600 MHz, CDCl3) 
Synthetic (this work) 
( 400 MHz, CDCl3) 
2 6.38 (s, 1H) 6.38 (s, 1H) 6.36 (s, 1H) 
4 6.35 (d, J = 0.4, 1H) 6.35 (s, 1H) 6.33 (s, 1H) 
5 4.31 (br s, 1H) 4.31 (dd, J = 3.7, 1.7, 1H) 4.31 (m, 1H) 
6α 2.14 (m, 1H) 2.15 (ddd, J = 14.7, 6.6, 
4.4, 1H) 
2.14 (m, 1H) 
6β 1.95 (m, 1H) 1.99-1.91(m, 1H) 1.95 (m, 1H) 
7α 2.82 (ddd, J = 19.2, 11.7, 7.2, 
1H) 
2.87-2.77 (m, 1H) 2.82 (ddd, J =19.2, 11.6, 
7.2, 1H) 
7β 2.38 (dd, J = 19.2, 6.2, 1H) 2.39 (dd, J = 19.1, 6.8, 
1H) 
2.38 (ddd, J = 19.2, 6.8, 
1.0, 1H) 
11 2.29 (d, J = 0.4, 3H) -- 2.28 (s, 3H) 
13 3.70 (s, 3H) 3.70 (s, 3H) 3.69 (s, 3H) 
1-OH 11.27 (s, 1H) 11.28 (s, 1H) 11.26 (s, 1H) 
5-OH 2.64 (d, J = 1.1, 1H) 2.66 (s, 1H) 2.74 (s, 1H)*  
8-OH 14.03 (s, 1H) 14.04 (s, 1H) 14.03 (s, 1H) 
*The chemical shift of the 5-OH peak was found to depend on concentration. 
 
 
B) 1H NMR spectrum of synthetic blennolide B in comparison with literature data:  
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Position 
δ (JH-H in Hz) 
Natural Product Isolation4 
( 500 MHz, CDCl3) 
Synthetic 
( 500 MHz, CDCl3) 
2 6.53 (dd, J = 8.3, 0.8, 1H) 6.53 (dd, J = 8.2, 0.8, 1H) 
3 7.36 (t, J = 8.3, 1H) 7.36 (t, J = 8.3, 1H) 
4 6.55 (dd, J = 8.2, 0.8, 1H) 6.55 (dd, J = 8.4, 0.8, 1H) 
5 3.92 (dd, J = 11.2, 2.6, 1H) 3.92 (dd, J = 11.2, 2.1, 1H) 
6 2.41 (m, 1H) 2.42 (m, 1H) 
7α 2.30 (dd, J = 19.1, 10.6, 1H) 2.30 (dd, J = 19.1, 10.7, 1H) 
7β 2.74 (dd, J =19.1, 6.2, 1H) 2.73 (dd, J = 19.1, 6.2, 1H) 
11 1.17 (d, J = 6.5, 3H) 1.17 (d, J = 6.5, 3H) 
13 3.69 (s, 3H) 3.69 (s, 1H) 
1-OH 11.22 (s, 1H) 11.23 (s, 1H) 
5-OH -- 2.77 (d, J = 2.4, 1H) 
8-OH 13.80 (s, 1H) 13.80 (s, 1H) 
 
 
C) 13C NMR spectrum of synthetic blennolide C in comparison with literature data: 
 
 
 
Position 
δ 
Natural Product Isolation4 
( 125 MHz, CDCl3) 
Synthetic (Nicolaou)38 
( 151 MHz, CDCl3) 
Synthetic (this work) 
( 125 MHz, CDCl3) 
1 161.9 161.84 161.8 
2 111.7 111.7 111.7 
3 149.9 149.92 149.9 
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4 108.7 108.70 108.7 
4a 157.6 157.55 157.5 
5 67.0 66.95 66.9 
6 23.1 23.02 23.0 
7 24.3 24.32 24.3 
8 179.1 179.07 179.1 
8a 100.1 100.10 100.1 
9 187.0 186.94 186.9 
9a 104.9 104.86 104.8 
10a 83.9 83.81 83.8 
11 22.5 22.48 22.4 
12 171.2 171.20 171.2 
13 53.4 53.42 53.4 
 
 
D) 13C NMR spectrum of synthetic blennolide B in comparison with literature data: 
 
 
 
Position 
δ 
Natural Product Isolation4 
( 125 MHz, CDCl3) 
Synthetic 
( 125 MHz, CDCl3) 
1 162.1 162.0 
2 110.7 110.7 
3 138.0 138.0 
4 107.9 107.9 
4a 158.8 158.8 
5 77.0 77.0 
6 29.3 29.2 
7 36.3 36.2 
8 177.5 177.5 
8a 101.7 101.6 
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9 187.1 187.0 
9a 107.2 107.0 
10a 84.7 84.7 
11 18.0 18.0 
12 170.3 170.3 
13 53.1 53.2 
 
 
2.9 X-ray Crystallographic Data 
 
X-ray crystallographic data for compound 113: 
 
Crystals of compound 113 suitable for X-ray analysis were obtained by slow evaporation 
from THF. Crystallographic data have been deposited with the Cambridge Cystallograhic 
Data Centre (CCDC# 794127). Copies of the data can be obtained free of charge on 
application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: (+44)-1223-
336-033; e-mail: deposit@ccdc.cam.ac.uk). 
Crystal data and structure refinement for 113 
Identification code  Compound 111 
Empirical formula  C15 H12 O7 
Formula weight  304.25 
64 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P¯1 
Unit cell dimensions a = 7.8769(3) Å = 70.325(1)°.  
 b = 8.1717(3) Å = 84.844(1)°.  
 c = 11.1984(5) Å  = 78.875(1)°.  
Volume 665.74(5) Å3 
Z 2 
Density (calculated) 1.518 Mg/m3 
Absorption coefficient 1.05 mm-1 
F(000) 316 
Crystal size 0.2 x 0.05 x 0.03 mm3 
Theta range for data collection 8.4 to 132.6°. 
Index ranges -9<=h<=8, -9<=k<=9, -13<=l<=13 
Reflections collected 7724 
Independent reflections 2281 [R(int) = 0.023] 
Completeness to theta = 132.6° 98.8 %  
Absorption correction Empirical (using intensity measurements) 
Max. and min. transmission 0.753 and 0.663 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2281 / 0 / 201 
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Goodness-of-fit on F2 0.91 
Final R indices [I>2sigma(I)] R1 = 0.030, wR2 = 0.083 
R indices (all data) R1 = 0.031, wR2 = 0.084  
Largest diff. peak and hole 0.26 and -0.16 e.Å-3 
Atomic coordinates and equivalent isotropic displacement parameters (Å2) for compound 
15. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z Ueq 
O(1) 1.26224 (11) -0.04513 (12) 0.62965 (9) 0.0265 (2) 
O(2) 1.00555 (11) 0.13372 (11) 0.62759 (8) 0.0199 (2) 
O(3) 0.56916 (10) 0.16995 (11) 0.76095 (8) 0.0179 (2) 
O(4) 0.80160 (11) 0.17678 (12) 1.07130 (8) 0.0220 (2) 
O(5) 0.49743 (11) 0.30425 (12) 1.15338 (8) 0.0220 (2) 
O(6) 0.84907 (11) 0.46428 (11) 0.73457 (8) 0.0227 (2) 
O(7) 0.64381 (11) 0.47550 (11) 0.60267 (8) 0.0217 (2) 
C(1) 1.10806 (16) -0.02988 (16) 0.64581 (11) 0.0204 (3) 
C(2) 0.82671 (15) 0.11249 (16) 0.64860 (11) 0.0188 (3) 
C(3) 0.74602 (15) 0.19619 (15) 0.74965 (11) 0.0171 (3) 
C(4) 0.46970 (16) 0.23199 (15) 0.84951 (11) 0.0174 (3) 
C(5) 0.29446 (16) 0.28471 (16) 0.82923 (12) 0.0206 (3) 
C(6) 0.19184 (16) 0.35006 (16) 0.91705 (12) 0.0216 (3) 
C(7) 0.26032 (16) 0.35984 (16) 1.02358 (12) 0.0205 (3) 
C(8) 0.99336 (17) -0.16221 (17) 0.68226 (11) 0.0228 (3) 
C(9) 0.83110 (17) -0.08140 (17) 0.68513 (11) 0.0216 (3) 
C(10) 0.83292 (15) 0.11114 (16) 0.87715 (11) 0.0178 (3) 
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C(11) 0.73098 (16) 0.17763 (15) 0.97728 (11) 0.0175 (3) 
C(12) 0.54532 (15) 0.23746 (15) 0.95736 (11) 0.0175 (3) 
C(13) 0.43619 (16) 0.30115 (15) 1.04568 (11) 0.0185 (3) 
C(14) 0.75285 (15) 0.39536 (16) 0.69682 (11) 0.0172 (3) 
C(15) 0.63985 (17) 0.66404 (16) 0.54117 (12) 0.0237 (3) 
 
X-ray crystallographic data for compound 140: 
 
Crystals of compound 140 suitable for X-ray analysis were obtained by slow evaporation 
from a solution of CH2Cl2/methanol (1: 1). Crystallographic data have been deposited 
with the Cambridge Cystallograhic Data Centre (CCDC# 793890). Copies of the data can 
be obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
Crystal data and structure refinement for 140 
Identification code  Compound 136 
Empirical formula  C16 H16 O7 
Formula weight  320.29 
Temperature  173(2) K 
67 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 13.2285(9) Å = 90°.  
 b = 7.9453(5) Å = 104.118(3)°.  
 c = 14.2764(9) Å  = 90°.  
Volume 1455.19(16) Å3 
Z 4 
Density (calculated) 1.462 Mg/m3 
Absorption coefficient 0.116 mm-1 
F(000) 672 
Crystal size 0.60 x 0.40 x 0.10 mm3 
Theta range for data collection 1.88 to 30.51°. 
Index ranges -18<=h<=18, -10<=k<=11, -20<=l<=18 
Reflections collected 15201 
Independent reflections 4439 [R(int) = 0.0269] 
Completeness to theta = 30.51° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9885 and 0.9337 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4439 / 0 / 272 
Goodness-of-fit on F2 1.053 
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Final R indices [I>2sigma(I)] R1 = 0.0430, wR2 = 0.1163 
R indices (all data) R1 = 0.0542, wR2 = 0.1249 
Largest diff. peak and hole 0.459 and -0.426 e.Å-3 
Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for compound 140. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________  
O(1) 1963(1) 7709(1) -39(1) 21(1) 
O(2) 4583(1) 6542(2) -1782(1) 52(1) 
O(3) 5060(1) 7655(2) 12(1) 66(1) 
O(4) 2187(1) 6117(1) 1680(1) 21(1) 
O(5) 961(1) 4160(1) 1288(1) 33(1) 
O(6) 2390(1) 10911(1) -123(1) 28(1) 
O(7) 3428(1) 11003(1) 1375(1) 34(1) 
C(1) 2281(1) 7150(1) -826(1) 21(1) 
C(2) 1502(1) 6611(2) -1599(1) 27(1) 
C(3) 1788(1) 6010(2) -2413(1) 37(1) 
C(4) 2814(1) 5968(2) -2471(1) 39(1) 
C(5) 3583(1) 6552(2) -1708(1) 35(1) 
C(6) 3332(1) 7123(2) -855(1) 27(1) 
C(7) 4139(1) 7495(2) 9(1) 34(1) 
C(8) 3776(1) 7499(2) 924(1) 27(1) 
C(9) 2710(1) 8344(1) 781(1) 20(1) 
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C(10) 2271(1) 7932(1) 1661(1) 19(1) 
C(11) 1179(1) 8561(1) 1695(1) 20(1) 
C(12) 472(1) 7120(1) 1239(1) 24(1) 
C(13) 1177(1) 5625(1) 1389(1) 22(1) 
C(14) 841(1) 10268(2) 1276(1) 28(1) 
C(15) 2880(1) 10248(2) 717(1) 24(1) 
C(16) 2487(1) 12727(2) -196(1) 33(1) 
________________________________________________________________________  
 
X-ray crystallographic data for compound 144: 
 
Crystals of compound 144 suitable for X-ray analysis were obtained by slow evaporation 
at -40 oC from a solution of CH2Cl2. Crystallographic data have been deposited with the 
Cambridge Cystallograhic Data Centre (CCDC# 794128). Copies of the data can be 
obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Crystal data and structure refinement for 144 
Identification code  Compound 144 
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Empirical formula  C16 H16 O7 
Formula weight  320.29 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 8.8482(3) Å = 90°.  
 b = 7.7305(2) Å = 98.759(1)°.  
 c = 21.7938(6) Å  = 90°.  
Volume 1473.33(7) Å3 
Z 4 
Density (calculated) 1.444 Mg/m3 
Absorption coefficient 0.97 mm-1 
F(000) 672 
Crystal size 0.10 x 0.07 x 0.07 mm3 
Theta range for data collection 1.88 to 30.51°. 
Index ranges -10<=h<=10, -8<=k<=9, -25<=l<=25 
Reflections collected 63241 
Independent reflections 2519 [R(int) = 0.035] 
Completeness to theta = 66.5° 97.2 %  
Absorption correction multi-scan 
Max. and min. transmission 0.753 and 0.712 
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Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2519 / 0 / 211 
Goodness-of-fit on F2 1.08 
Final R indices [I>2sigma(I)] R1 = 0.032, wR2 = 0.0948 
R indices (all data) R1 = 0.0359, wR2 = 0.109 
Largest diff. peak and hole 0.31 and -0.25 e.Å-3 
Atomic coordinates and equivalent isotropic displacement parameters (Å2) for compound 
144. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________  
x y z U(eq) 
________________________________________________________________________  
O(1)                    0.37511(11)     0.56253(14)     0.83172(5)      0.0187(3) 
O(2)                    0.17603(13)     0.45911(17)     0.76685(6)      0.0291(3) 
O(3)                    0.66530(12)     1.14590(14)     0.88073(5)      0.0213(3) 
O(4)                    0.58321(11)     0.65924(14)     0.94068(5)      0.0175(3) 
O(5)                    0.76948(14)     1.23362(15)     0.99609(5)      0.0271(3) 
O(6)                    0.87475(13)     0.75508(16)     0.85822(6)      0.0302(3) 
O(7)                    0.84016(11)     0.84016(14)     0.90995(5)      0.0218(3) 
C(1)                    0.75885(19)     1.0225(2)       1.07287(7)      0.0247(4) 
C(2)                    0.73491(17)     1.0708(2)       1.01072(7)      0.0210(3) 
C(3)                    0.67466(16)     0.9502(2)       0.96463(7)      0.0176(3) 
C(4)                    0.64192(16)     0.9987(2)       0.89927(7)      0.0178(3) 
C(5)                    0.57259(17)     0.8610(2)       0.85479(7)      0.0177(3) 
C(6)                    0.62004(16)     0.6820(2)       0.87866(6)      0.0165(3) 
C(7)                    0.53938(16)     0.5293(2)       0.84313(7)      0.0170(3) 
72 
C(8)                    0.31206(18)     0.4634(2)       0.78284(7)      0.0208(4) 
C(9)                    0.43678(18)     0.3680(2)       0.75677(7)      0.0233(4) 
C(10)                   0.57966(18)     0.4745(2)       0.77977(7)      0.0211(4) 
C(11)                   0.6000(2)       0.6200(2)       0.73427(7)      0.0273(4) 
C(12)                   0.72038(17)     0.8565(2)       1.08912(7)      0.0234(4) 
C(13)                   0.66067(16)     0.7346(2)       1.04517(7)      0.0194(3) 
C(14)                   0.64008(15)     0.7824(2)       0.98318(7)      0.0170(3) 
C(15)                   0.79444(16)     0.6565(2)       0.88100(7)      0.0176(3) 
C(16)                   1.00180(17)     0.4686(2)       0.91294(8)      0.0264(4) 
________________________________________________________________________  
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2.10 Select NMR Spectra 
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Chapter 3 
 
Total Syntheses of Secalonic Acids A and D 
 
3.1 Introduction to Secalonic Acids and Related 2,2’-linked Biaryl 
Tetrahydroxanthone Natural Products 
       Ergochromones are a group of 2,2’-linked dimeric tetrahydroxanthone natural 
products including the secalonic acids, ergoflavins, and ergochrysins. These compounds 
are a diverse assembly of homodimers, heterodimers, and symmetrical dimers. Although 
ergochromones have a variety of structures, these compounds all share six monomer 
fragments, A to F 66 which include ent-blennolide B (ent-2), blennolide A (1), caged 
blennolide A (152), hydroxylated blennolide A (153), blennolide B (2), and ent-
blennolide A (ent-1). Franck and coworkers found that the D unit (153) has be converted 
to the lactone C (152) under acidic conditions.67 Secalonic acids are a smaller family of 
natural products that belong to the ergochromone class and consist of blennolide A (1), 
ent-blennolide A (ent-1), blennolide B (2), and ent-blennolide B (ent-2) that were isolated 
from various fungi and lichens beginning in the 1950s.68 Secalonic acid A (ent-5) is a 
homodimer of ent-blennolide B (ent-2) and the enantiomer of secalonic acid D (5). 
Secalonic acid B (4) is the dimeric form of unit B and the enantiomer of secalonic acid E 
(ent-4). Secalonic acids C (155), F (156), and G (157) are the heterodimers of the 
blennolide units. Another important homodimer is ergoflavin (154)69 which of lactone C 
86 
(152). The ergoflavin structure was verified by X-ray crystal structure analysis. 
Heterodimers are also found in this family and include ergochromone AC (ergochrysin 
A, 158) which is a homodimer of monomers A (ent-2) and C (153).  
3.2 Synthetic Plan to the Secalonic Acids 
     After we developed a concise approach to monomeric tetrahydroxanthones, we turned 
our efforts to syntheses of the dimeric tetrahydroxanthones as they are a significant 
Figure 3.1 Ergochromones Natural Products 
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synthetic challenge and also exhibit interesting biological profiles. Among the 2,2’-linked 
dimers, secalonic acid D (SAD, 5) has been studied by biologists for decades and has 
shown interesting biological properties (Chapter 1). Therefore, secalonic acid D (5) as 
well as its enantiomer secalonic acid A (ent-5) were chosen as our first synthetic targets.   
      Based on the proposed biosynthetic relationship between tetrahydroxanthones and 
chromone lactones and our previous synthetic studies, we anticipated that secalonic acid 
D (5) could be obtained from the dimeric chromone lactone 159 via double Dieckmann 
cyclization (Figure 3.2). We envisioned that oxidative coupling of chromone lactone 140 
could be used to access the 2,2’-biaryl linked dimeric precursor 159. Following our 
developed methodology, substrate 140 may be obtained by vinylogous addition of 2-
(trimethylsiloxy)furan to a siloxybenzopyrylium species derived from chromone ester 
100. 
 
Figure 3.2 Retrosynthetic Analysis for Secalonic Acid D 
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3.3 Synthetic Studies towards the Dimerization of Chromone Lactones 
and Tetrahydroxanthones 
We first evaluated the possibility for oxidative coupling of a chromone lactone 
monomer due to the likely instability of the tetrahydroxanthone core structure. 
Accordingly, we prepared the model chromone lactone 114 (Scheme 3.1) on a gram-
scale and investigated a number of oxidative coupling conditions 70  (e.g. VOCl3, 
Mn(acac)3, FeCl3). We found that only oxidants using the V(V) (e.g. VOCl3 ) afforded 
2,2’-linked chromone lactone dimers 160 in low yield and, 2,4’-linked dimers 161 as well 
(Scheme 3.1). Since the starting material is chiral, racemic, both dimer products were 
produced as an inseparable mixture of C2 and Cs products. The main side products were a 
chlorinated chromone lactone as well as chlorinated dimers, which both persisted in 
reaction mixtures even after screening various additives. 
Scheme 3.1 Attempted Oxidative Dimerization of Chromone Lactone 
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  We then changed our focus to prefunctionalize the monomers to achieve 
dimerization of the chromone lactone which we anticipated could provide selectivity for 
biaryl coupling. Both thallium acetate-directed71 or Me3NBnICl2-directed iodination72 of  
chromone lactone 114 afforded a major ortho-iodinated product which was followed by 
base-mediated O-methylation to provide aryl iodide 162 (Scheme 3.2). Stannylation of 
162 was mediated by Pd(0) catalysis in which case nBu4NI73  was found to be an essential 
additive to obtain full conversion of starting material. With both iodide 162 and stannane 
163 in hand, a number of palladium sources, ligands, and solvents were investigated for 
biaryl couplings. However, in these experiments the desired dimer was obtained in trace 
amounts. Intriguingly, we found that stannane 163 was converted into an inseparable 
mixture of C2 symmetric dimer 164 and Cs symmetric dimer 165 when the commercial 
reagent CuCl74,75 was used as additive for Pd(0)-mediated cross coupling.  
Scheme 3.2 Attempted Stille Coupling 
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Table 3.1 Copper Source Screening for Dimerizations 
 
 
 
Cu source 164/165 sm 166 
CuI 0 100 0 
CuBr·SMe2 13 74 13 
CuCl 34 24 42 
CuTC 0 0 100 
Cu(MeCN)6PF6 0 0 100 
CuCl2 0 100 0 
Cu(OAc)2·H2O 0 0 100 
Cu(NO3)2·3H2O 37 6 59 
                                           *Conversion by 1H NMR analysis  
 
Table 3.2 Solvent Screening for Dimerization 
 
 
 
Solvent 164/165 sm 166 
DMF 41 0 59 
DMA 68 0 32 
NMP 47 0 53 
                                           *Conversion by 1H NMR analysis  
 
Table 3.3 Oxidant Evaluation for Dimerization 
 
 
 
Conditions 164/165 sm 166 
5 eq CuCl 2 h <5 0 >95 
5 eq CuCl 2 h quench with air  31 9 60 
5 eq CuCl in air  12 h  60 24 8 
5 eq CuCl 1 eq CuCl2  12h  61 27 12 
5 eq Cu(NO3)2·3(H2O) 2 h  40 0 60 
                                           *Conversion by 1H NMR analysis  
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 After realizing that copper (I) catalysis could promote aryl stannane dimerization, we 
screened various copper sources (Table 3.1) and found that CuCl led to a higher yield 
than both CuBr and CuI which may be attributed to CuCl being a better reagent for 
transmetallation of the tributyltin. Another promising reagent identified was 
Cu(NO3)2·3(H2O), which has been reported by Kyler for stannane coupling reactions.76d 
During the solvent screening (Table 3.2), we found that aprotic, polar solvents such as 
DMF, DMA, and NMP could yield the desired products, while other solvents did not 
afford dimers. Surprisingly, this pathway was totally suppressed when freshly prepared 
CuCl and degassed solvent was used (Table 3.3). It turned out that an ambient oxidant 
such as air or CuCl2 was critical to enable reproducible dimerization chemistry (Scheme 
3.3). Cu(NO3)2·3(H2O) could also perform this reaction, even without an external oxidant. 
Treatment of the resulting dimers 164/165 with BBr3 cleanly afforded the deprotected 
dimers 166/167 (Scheme 3.3).  
Scheme 3.3 Dimerization of Chromone Lactone 
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Regarding the possible mechanism of this copper-mediated dimerization, we 
considered the first step to be transmetallation between CuCl and aryl stannane 163 
(Scheme 3.4), a step which could be enhanced in the polar solvent DMA. The resulting 
aryl Cu(I) species 168 has be oxidized to a aryl Cu(II) species 169. A similar intermediate 
could be obtained by treatment of 168 with a Cu(II) salt. After ligand exchange with 
another Cu(I) species 168, biaryl Cu(II) 170 has been generated. Followed by reductive 
Scheme 3.4 Possible Generic Mechanism for Copper Dimerization 
 
 
Figure 3.3 High-order Copper Cluster and 3-Center, 2-Electron Bond 
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elimination, dimeric products 164/165 were formed.70 The Cu (I) species 168 also could 
form high order cluster in solution through a 3-center, 2-electron bond between copper 
and another two aryl carbons. This type of compound has been widely observed in high-
order copper clusters such as tetramer 171 (Figure 3.3).76     
With the chromone lactone dimers in hand, we anticipated that double Dieckmann 
cyclization could provide access to the dimeric tetrahydroxanthone. However, treatment 
of dimers 166/167 under basic conditions (e.g. NaH/THF, NaH/Mg(OTf)2, 
Et3N/TMSOTf), did not lead to significant production of dimeric tetrahydroxanthone 
products or mono-rearranged products and only led to decomposition of starting material 
(Scheme 3.5). It is also possible the double Dieckmann cyclization may proceed to 
tetrahydroxanthone products. However, we later found that dimeric tetrahydroxanthones 
are unstable under basic conditions (vide infra). 
Scheme 3.5 Attempted double Dieckmann cyclization 
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   Accordingly, we investigated dimerization of the tetrahydroxanthone core structure. 
Protection of the enol moiety was necessary due to its high reactivity. 
Tetrahydroxanthone 130 was successfully methylated with (trimethylsilyl)diazomethane 
to afford the desired enol ether 173 in 57 % yield along with isomer 172 (20 %) (Scheme 
3.6). Strict control of reaction temperature and time was required to prevent double O-
methylation. Employing the previous ortho-iodination conditions, iodide 174 was 
obtained in 80 % yield. After investigating different protecting groups for the phenol (e.g. 
Scheme 3.6 Synthesis of a Chiral, Racemic 2,2‘ Model Dimer 
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-Me, -Ac), we found that the MOM group was easier to remove at the final stage. We 
prepared the MOM-protected monomer 175 in 81 % yield which was subsequently 
stannylated to afford the key intermediate 176 (Scheme 3.6). As before, the additive 
nBu4NI was found to be crucial for Pd(0)-catalyzed stannylation. Copper-mediated 
stannane coupling smoothly provided an inseparable mixture of the C2 symmetric 
compound 177 and the Cs symmetric compound 178, which could be cleanly deprotected 
to tetrahydroxanthones 179 and 180. Similarly, (±)-secalonic acid A/D were prepared in 
similar manner. 
 
3.4 Asymmetric Synthesis of Secalonic Acid D 
    In order to achieve an asymmetric synthesis of secalonic acid D (5), it has essential to 
obtain enantioriched tetrahydroxanthone monomers. Since natural products have both 
enantiomeric units in this family, we envisioned that kinetic resolution, in particular 
kinetic acylation77 could be ideal to achieve this goal. Tetrahydroxanthones have a flat 
and relatively electron-rich conjugated system in which we envisioned that there may be 
π-stacking between Birman’s benzotetramisole ligand 78  and substrate. We prepared 
several generations of Birman’s catalysts and performed the screening on advanced 
iodide tetrahydroxanthone 174 (Scheme 3.7). The benzotetramisole ligand 181 at 0 oC 
provided us acylated tetrahydroxanthone 182 in 35 to 38 % conversion, but in excellent 
ee. This promising result confirmed our hypothesis that there was a strong interaction 
between our substrate and Birman’s catalysts. However, after screening reaction time, 
solvent, reagent loading loading, and solvent, the conversion was typically below 40 %. 
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Later, we found that this catalyst was not very stable and could hydrolyze to byproduct 
183 in the presence of trace amounts of water. Accordingly, we evaluated the more stable 
homobenzotetramisole (HBTM) ligand 184. After several trials, we indeed obtained 182 
in a much higher yield while maintaining high ee. Even the more sterically hindered 
HBTM ligand 185 was screened, but the ee did not exceed that obtained when ligand 184 
was used. 
   After further screening, kinetic acylations with homobenzotetramisole (HBTM) 
catalyst 184 proceeded smoothly to afford (-)-174 in 48 % yield (96 % ee) and (+)-186 in 
49 % yield (96 % ee) (s = 146) (Scheme 3.8). Furthermore, we were able to obtain (-)-
174 in 99 % ee using a longer reaction time (13 h). The absolute stereochemistry for 
kinetic resolution products was verified by single crystal analysis of the deiodinated 
Scheme 3.7 Screening of Birman’s Catalysts 
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analogue (-)-173 which was prepared in the similar manner. We propose that the 
observed high selectivity for the kinetic resolution results from π-stacking between the 
tetrahydroxanthone substrate and the HBTM catalyst leading to an assembly which 
minimizes steric repulsion (Scheme 3.9, A). Steric repulsion between the phenyl group 
and the tetrahydroxanthone in B renders the latter assembly less favorable. This model 
does not take into account counterions which may also be important for selectivity.79 
Scheme 3.8 Synthesis of Enantiopure Model Tetrahydroxanthone 
 
 
Scheme 3.9 Possible Assemblies of Tetrahydroxanthones and Birman’s Catalyst 
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However, the methy ester in the axial position could also disfavor assembly A. Therefore, 
we considered that it is possible the phenyl group of HBTM catalyst has π-stacking with 
tetrahydroxanthone which do not have obvious steric repulsion (Scheme 3.9, A‘). 
With enantiopure monomer (-)-174 in hand, we followed the same procedure of 
protection and stannylation to (+)-176 (Scheme 3.10). Gratifyingly, copper-mediated 
coupling of (+)-176 proceeded smoothly to afford the 2,2’-linked dimer (-)-177 in 60 % 
yield. Finally, treatment of 177 with 3M HCl led to the fully deprotected 
tetrahydroxanthone dimer (-)-179 in 89 % yield. 
 
Encouraged by our model studies, we initiated syntheses of secalonic acids A (ent-5) 
and D (5) using chiral, racemic blennolide B (2). Following previously optimized 
conditions, methyl enol ether protection and ortho-iodination afforded blennolide 
derivative 189 (Scheme 3.11). Due to the presence of an additional methyl group on the 
Scheme 3.10 Synthesis of a Model 2,2'-Linked Tetrahydroxanthone Dimer 
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C ring, acylative kinetic resolution was much slower in comparison to the model 
substrate (25 h, 0 oC). However, a longer reaction time and higher temperature provided 
both (-)-189 and (+)-190 in excellent yield and enantioselectivity. However, since the C2 
and Cs dimers are inseparable, the enantiopurity of the tetrahydroxanthone was very 
Scheme 3.11 Synthesis of Chiral Tetrahydroxanthone Monomer 
 
 
Scheme 3.12 Synthesis of Secalonic Acid D 
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important in this case to provide diastereopure dimer. Fortunately, after recrystallization, 
both (+)-190 and (-)-189 could be obtained in >99 % ee 
With (+)-190 in hand, we conducted MOM protection followed by stannane formation 
to obtain enantioenriched tetrahydroxanthone 191 (Scheme 3.12). Copper-mediated 
Figure 3.4 X-ray Crystal Structure of (+)-192 
 
 
Scheme 3.13 Synthesis of Secalonic Acid A 
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oxidative coupling provided a single dimeric product 192 whose absolute and relative 
stereochemistry were unambiguously verified by single crystal X-ray analysis (Figure 
3.4). Global deprotection under acidic conditions provided secalonic acid D (5) in 80 % 
yield. NMR spectra, UPLC retention times, and aD values for 5 were found to be identical 
to those reported for the natural sample. 
    In a similar manner, the other compound accessed from kinetic resolution, (-)-189, 
was advanced to secalonic acid A (ent-5) (Scheme 3.13). After MOM protection and 
stannane synthesis, (+)-193 was obtained in 49 % yield after two steps. Treatment of (+)-
193 with CuCl and air led to the production of dimer (-)-194 in 65 % yield. Final 
deprotection using 3M HCl/acetonitrile afforded secalonic acid A (ent-5), the enantiomer 
Figure 3.5 Importance of Enantiopure Monomer (-)-194 
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of secalonic acid D, in 85 % yield.  
Through analysis the NMR spectra of (-)-194 prepared from (-)-184 in different 
enantioselective excess, we can clearly see the importance of enantiopure monomers to 
avoid Cs dimeric product (Figure 3.5).  
 
3.5 Conclusion 
      In summary, the bioactive tetrahydroxanthone dimers secalonic acids A and D have 
been synthesized for the first time after more than fifty years since their isolation. 
Birman's homobenzotetramisole (HBTM) catalysts were found to be highly effective for 
kinetic resolution of highly functionlized tetrahydroxanthone monomers. In addition, we 
found that copper (I) chloride under mild oxidative conditions could be used to access 
2,2’ biphenols from complex arylstannanes. These extremely mild dimerization 
conditions show excellent functional group tolerance and should be useful for the 
synthesis of a range of dimeric 2,2'-linked chromone lactone and tetrahydroxanthone 
natural products. 
 
3.6 Experimental Section 
General Information: 1H NMR spectra were recorded at 400 MHz at ambient 
temperature with CDCl3 (Cambridge Isotope Laboratories, Inc.) as the solvent unless 
otherwise stated. 13C NMR spectra were recorded at 100.0 MHz at ambient temperature 
with CDCl3 as the solvent unless otherwise stated. Chemical shifts are reported in parts 
per million relative to CDCl3 (1H, δ 7.26; 13C, δ 77.0). Data for 1H NMR are reported as 
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follows: chemical shift, integration, multiplicity (app = apparent, br = broad, par obsc = 
partially obscure, ovrlp = overlapping, s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet) and coupling constants. All 13C NMR spectra were recorded with complete 
proton decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
Chemical Instrumentation Center using a Waters Q-TOF mass spectrometer. Melting 
points were recorded on a Mel-temp (Laboratory Devices). Analytical thin layer 
chromatography was performed using 0.25 mm silica gel 60-F plates. Flash 
chromatography was performed using 200-400 mesh silica gel (Sorbent Technologies, 
Inc.). Preparative TLC was conducted with glass backed 1000μm silica gel 60-F plates 
(Silicycle, Inc.) Yields refer to chromatographically and spectroscopically pure 
compounds, unless otherwise stated.  All other reactions were carried out in oven-dried 
glassware under an argon atmosphere unless otherwise noted. The ArthurTM Suite 
Reaction Planner (Symyx Technologies, Inc.) was used for experimental procedure 
planning. Analytical LC-MS experiments were performed using a Waters Acquity UPLC 
(Ultra Performance Liquid Chromatography) with a Binary solvent manager, SQ mass 
spectrometer, Water 2996 PDA (PhotoDiode Array) detector, and Evaporative Light 
Scattering Detector (ELSD). An Acquity UPLC BEH C18 1.7 μm column was used for 
analytical UPLC-MS analysis. Preparative HPLC purification was performed on a Gilson 
PLC 2020 Personal Purification System. A Chiralcel®OD (Chiral Technologies Inc., 250 
× 4.6 mm I.D.) column was used for enantiomeric excess determination. HPLC grade 
tetrahydrofuran, methylene chloride, diethyl ether, toluene and hexanes were purchased 
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from Fisher and VWR and were purified and dried by passing through a PURE SOLV® 
solvent purification system (Innovative Technology, Inc.). Methanol was purchased from 
Fisher and used without further purification. Other ACS grade solvents were purchased 
from Clean Harbors. 
Commercial CuCl was purchased from Sigma-Aldrich (≥99.995% trace metals basis) and 
Strem (99.99%-Cu). Fresh CuCl was prepared following the reported procedure.80 All 
other reagents and relevant catalysts were purchased from Sigma-Aldrich, Acros, Alfa 
Aesar, and Strem Chemicals. 
 
 
 
Ortho-Iodo Chromone lactone 162: Me3NBnICl2 Method: Chromone lactone 114 (1.0 
g, 3.27 mmol), calcium carbonate (2.29 g, 22.86 mmol, 7.0 equiv), and Me3NBnICl2 
(1.19 g, 3.43 mmol, 1.05 equiv) were added to a solution of CH2Cl2/MeOH (5 : 1, 36 
mL). After stirring at room temperature for 12 h, the reaction mixture was directly 
filtered to remove calcium carbonate. After concentration in vacuo, the crude product was 
purified by silica gel chromatography (CH2Cl2/EtOAc = 30: 1) to afford a mixture of 
iodinated chromone lactones. By 1H NMR integration, the ratio of ortho: para: diiodide: 
starting material was approximately 63: 5: 12: 10. 
The major ortho-iodide product was verified by the following key HMBC correlation: 
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The aforementioned compound mixture was dissolved in 30 mL of acetone, and cesium 
carbonate (2.12 g, 6.53 mmol, 2.0 equiv) and dimethyl sulfate (0.824 g, 0.59 mL, 6.53 
mmol, 2.0 equiv) were added to the solution. The reaction mixture was warmed to 60 oC 
and stirred for 2 h. After cooling to room temperature, cesium carbonate was removed by 
filtration. After removing volatiles in vacuo, the residue was purified by silica gel 
chromatography (hexanes/EtOAc = 3: 1) to afford the protected ortho-iodo chromone 
lactone 162 (889 mg, 61 %) as a colorless to pale yellow oil. Rf = 0.28 (hexanes/EtOAc = 
1: 1); IR (thin film): νmax 2937, 1788, 1753, 1697, 1585, 1458, 1223, 1060, 759 cm-1; 1H 
NMR (CDCl3, 400 MHz): δ 7.83 (d, J = 8.9 Hz, 1H), 6.65 (d, J = 8.9 Hz, 1H), 4.80 (dd, J 
= 8.4, 4.6 Hz, 1H), 3.78 (s, 3H), 3.70 (s, 3H), 3.36 (d, J = 16.5 Hz, 1H), 3.01 (d, J = 16.5 
Hz, 1H), 2.75 (ddd, J = 18.0, 10.2, 7.8 Hz, 1H), 2.56 (ddd, J = 18.0, 10.5, 5.5 Hz, 1H), 
2.43 (m, 1H), 2.33 (m, 1H); 13C NMR (CDCl3, 100 MHz) : δ 186.2, 175.8, 168.7, 160.9, 
159.3, 144.9, 115.8, 115.4, 85.0, 84.6, 79.5, 61.6, 53.6, 41.8, 27.6, 21.6; HRMS-ESI 
(m/z): [M+H]+ calcd for C16H16IO7, 446.9941; found, 446.9933. 
 
 
Chromone Lactone Stannane 163: Iodide chromone lactone 162 (889 mg, 1.99 mmol), 
nBu4NI (736 mg, 1.99 mmol, 1.0 equiv), Pd2(dba)3 (182 mg, 0.20 mmol, 0.1 equiv), 
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PtBu3 (162 mg, 0.80 mmol, 0.4 equiv) and bis(tributyltin) (2.31 g, 1.53 mL, 3.98 mmol, 
2.0 equiv) were added to a flame-dried flask. Under a N2 atmosphere, 20 mL of 
anhydrous toluene was added. The flask was warmed to 60 oC and stirred for 12 h. The 
crude mixture was directly purified by silica gel chromatography (hexanes/EtOAc = 4: 1) 
to afford the chromone lactone stannane 163 (894 mg, 72 %) as a colorless oil. Rf = 0.51 
(hexanes/EtOAc = 1: 1); IR (thin film): νmax 2955, 2927, 1790, 1756, 1690, 1580, 1455, 
1377, 1287, 1161, 1058, 840 cm-1; 1H NMR (CDCl3, 400 MHz): δ 7.46 (d, J = 8.1 Hz, 
1H), 6.79 (d, J = 8.1 Hz, 1H), 4.81 (dd, J = 4.3, 4.3 Hz, 1H), 3.72 (s, 3H), 3.71 (s, 3H), 
3.37 (d, J = 16.5 Hz, 1H), 3.02 (d, J = 16.5 Hz, 1H), 2.80 (ddd, J = 17.5, 10.1, 7.8 Hz, 
1H), 2.56 (ddd, J = 17.8, 10.5, 5.1 Hz, 1H), 2.49 (m, 1H), 2.32 (m, 1H), 1.49 (m, 6H), 
1.31 (m, 6H), 1.04 (m, 6H), 0.87 (t, J = 7.3 Hz, 9H); 13C NMR (CDCl3, 100 MHz) : δ 
187.4, 176.1, 169.2, 165.0, 161.5, 144.3, 128.7, 113.6, 113.3, 84.2, 79.7, 62.2, 53.4, 42.2, 
29.0, 27.7, 27.3, 21.7, 13.6, 9.9; HRMS-ESI (m/z): [M+H]+ calcd for C28H43O7Sn, 
611.2037; found, 611.2049. 
 
 
Dimeric Chromone Lactones 164 and 165: Chromanone stannane 163 (100 mg, 0.16 
mmol), and freshly prepared CuCl (81 mg, 0.82 mmol, 5 equiv) were placed in an open 
tube (Note: if commercial CuCl was used, the reaction could proceed under a N2 
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atmosphere in comparable yield). Next, 1.6 mL of DMA was added into the tube and the 
reaction mixture was stirred at room temperature for 12 h. (Note: the reaction mixture 
turned from clear yellow to cloudy to completely dark). The mixture was quenched with 
3 mL of saturated NH4Cl solution and was extracted 5 times with 5 mL of EtOAc After 
concentrating the reaction mixture at 40 oC in vacuo, the crude product was directly 
purified by column chromatography (hexanes/EtOAc = 1: 2 to pure EtOAc) to afford the 
dimeric chromone lactones 164 and 165 (26-31 mg, 50-61 %, dr 1: 1, inseparable by 
silica gel chromatography) as a colorless gel. 164 and 165: Rf = 0.11 (hexanes/EtOAc = 1: 
2); 1H NMR (CDCl3, 400 MHz) (Note: Cs- and C2-symmtric compounds have highly 
overlapping signals in the 1H NMR spectra except for protons 7, 2a, and 13, see below); 
HRMS-ESI (m/z): [M+H]+ calcd for C32H31O14, 639.1714; found, 639.1703. 
ppm (f1)
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3.4003.4503.5003.550
ppm (f1)
7.4507.5007.550
 
 
 
 
108 
O-Methyl-protected Tetrahydroxanthones 172 and 173: (±)-Tetrahydroxanthone 130 
(900 mg, 2.94 mmol) was placed into a flask under a N2 atmosphere. 30 mL of 
CH2Cl2/MeOH (1: 1) was next added into the flask which was cooled down to 0 oC and 
stirred to fully dissolve the compound. (Note: If solids remain undissolved, an additional 
1 ~ 2 mL CH2Cl2 was added to the solution.) Next, (trimethylsilyl)diazomethane solution 
(2M in ether, 7.34 mL, 14.69 mmol, 5 equiv) was added dropwise. After stirring at 0 oC 
for 10 to 15 min, the reaction was quenched with 10 % aqueous AcOH. After warming to 
room temperature, the reaction was extracted twice with 30 mL of EtOAc. The organic 
phase was combined, washed with brine, dried over sodium sulfate and calcium 
carbonate, filtered, and concentrated in vacuo. Purification by column chromatography 
(hexane/EtOAc = 1: 1 to 1: 2) afforded product 172 (188 mg, 20 %) as a pale yellow 
powder and 173 (531 mg, 57 %) as a yellow solid. 172: Rf = 0.48 (EtOAc); mp 136-137 
°C (CH2Cl2); IR (thin film): νmax 3423, 1752, 1730, 1590, 1468, 1325, 1217, 1056, 760 
cm-1; 1H NMR (CDCl3, 400 MHz): δ 8.38 (s, 1H), 7.21 (t, J = 8.3 Hz, 1H), 6.59 (d, J = 
8.1 Hz, 1H), 6.51 (d, J = 8.3 Hz, 1H), 4.50 (dd, J = 10.5, 7.3 Hz, 1H), 3.92 (s, 3H), 3.69 
(s, 3H), 2.99 (d, J = 1.5 Hz, 1H, OH, chemical shift and coupling varies with 
concentration), 2.69 (ddd, J = 17.0, 5.1, 2.8 Hz, 1H), 2.54 (ddd, J = 17.0, 8.9, 5.5 Hz, 
1H), 2.19 (m, 2H); 13C NMR (CDCl3, 100 MHz) : δ 194.8, 169.6, 160.0, 156.8, 155.4, 
134.1, 111.5, 109.7, 108.2, 106.0, 85.0, 73.1, 63.0, 53.0, 38.2, 25.2; HRMS-ESI (m/z): 
[M+H]+ calcd for C16H17O7, 321.0974 ; found, 321.0980.  
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173: Rf = 0.38 (EtOAc); mp 192-193 °C (CH2Cl2); IR (thin film): νmax 3448, 3014, 1733, 
1633, 1562, 1458, 1356, 1220, 1071, 986, 752 cm-1; 1H NMR (CDCl3, 400 MHz): δ 
12.62 (s, 1H), 7.31 (t, J = 8.3 Hz, 1H), 6.49(1) (d, J = 8.3 Hz, 1H), 6.48(7) (d, J = 8.3 Hz, 
1H), 4.27 (dd, J = 12.5, 4.5 Hz, 1H), 3.94 (s, 3H), 3.67 (s, 3H), 2.99 (s, 1H, OH, chemical 
shift and coupling varies with concentration), 2.80 (ddd, J = 18.7, 6.2, 1.5 Hz, 1H), 2.65 
(ddd, J = 18.7, 10.8, 6.7 Hz, 1H), 2.21 (dddd, J = 23.7, 13.0, 6.4, 1.4 Hz, 1H), 2.08 (m, 
1H); 13C NMR (CDCl3, 100 MHz) : δ 185.1, 170.0, 169.1, 162.9, 158.5, 137.1, 110.4, 
108.2, 106.8, 105.4, 86.1, 71.6, 56.3, 53.2, 24.7, 23.7; HRMS-ESI (m/z): [M+H]+ calcd 
for C16H17O7, 321.0974 ; found, 321.0969. 
 
 
 
Ortho-iodo Tetrahydroxanthone 174: O-Methyl-protected tetrahydroxanthone 173 (500 
mg, 1.56 mmol), calcium carbonate (1.09 g, 10.93 mmol, 7.0 equiv), and Me3NBnICl2 
(570 mg, 1.64 mmol, 1.05 equiv) were added to a solution of CH2Cl2/MeOH (5 : 1, 16 
mL). After stirring at room temperature for 12 h, the reaction mixture was directly 
filtered to remove calcium carbonate. After concentration in vacuo, the crude product was 
purified by silica gel chromatography (CH2Cl2/EtOAc = 20: 1) to afford iodide 174 (556 
mg, 80 %) as a yellow powder. Rf = 0.29 (hexanes/EtOAc = 1: 2) mp decomp 170 °C 
(CH2Cl2); IR (thin film): νmax 3478, 3018, 1748, 1628, 1567, 1425, 1353, 1220, 1066, 759 
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cm-1; 1H NMR (CDCl3, 400 MHz): δ 13.57 (s, 1H), 7.73 (d, J = 8.7 Hz, 1H), 6.39 (d, J = 
8.7 Hz, 1H), 4.28 (dd, J = 12.6, 4.6 Hz, 1H), 3.96 (s, 3H), 3.68 (s, 3H), 2.82 (ddd, J = 
18.8, 6.4, 3.9 Hz, 1H), 2.82 (s, 1H, OH, chemical shift and coupling varies with 
concentration), 2.66 (ddd, J = 17.7, 10.8, 6.8 Hz, 1H), 2.21 (dddd, J = 24.2, 10.9, 6.5, 2.2 
Hz, 1H), 2.10 (m, 1H); 13C NMR (CDCl3, 125 MHz) : δ 184.3, 170.1, 169.7, 161.5, 158.9, 
145.5, 109.3, 108.5, 104.7, 86.4, 75.1, 71.6, 56.5, 53.3, 24.9, 23.7; HRMS-ESI (m/z): 
[M+H]+ calcd for C16H16O7I, 446.9941 ; found, 446.9951. 
O
O O OMe
CO2Me
OH
I
H
Observed
Key
HMBC
174  
 
 
Chiral, Non-Racemic Tetrahydroxanthones (+)-186 and (-)-174: (±)-
Tetrahydroxanthone 174 (100 mg, 0.22 mmol) and 5 mL of CDCl3 was added to a flame-
dried flask. The solution was gently warmed at 40 oC for 5 min until the substrate was 
fully dissolved. The solution was cooled to -40 oC. To a flame-dried tube was added (R)-
HBTM 184 (6 mg, 0.022 mmol, 0.1 equiv), DIEA (17 mg, 23 µL, 0.13 mmol, 0.6 equiv), 
and (EtCO)2O (17 mg, 18 µL, 0.13 mmol, 0.6 equiv) with 1 mL of CDCl3 and the 
contents were mixed for 3 min. The latter solution was transferred dropwise to a solution 
of 169. After stirring at -40 oC for 11 h, the reaction was quenched by 0.2 mL of MeOH 
and was warmed to room temperature. After concentrating in vacuo, the crude reaction 
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product was subjected to 1H NMR analysis to monitor conversion (δ 6.39, 3-H for (-)-
174; δ 6.31, 3-H for (+)-186). The crude product was purified by silica gel 
chromatography (CH2Cl2/EtOAc = 20: 1 to 10: 1) to afford product (+)-186 (55 mg, 49 
%) as a yellow solid and (-)-174 (48 mg, 48 %) as a yellow powder. (+)-186: Rf = 0.63 
(hexanes/EtOAc = 1: 2) mp decomp 180 °C (CH2Cl2); IR (thin film): νmax 1750, 1633, 
1572, 1427, 1356, 1278, 1226, 1073, 761 cm-1; 1H NMR (CDCl3, 500 MHz): δ 13.44 (s, 
1H), 7.68 (d, J = 8.7 Hz, 1H), 6.31 (d, J = 8.7 Hz, 1H), 5.40 (d, J = 12.1, 4.4 Hz, 1H), 
3.92 (s, 3H), 3.65 (s, 3H), 2.77 (ddd, J = 18.7, 6.4, 2.6 Hz, 1H), 2.71 (ddd, J = 18.7, 12.4, 
6.3 Hz, 1H), 2.35 (q, J = 7.5 Hz, 2H), 2.34 (m, 1H), 2.08 (m, 1H), 1.14 (t, J = 7.6 Hz, 
3H); 13C NMR (CDCl3, 125 MHz) : δ 184.3, 173.0, 169.3 (two carbons overlapped, 
CO2Me and C=COMe), 161.2, 159.1, 145.4, 109.5, 108.4, 104.8, 84.0, 74.5, 71.7, 56.5, 
53.1, 27.6, 24.3, 22.5, 8.9; HRMS-ESI (m/z): [M+H]+ calcd for C19H20O8I, 503.0203; 
found, 503.0212. Enantiomers were separated using chiral UPLC analysis [10% IPA 
Chiralcel®OD (Chiral Technologies Inc., 250 × 4.6 mm I.D.) column]. The enantiomeric 
excess for (+)-186 after kinetic resolution was 96 %. [α]D28= 55.4 ° (c= 0.1, CH2Cl2). 
(±)- 186: 
 96 % ee (+)-186:  
 
(-)-174:1H NMR, 13C NMR, IR, and HRMS for 
(±)-174. Enantiomers were separated by 10% IPA
Inc., 250 × 4.6 mm I.D.) column
resolution was 95 %. 
(±)-174: 
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(-)-174 were identical to data reported for 
 Chiralcel®OD (Chiral Technologies 
. The enantiomeric excess for (-)-174 after kinetic 
 
 95 % ee (-)-174:  
>99 % ee (-)-174: Follow the previous procedure (Kinetic resolution was performed at 
40 oC for 13 h). Following this protocol, 
84.5° (c= 0.1, CH2Cl2).    
>99 % ee (-)-174: 
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(-)-174 (46 mg, 46 %) was obtained. [
-
α]D27= -
 O
MOMO O OMe
CO2Me
OMOM
Bu3Sn
(+)-176
Dimeric Tetrahydroxanthone
mmol), and freshly prepared CuCl (
tube (Note: if commercial CuCl was used, th
atmosphere in comparable yield)
reaction mixture was stirred at room temperature for 12 h. (Note: 
from clear yellow to cloudy to completely dark
saturated NH4Cl solution and was 
oC in vacuo, the crude product was 
afford the dimeric tetrahydroxanthone
= 0.44 (pure EtOAc); melting point: >2
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O
OH O OMe
CO2Me
OMOM
O
OHOOMe
CO2Me
MOMO
(-)-177
CuCl (5 equiv), air
DMA, rt, 12 h
60 %
 
 (-)-177: MOM-protected stannane (+)-176 (30 mg, 0.
21 mg, 0.22 mmol, 5 equiv) were placed in an open 
e reaction could proceed under 
. Next, 0.5 mL of DMA was added into the tube
Note: the reaction turn
). The mixture was quenched with
extracted 5 times with 3 mL. After concentrat
directly purified by preparative TLC (EtOAc
 (-)-177 (9 mg, 60 %) as a yellow solid. (-)
20 oC (CH2Cl2/MeOH); IR (thin film): νmax
043 
a N2 
 and the 
s 
 3 mL of 
ing at 40 
) to 
-177: Rf 
 2950, 
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1777, 1633, 1584, 1560, 1432, 1224, 1039, 818 cm-1; 1H NMR (CDCl3, 400 MHz): δ 
12.95 (s, 2H), 7.43 (d, J = 8.5 Hz, 2H), 6.52 (d, J = 8.5 Hz, 2H), 5.04 (d, J = 6.7 Hz, 2H), 
4.75 (d, J = 6.7 Hz, 2H), 4.24 (dd, J = 11.9, 4.3 Hz, 2H), 3.89 (s, 6H), 3.69 (s, 6H), 3.45 
(s, 6H), 2.76 (ddd, J = 18.1, 6.0, 2.9 Hz, 2H), 2.62 (ddd, J = 18.1, 10.4, 6.1 Hz, 2H), 2.32 
(m, 2H), 2.06 (m, 2H); 13C NMR (CDCl3, 100 MHz) : δ 185.7, 170.0, 167.8, 160.3, 158.3, 
139.6, 117.7, 108.2, 106.4, 106.1, 96.4, 86.1, 75.3, 56.3, 55.8, 53.0, 24.6, 23.9; 
HRMS-ESI (m/z): [M+H]+ calcd for C36H39O16, 727.2238; found, 727.2233; [α]D28= -
23.5 ° (c= 0.1, CH2Cl2). 
 
 
Dimeric Tetrahydroxanthone (-)-179: Dimeric tetrahydroxanthone (-)-177 (5.0 mg, 
0.0069 mmol) was dissolved in 1.5 mL of acetonitrile and 1.5 mL of 3M aqueous HCl. 
The reaction was warmed up to 60 oC and was stirred for 30 min. After cooling to room 
temperature, the solution was purified by preparative HPLC (C18, 10-75% CH3CN/water). 
The fractions were extracted with EtOAc, washed with brine, dried over Na2SO4, and 
concentrated to afford (-)-179 (3.8 mg, 89 %) as a pale yellow solid. (-)-179: mp: 223-
225 oC (CH2Cl2); IR (thin film): νmax 3462, 2926, 1737, 1607, 1590, 1562, 1430, 1243, 
1059 cm-1; 1H NMR (CDCl3, 400 MHz) (Note: Compound (-)-179 has moderate 
solubility in CDCl3; however, decomposition or isomerization was not observed in 
CDCl3): δ 13.93 (s, 2H), 11.75 (s, 2H), 7.46 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 
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4.34 (dd, J = 11.8, 5.2 Hz, 2H), 3.74 (s, 6H), 2.83 (d, J = 1.0 Hz, 1H, OH, chemical shift 
and coupling varies with concentration), 2.68 (m, 4H), 2.22 (m, 2H), 2.12 (m, 2H); 13C 
NMR (CDCl3, 125 MHz) : δ 187.2, 178.4, 170.1, 159.4, 158.2, 140.2, 118.3, 107.6, 106.9, 
101.3, 84.4, 72.0, 53.3, 27.6, 23.8; HRMS-ESI (m/z): [M+H]+ calcd for C30H27O14, 
611.1401; found, 611.1398; [α]D29= -54.3° (c= 0.1, CH2Cl2). 
 
 
 
Ortho-iodo Tetrahydroxanthone 189: O-Methyl-protected blennolide B 188 (500 mg, 
1.50 mmol), calcium carbonate (1.05 g, 10.50 mmol, 7.0 equiv), and Me3NBnICl2 (548 
mg, 1.58 mmol, 1.05 equiv) were added to a solution of CH2Cl2/MeOH (5 : 1, 15 mL). 
After stirring at room temperature for 12 h, the reaction mixture was directly filtered to 
remove calcium carbonate. After concentration in vacuo, the crude product was purified 
by silica gel chromatography (CH2Cl2/EtOAc = 30: 1) to afford product 189 (557 mg, 81 
%) as a yellow powder. Rf = 0.41 (hexanes/EtOAc = 1: 2) mp >230 °C (CH2Cl2); IR (thin 
film): νmax 3529, 2951, 1732, 1628, 1566, 1425, 1217, 1071, 1029, 750 cm-1; 1H NMR 
(CDCl3, 400 MHz): δ 13.56 (s, 1H), 7.73 (d, J = 8.7 Hz, 1H), 6.39 (d, J = 8.7 Hz, 1H), 
3.96 (s, 3H), 3.89 (d, J = 11.6 Hz, 1H), 3.67 (s, 3H), 2.86 (dd, J = 18.5, 5.7 Hz, 1H), 2.77 
(d, J = 1.0 Hz, 1H, OH, chemical shift and coupling varies with concentration), 2.42 (m, 
1H), 2.25 (dd, J = 18.5, 10.7 Hz, 1H), 1.18 (d, J = 6.4 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) : δ 184.2, 169.8, 169.3, 161.5, 159.0, 145.5, 109.3, 108.5, 104.8, 86.7, 76.5, 75.0, 
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56.4, 53.3, 33.5, 28.9, 17.8; HRMS-ESI (m/z): [M+H]+ calcd for C17H18O7I, 461.0097 ; 
found, 461.0101. 
 
 
Chiral, Non-Racemic Tetrahydroxanthones (+)-190 and (-)-189: (±)-
Tetrahydroxanthone 189 (200 mg, 0.43 mmol) and 20 mL of CDCl3 were added to a 
flame-dried flask. The solution was gently warmed at 40 oC for 5 min until the substrate 
was fully dissolved. The solution was cooled to 0 oC. To a flame-dried tube was added ®-
HBTM 184 (11.5mg, 0.043 mmol, 0.1 equiv), DIEA (38.9 mg, 52.3 µL, 0.30 mmol, 0.7 
equiv), and (EtCO)2O (39.0 mg, 38.5 µL, 0.30 mmol, 0.7 equiv) with 2 mL of CDCl3 and 
the contents were mixed for 3 min. The latter solution was transferred dropwise to a 
solution of 189. After stirring at 0 oC for 25 h, the reaction was quenched by 0.2 mL of 
MeOH, and was warmed to room temperature. After concentrating in vacuo, the crude 
reaction product was subjected to 1H NMR analysis to monitor conversion (δ 6.49, 3-H 
for (-)-189; δ 6.39, 3-H for (+)-190). The crude product was purified by silica gel 
chromatography (CH2Cl2/EtOAc = 30: 1 to 10: 1) to afford product (+)-190 (110 mg, 49 
%) as a yellow solid and (-)-189 (96 mg, 48 %) as a yellow powder. (+)-190: Rf = 0.33 
(hexanes/EtOAc = 1: 1) mp >230 °C (CH2Cl2); IR (thin film): νmax 2951, 1751, 1634, 
1570, 1426, 1351, 1218, 1079, 734 cm-1; 1H NMR (CDCl3, 400 MHz): δ 13.44 (s, 1H), 
7.70 (d, J = 8.7 Hz, 1H), 6.31 (d, J = 8.7 Hz, 1H), 5.36 (d, J = 12.1 Hz, 1H), 3.95 (s, 3H), 
3.67 (s, 3H), 2.88 (dd, J = 18.4, 5.6 Hz, 1H), 2.62 (m, 1H), 2.41 (q, 
(dd, J = 18.4, 10.8 Hz, 1H), 1.20 (t, 
(CDCl3, 100 MHz) : δ 184.2, 173.4, 169.4, 168.5, 161.2, 159.2, 145.5, 109.7, 108.4, 
105.2, 85.0, 75.5, 74.6, 56.6, 53.2, 33.3, 28.4, 27.6, 17.1, 9.2
calcd for C20H22O8I, 517.0359 
IPA Chiralcel®OD (Chiral T
enantiomeric excess for (+)-190
(±)-190: 
93 % ee (+)-190: 
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J = 7.7 Hz, 2H), 2.36 
J = 7.6 Hz, 3H), 1.03 (d, J = 6.5 Hz, 3H); 13
; HRMS-ESI (m/z): [M+H
; found, 517.0358. Enantiomers were separated using a 10% 
echnologies Inc., 250 × 4.6 mm I.D.) column
 after kinetic resolution was 93 %. 
 
 
C NMR 
]+ 
. The 
Recrystallization of (+)-190: 110 mg 93 % ee 
which followed by the addition of hexanes (10 mL). The reaction mixture was placed in a 
-20 °C refrigerator overnight in which case the racemate precipitated from the solution. 
After filtration of the solid, the solution was concentrated 
mg, 83 %). [α]D27= 84.3 ° (c= 0.1, CH
>99 % ee (+)-190: 
(-)-189: 1H NMR, 13C NMR, IR, and HRMS for 
for (±)-189. Enantiomers were separated by 10% IPA
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(+)-190 was dissolved in 3 mL of CH
in vacuo, to afford (+)
2Cl2).  
 
(-)-189 were identical to data reported 
 Chiralcel®OD (Chiral 
2Cl2, 
-190 (91 
Technologies Inc., 250 × 4.6 mm 
kinetic resolution was 93 %. 
(±)-189: 
93 % ee (-)-189: 
 
Recrystallization of (-)-189: 96 mg 93 % ee 
by rotovaping of the solvent afforded an oily residue. The corresponding oil was left on 
the bench overnight in which case 
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I.D.) column. The enantiomeric excess for (-)-18
 
 
 
 
(-)-189 was dissolved in CH2Cl2, 
(-)-189 was obtained as clear yellow crystals. After 
9 after 
followed 
removal of the residue oil, (-)-18
CH2Cl2).    
>99 % ee (-)-189: 
 
O
MOMO O OMe
CO2Me
OCOEt
Bu3Sn
Me
(-)-191
Ester Dimeric Tetrahydroxanthone
0.069 mmol), and freshly prepared 
open tube (Note: if commercial CuCl was used, th
atmosphere in comparable yield)
reaction mixture was stirred at room temperature for 12 h. 
clear yellow to cloudy to completely dark
saturated NH4Cl solution and 
concentrating at 40 oC in vacuo
TLC (hexanes/EtOAc = 1: 2) to 
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9 (82 mg, 85 %) was obtained. [α]D28= -55.3 °
 
 
CuCl (5 equiv)
DMA, air, rt, 12 h
60 %
O
OH O OMe
OCOEtMeO O
O
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O
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 (+)-192: MOM-protected stannane (-)-191
CuCl (34 mg, 0.35 mmol, 5 equiv) were placed
e reaction could proceed under 
. Next, 0.7 mL of DMA was added into the tube and 
(Note: the reaction turn
). The mixture was quenched with 
was extracted 5 times with 3 mL EtOAc. After 
, the crude product was directly purified by preprative
afford dimeric tetrahydroxanthone (+)-192 (16
 (c= 0.1, 
 (50 mg, 
 in an 
a N2 
the 
ed from 
3 mL of 
 
 mg, 60 
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%) as a yellow solid. (Note: The C2 and Cs dimers have similar 1H NMR spectra, and 
were inseparable by silica gel chromatography. If the Cs compound was present, an 
additional phenol signal δ = 12.93 could be observed in the 1H NMR spectrum). (+)-192: 
Rf = 0.31 (hexanes/EtOAc = 1: 2); melting point: >230 oC (CH2Cl2); IR (thin film): νmax 
2962, 1754, 1633, 1584, 1566, 1422, 1357, 1220, 1042, 816 cm-1; 1H NMR (CDCl3, 500 
MHz): δ 12.90 (s, 2H), 7.40 (d, J = 8.5 Hz, 2H), 6.45 (d, J = 8.5 Hz, 2H), 5.37 (d, J = 
12.0 Hz, 2H), 3.91 (s, 6H), 3.69 (s, 6H), 2.85 (dd, J = 18.3, 5.5 Hz, 2H), 2.61 (m, 2H), 
2.42(1) (q, J = 7.6 Hz, 2H), 2.41(5) (q, J = 7.6 Hz, 2H), 2.36 (dd, J = 18.3, 10.8 Hz, 2H), 
1.21 (dd, J = 7.6, 7.6 Hz, 6H), 1.03 (d, J = 6.5 Hz, 6H); 13C NMR (CDCl3, 100 MHz) : δ 
185.2, 173.5, 169.7, 167.1, 160.1, 158.1, 139.7, 117.7, 108.0, 106.6, 106.2, 84.8, 75.8, 
56.5, 53.1, 33.4, 28.5, 27.7, 17.1, 9.2; HRMS-ESI (m/z): [M+H]+ calcd for C40H43O16, 
779.2551; found, 779.2559; [α]D25= 52.7 ° (c= 0.1, CH2Cl2). 
 
 
Secalonic Acid D (5): Dimeric tetrahydroxanthone (+)-192 (7.0 mg, 0.0090 mmol) was 
dissolved in 4 mL of acetone and 2 mL of 3M HCl solution was added. The reaction was 
warmed to 60 oC and was stirred under argon for 20 h. After cooling down to room 
temperature, the solution was diluted with 5 mL of ethyl acetate and the organics were 
washed 1 x 5 mL water, followed by brine, dried over sodium sulfate, filtered, and 
concentrated in vacuo to afford a yellow residue which was purified by preparative 
HPLC (C18, 10-75% CH3CN/water). The fractions were extracted with EtOAc, washed 
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with brine, dried over sodium sulfate, and concentrated to afford secalonic acid D 5 (4.6 
mg, 81 %) as a pale yellow solid. 5: melting point: >230 oC (CH2Cl2) (lit: 281-283 oC in 
evacuated capillary, 255-259 oC on hot stage; 253-255 oC); IR (thin film): νmax 3464, 
1726, 1610, 1585, 1566, 1436, 1233, 1067 cm-1; 1H NMR (CDCl3, 500 MHz): δ 13.78(s, 
2H), 11.75(s, 2H), 7.46 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 3.93 (dd, J = 11.3, 
1.6 Hz, 2H), 3.73 (s, 6H), 2.81 (d, J = 2.2 Hz, 2H), 2.74 (dd, J = 19.1, 6.2 Hz, 2H), 2.41 
(m, 2H), 2.32 (dd, J = 19.1, 10.6 Hz, 2H), 1.17 (d, J = 6.4 Hz, 6H); 1H NMR (D6-DMSO, 
500 MHz): δ 13.60(s, 2H), 11.66(s, 2H), 7.45 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 
2H), 6.01 (d, J = 5.4 Hz, 2H), 3.81 (dd, J = 10.9, 5.6 Hz, 2H), 3.60 (s, 6H), 2.66 (dd, J = 
19.2, 5.4 Hz, 2H), 2.47 (dd, J = 19.2, 10.8 Hz, 2H), 2.41 (m, 2H), 1.03 (d, J = 5.5 Hz, 
6H);13C NMR (CDCl3, 125 MHz) : δ 187.2, 177.5, 170.3, 159.4, 158.3, 140.2, 118.2, 
107.6, 106.9, 101.5, 84.7, 76.9(7), 53.3, 36.3, 29.2, 18.0; HRMS-ESI (m/z): [M+H]+ 
calcd for C32H31O16, 639.1714; found, 639.1716; [α]D26= 62.0 ° (c= 0.1, CHCl3) (lit. 
[α]D26= 64.0 ° (c= 0.14, CHCl3)). 
 
 
Dimeric Tetrahydroxanthone (-)-194: MOM-protected stannane (+)-193 (50 mg, 0.071 
mmol), and freshly prepared CuCl (34 mg, 0.35 mmol, 5 equiv) were placed in an open 
tube (Note: if commercial CuCl was used, the reaction could proceed under a N2 
atmosphere in comparable yield). Next, 0.7 mL of DMA was added into the tube and the 
reaction mixture was stirred at room temperature for 12 h. (Note: the reaction turned from 
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clear yellow cloudy to completely dark). The mixture was quenched with 3 mL of a 
saturated NH4Cl solution and was extracted 5 times with 3 mL EtOAc. After 
concentrating at 40 oC in vacuo, the crude product was directly purified by preparative 
TLC (hexane/EtOAc = 1: 2) to afford dimeric tetrahydroxanthone (-)-194 (16 mg, 60 %) 
as a yellow solid. (Note: The C2 and Cs dimers have similar 1H NMR spectra and were 
inseparable by silica gel chromatography. If any Cs compound was present, an additional 
phenol signal δ = 12.95 could be observed). (-)-194: Rf = 0.33 (hexanes/EtOAc = 1: 2); 
melting point: >230 oC (CH2Cl2/MeOH); IR (thin film): νmax 2953, 1753, 1632, 1586, 
1566, 1426, 1354, 1220, 1034, 816 cm-1; 1H NMR (CDCl3, 400 MHz): δ 12.92 (s, 2H), 
7.43 (d, J = 8.5 Hz, 2H), 6.50 (d, J = 8.5 Hz, 2H), 5.26 (d, J = 6.7 Hz, 2H), 4.76 (d, J = 
6.7 Hz, 2H), 3.90 (d, J = 12.8 Hz, 2H), 3.88 (s, 6H), 3.68 (s, 6H), 3.49 (s, 6H), 2.79 (dd, J 
= 18.2, 5.3 Hz, 2H), 2.53 (m, 2H), 2.26 (dd, J = 18.3, 11.1 Hz, 2H), 1.17 (d, J = 6.4 Hz, 
6H); 13C NMR (CDCl3, 100 MHz) : δ 185.6, 169.9, 167.1, 160.2, 158.3, 139.6, 117.7, 
108.2, 106.5, 106.4, 97.6, 87.7, 80.5, 56.6, 56.3, 53.0, 33.6, 29.7, 18.1; HRMS-ESI (m/z): 
[M+H]+ calcd for C38H43O16, 755.2551; found, 755.2563; [α]D29= -56.5 ° (c= 0.1, 
CH2Cl2). 
 
 
Secalonic Acid A (ent-2): Dimeric tetrahydroxanthone (-)-194 (5.0 mg, 0.0066 mmol) 
was dissolved in 1.5 mL of acetonitrile and 1.5 mL of 3M HCl solution. The reaction was 
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warmed to 60 oC and stirred for 30 min. After cooling to room temperature, the solution 
was directly purified by preparative HPLC (C18, 10-75% CH3CN in water). The fractions 
were extracted with EtOAc, washed with brine, dried over sodium sulfate, and 
concentrated in vacuo to afford secalonic acid A (ent-5) (3.6 mg, 85 %) as a pale yellow 
solid. ent-5:1H NMR, 13C NMR, IR, and HRMS for ent-5 were identical to data reported 
for 5. [α]D26= -64.1 ° (c= 0.1, CHCl3). 
 
 
3.7 NMR Data and UPLC Comparisons for Secalonic Acid D 
A) 1H NMR spectrum of synthetic secalonic acid D in comparison with literature data (CDCl3, 
7.26 ppm):  
 
 
 
 
 
Position 
δ (JH-H in Hz) 
Natural Product (this work) 
( 400 MHz, CDCl3)81 
Natural Products 
( 100 MHz, CDCl3)3g 
Synthetic (this work) 
( 500 MHz, CDCl3) 
3/3' 7.46 (d, J = 8.5, 2H) 7.74 (d, J = 8, 2H) 7.46 (d, J = 8.5, 2H) 
4/4' 6.63 (d, J = 8.5, 2H) 6.60 (d, J = 8, 2H) 6.63 (d, J = 8.5, 2H) 
5/5' 3.93 (dd, J = 11.2, 1.9, 2H) 3.88 (br d, J = 11, 2H) 3.93 (dd, J = 11.3, 1.6, 2H) 
6/6' 2.41 (m, 2H) -- 2.41 (m, 2H) 
7α/7α' 2.32 (dd, J = 18.8, 10.6, 2H) -- 2.32 (dd, J = 19.1, 10.6, 2H) 
7β/7β' 2.74 (dd, J = 18.8, 5.9, 2H) 2.74 (br d, 2H) 2.74 (dd, J = 19.1, 6.2, 2H) 
11/11' 1.17 (d, J = 6.3, 6H) 1.16 (d, J = 6, 6H) 1.17 (d, J = 6.4, 6H) 
13/13' 3.73 (s, 6H) 3.68 (s, 6H) 3.73 (s, 3H) 
1-OH/1'-OH 11.76 (s, 2H) 11.70 (s, 2H) 11.75 (s, 2H) 
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5-OH/5'-
OH* 
2.81 (d, J = 2.2, 2H) 1.54 (br s, 2H) 2.81 (d, J = 2.2, 2H) 
8-OH/8'-OH 13.78 (s, 2H) 13.78 (s, 2H) 13.78 (s, 2H) 
*The chemical shift of the 5-OH peak was found to vary with concentration. 
 
 
B) 1H NMR spectrum of synthetic secalonic acid D in comparison with literature data (D6-
DMSO, 2.50 ppm):  
 
 
 
 
 
Position 
δ (JH-H in Hz) 
Natural Product (this work) 
( 400 MHz, D6-DMSO) 
Natural Product 
( 600 MHz, D6-DMSO)82 
Synthetic (this work) 
( 500 MHz, D6-DMSO) 
3/3' 7.46 (d, J = 8.5, 2H) 7.45 (d, J = 8.42, 2H) 7.45 (d, J = 8.5, 2H) 
4/4' 6.63 (d, J = 8.5, 2H) 6.63 (d, J = 8.42, 2H) 6.62 (d, J = 8.5, 2H) 
5/5' 3.81 (dd, J = 11.1, 5.7, 2H) 3.81 (d, J = 9.51, 2H) 3.81 (dd, J = 10.9, 5.6, 2H) 
6/6' 2.30 (m, 2H) 2.31 (m, 2H) 2.30 (m, 2H) 
7α/7α' 2.48 (dd, J = 19.1, 10.9, 2H) 2.49 (dd, J = 19.80, 6.22, 
2H) 
2.47 (dd, J = 19.2, 10.8, 
2H) 
7β/7β' 2.66 (dd, J = 19.0, 6.0, 2H) 2.65 (dd, J = 19.80, 8.42, 
2H) 
2.66 (dd, J = 19.2, 5.4, 2H) 
11/11' 1.03 (d, J = 6.5, 6H) 1.03 (d, J = 6.22, 6H) 1.03 (d, J = 5.5, 6H) 
13/13' 3.61 (s, 6H) 3.61 (s, 6H) 3.60 (s, 3H) 
1-OH/1'-OH 11.64 (s, 2H) 11.62 (s, 2H) 11.66 (s, 2H) 
5-OH/5'-
OH* 
6.04 (d, J = 5.8, 2H) -- 6.01 (d, J = 5.4, 2H) 
8-OH/8'-OH 13.60 (s, 2H) 13.60 (s, 2H) 13.60 (s, 2H) 
*The chemical shift of the 5-OH peak was found to vary with concentration. 
 
 
C) 13C NMR spectrum of synthetic secalonic acid D in comparison with literature data: 
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Position 
δ 
Natural Product (this work) 
( 100 MHz, CDCl3) 
Synthetic (this work) 
( 125 MHz, CDCl3) 
Natural Product  
( 150 MHz, D6-
DMSO)82 
1 159.4 159.4 158.9 
2 118.2 118.2 117.3 
3 140.2 140.2 140.2 
4 107.6 107.6 107.5 
4a 158.3 158.3 158.5 
5 --* 76.9(7)** 75.2 
6 29.2 29.2 29.9 
7 36.2 36.3 35.8 
8 177.5 177.5 178.2 
8a 101.5 101.5 101.7 
9 187.1 187.2 186.6 
9a 106.8 106.9 106.3 
10a 84.7 84.7 85.2 
11 18.0 18.0 17.8 
12 170.3 170.3 170.0 
13 53.3 53.3 52.6 
*Due to limited amount, the signal was overlapped with the CDCl3 peak. 
**This chemical shift was also verified by HMQC correlation. 
 
D) UPLC comparison between synthetic secalonic acid D and the natural sample: 
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Natural Sample
Synthetic Sample
Natural Sample and Synthetic Sample coinjection
 
 
3.8 X-ray Crystallographic Data 
X-ray crystallographic data for compound (-)-173: 
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Crystals of compound (-)-173 suitable for X-ray analysis were obtained by slow 
evaporation from CHCl3/MeOH. Crystallographic data have been deposited with the 
Cambridge Cystallograhic Data Centre (CCDC# 961591). Copies of the data can be 
obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Data collection: APEX2 (Bruker, 2006); cell refinement: SAINT (Bruker, 2006); data 
reduction: SAINT (Bruker, 2006); program(s) used to solve structure: SHELXS97 
(Sheldrick, 1990); program(s) used to refine structure: SHELX, G.M. Sheldrick, Acta 
Cryst. (2008). A64, 112-122; molecular graphics: O. V. Dolomanov, L. J. Bourhis, R. J. 
Gildea, J. A. K. Howard and H. Puschmann, OLEX2: a complete structure solution, 
refinement and analysis program. J. Appl. Cryst. 2009, 42, 339-341.; software used to 
prepare material for publication: O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. 
Howard and H. Puschmann, OLEX2: a complete structure solution, refinement and 
analysis program. J. Appl. Cryst. 2009, 42, 339-341. 
Crystal data 
  C16H16O7 Z = 4 
Mr = 320.29 F(000) = 672 
Triclinic, P1 Dx = 1.432 Mg m-3 
a = 7.5282 (2) Å Cu Ka radiation, l = 1.54178 Å 
b = 13.8718 (4) Å Cell parameters from 9941 reflections 
c = 14.4637 (4) Å q = 3.1–66.6° 
a = 95.790 (1)° m = 0.96 mm-1 
b = 97.794 (1)° T = 100 K 
g = 92.714 (1)° , colorless 
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V = 1485.99 (7)  Å3 0.14 × 0.04 × 0.03 mm 
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
9780 independent reflections 
Radiation source: rotating anode 9524 reflections with I > 2s(I) 
multilayer Rint = 0.040 
f & w scans qmax = 66.6°, qmin = 3.1° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -8Æ8 
Tmin = 0.684, Tmax = 0.753 k = -16Æ15 
27726 measured reflections l = -17Æ17 
 
    
Refinement 
  Refinement on F2 Hydrogen site location: mixed 
Least-squares matrix: full H atoms treated by a mixture of independent 
and constrained refinement 
R[F2 > 2s(F2)] = 0.045  w = 1/[s2(Fo2) + (0.0667P)2 + 1.193P]   
where P = (Fo2 + 2Fc2)/3 
wR(F2) = 0.130 (D/s)max = 0.018 
S = 1.12 Dñmax = 0.24 e Å-3 
9780 reflections Dñmin = -0.28 e Å-3 
847 parameters Absolute structure:  Flack x determined using 
4416 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Parsons 
and Flack (2004), Acta Cryst. A60, s61). 
3 restraints Flack parameter: 0.02 (14) 
 
     
Special details 
 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  are 
estimated using the full covariance matrix.  The cell esds are taken  into account individually in 
the estimation of esds in distances, angles  and torsion angles; correlations between esds in cell 
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parameters are only  used when they are defined by crystal symmetry.  An approximate 
(isotropic)  treatment of cell esds is used for estimating esds involving l.s. planes. 
 
Refinement. CheckCIF Alerts and Discussion: 
 PLAT089_ALERT_3_C Poor Data / Parameter Ratio (Zmax < 18) .. 6.19  
PLAT340_ALERT_3_C Low Bond Precision on  C-C Bonds .. 0.0064 Ang.  
 Discussion:  The low data-to-parameter ratio is intrinsic for this sample in P1  with Z' = 4 
and copper radiation.  The resolution limit on this instrument is  0.84 Angstroms, and to that 
resolution there are not enough data to achieve a  ratio of greater than 8 for 847 parameters.  An 
attempt was made to use  restraints via the SHELX SAME command to relate the two pairs of 
isostructural  independent residues, however the imposition of these restraints led to a  
significantly poorer model as evidenced by the eleveated R1 value of over 9%. 
 The low data-to-parameter ratio also gives rise to the low C-C bond precision.   Despite these 
limitations the resulting model is more than adequate to satisfy  the goals of this crystallographic 
experiment. 
 
 
      
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq  
C1B 0.9772 (6) 0.2553 (4) 0.7593 (3) 0.0218 (10)  
H1BA 0.8794 0.2169 0.7181 0.033*  
H1BB 1.0857 0.2188 0.7636 0.033*  
H1BC 1.0010 0.3165 0.7335 0.033*  
C2B 0.7678 (6) 0.3113 (3) 0.8617 (3) 0.0157 (9)  
C3B 0.6278 (6) 0.3108 (4) 0.7771 (3) 0.0182 (9)  
H3BA 0.5813 0.2431 0.7557 0.022*  
H3BB 0.6835 0.3364 0.7257 0.022*  
C4B 0.4721 (6) 0.3719 (4) 0.7983 (3) 0.0197 (10)  
H4BA 0.5120 0.4416 0.8048 0.024*  
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H4BB 0.3728 0.3600 0.7453 0.024*  
C5B 0.4048 (6) 0.3474 (3) 0.8878 (3) 0.0167 (9)  
H5B 0.3664 0.2768 0.8814 0.020*  
C6B 0.5546 (6) 0.3704 (3) 0.9723 (3) 0.0162 (9)  
C7B 0.7375 (6) 0.3415 (3) 0.9508 (3) 0.0162 (9)  
C8B 0.5569 (6) 0.4811 (4) 1.0028 (3) 0.0192 (10)  
C9B 0.4424 (8) 0.6018 (4) 1.0986 (4) 0.0307 (12)  
H9BA 0.5604 0.6364 1.1172 0.046*  
H9BB 0.3722 0.6093 1.1509 0.046*  
H9BC 0.3790 0.6288 1.0443 0.046*  
C10B 0.8728 (6) 0.3447 (3) 1.0328 (3) 0.0155 (9)  
C11B 0.8044 (6) 0.3439 (3) 1.1235 (3) 0.0175 (9)  
C12B 0.6199 (6) 0.3287 (3) 1.1266 (3) 0.0160 (9)  
C13B 0.5537 (6) 0.3179 (3) 1.2105 (3) 0.0183 (9)  
H13B 0.4288 0.3054 1.2115 0.022*  
C14B 0.6745 (6) 0.3259 (4) 1.2926 (3) 0.0200 (10)  
H14B 0.6301 0.3203 1.3504 0.024*  
C15B 0.8589 (6) 0.3420 (3) 1.2934 (3) 0.0183 (9)  
H15B 0.9387 0.3472 1.3507 0.022*  
C16B 0.9238 (6) 0.3503 (3) 1.2089 (3) 0.0163 (9)  
O1B 0.9261 (4) 0.2756 (3) 0.8518 (2) 0.0204 (7)  
O2B 0.2550 (4) 0.4026 (3) 0.8990 (2) 0.0223 (7)  
H2B 0.1887 0.3748 0.9317 0.033*  
O3B 0.4652 (4) 0.5004 (3) 1.0744 (2) 0.0249 (8)  
O4B 0.6286 (5) 0.5409 (3) 0.9633 (2) 0.0255 (8)  
O5B 0.4994 (4) 0.3179 (3) 1.0458 (2) 0.0192 (7)  
O6B 1.0385 (4) 0.3465 (3) 1.0312 (2) 0.0205 (7)  
O7B 1.1034 (4) 0.3628 (3) 1.2094 (2) 0.0211 (7)  
H7B 1.1254 0.3642 1.1541 0.032*  
O2C -0.3640 (4) 0.6661 (3) 0.6765 (2) 0.0233 (7)  
H2C -0.444 (9) 0.626 (5) 0.641 (5) 0.035*  
C1C 0.3724 (6) 0.8163 (3) 0.5485 (3) 0.0197 (9)  
H1CA 0.2858 0.8521 0.5105 0.029*  
H1CB 0.4826 0.8120 0.5196 0.029*  
H1CC 0.4005 0.8504 0.6119 0.029*  
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C2C 0.1400 (6) 0.7086 (3) 0.5868 (3) 0.0157 (9)  
C3C 0.0290 (6) 0.7942 (4) 0.6004 (3) 0.0200 (10)  
H3CA -0.0229 0.8117 0.5382 0.024*  
H3CB 0.1078 0.8502 0.6326 0.024*  
C4C -0.1221 (6) 0.7758 (4) 0.6572 (3) 0.0216 (10)  
H4CA -0.2072 0.8278 0.6512 0.026*  
H4CB -0.0720 0.7774 0.7243 0.026*  
C5C -0.2221 (6) 0.6775 (3) 0.6236 (3) 0.0182 (9)  
H5C -0.2739 0.6773 0.5562 0.022*  
C6C -0.0954 (6) 0.5942 (3) 0.6319 (3) 0.0170 (9)  
C7C 0.0851 (6) 0.6164 (4) 0.6006 (3) 0.0170 (9)  
C8C -0.0764 (5) 0.5645 (4) 0.7327 (3) 0.0173 (9)  
C9C 0.0270 (7) 0.6102 (4) 0.8918 (3) 0.0251 (11)  
H9CA -0.0923 0.5912 0.9063 0.038*  
H9CB 0.0770 0.6678 0.9337 0.038*  
H9CC 0.1062 0.5568 0.9005 0.038*  
C10C 0.1897 (6) 0.5325 (3) 0.5845 (3) 0.0147 (9)  
C11C 0.0899 (6) 0.4379 (4) 0.5674 (3) 0.0167 (9)  
C12C -0.0994 (6) 0.4316 (3) 0.5601 (3) 0.0156 (9)  
C13C -0.1983 (6) 0.3429 (3) 0.5370 (3) 0.0156 (9)  
H13C -0.3257 0.3395 0.5319 0.019*  
C14C -0.1067 (6) 0.2597 (4) 0.5218 (3) 0.0189 (9)  
H14C -0.1732 0.1989 0.5061 0.023*  
C15C 0.0789 (6) 0.2623 (3) 0.5287 (3) 0.0169 (9)  
H15C 0.1383 0.2040 0.5189 0.020*  
C16C 0.1773 (6) 0.3508 (4) 0.5502 (3) 0.0170 (9)  
O1C 0.2967 (4) 0.7206 (2) 0.5535 (2) 0.0190 (7)  
O3C 0.0123 (4) 0.6323 (2) 0.7945 (2) 0.0206 (7)  
O4C -0.1364 (4) 0.4872 (3) 0.7514 (2) 0.0249 (8)  
O5C -0.1919 (4) 0.5129 (2) 0.5718 (2) 0.0167 (6)  
O6C 0.3555 (4) 0.5370 (2) 0.5822 (2) 0.0198 (7)  
O7C 0.3582 (4) 0.3528 (3) 0.5536 (2) 0.0207 (7)  
H7C 0.4004 0.4106 0.5622 0.031*  
C1D 0.5586 (7) 0.5644 (4) 0.3786 (4) 0.0278 (11)  
H1DA 0.4976 0.5343 0.4251 0.042*  
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H1DB 0.6884 0.5704 0.3997 0.042*  
H1DC 0.5340 0.5238 0.3182 0.042*  
C2D 0.3212 (6) 0.6686 (4) 0.3362 (3) 0.0198 (10)  
C3D 0.1922 (6) 0.5822 (4) 0.3309 (3) 0.0224 (10)  
H3DA 0.1770 0.5688 0.3954 0.027*  
H3DB 0.2438 0.5250 0.3004 0.027*  
C4D 0.0090 (7) 0.5955 (4) 0.2768 (4) 0.0243 (10)  
H4DA 0.0163 0.5871 0.2086 0.029*  
H4DB -0.0785 0.5450 0.2900 0.029*  
C5D -0.0559 (6) 0.6944 (4) 0.3029 (3) 0.0221 (10)  
H5D -0.0646 0.7023 0.3716 0.027*  
C6D 0.0758 (6) 0.7755 (4) 0.2811 (3) 0.0191 (10)  
C7D 0.2707 (6) 0.7576 (3) 0.3138 (3) 0.0167 (9)  
C8D 0.0459 (6) 0.7794 (3) 0.1735 (3) 0.0176 (9)  
C9D -0.1176 (7) 0.8383 (4) 0.0447 (3) 0.0275 (11)  
H9DA -0.0132 0.8583 0.0159 0.041*  
H9DB -0.2148 0.8812 0.0298 0.041*  
H9DC -0.1581 0.7713 0.0203 0.041*  
C10D 0.3943 (6) 0.8413 (4) 0.3160 (3) 0.0186 (10)  
C11D 0.3151 (6) 0.9357 (4) 0.3128 (3) 0.0183 (9)  
C12D 0.1326 (6) 0.9451 (4) 0.3226 (3) 0.0180 (9)  
C13D 0.0585 (6) 1.0337 (4) 0.3289 (3) 0.0210 (10)  
H13D -0.0639 1.0386 0.3372 0.025*  
C14D 0.1675 (6) 1.1165 (4) 0.3229 (3) 0.0202 (10)  
H14D 0.1173 1.1781 0.3261 0.024*  
C15D 0.3472 (6) 1.1109 (4) 0.3123 (3) 0.0210 (10)  
H15D 0.4184 1.1682 0.3077 0.025*  
C16D 0.4227 (6) 1.0216 (4) 0.3085 (3) 0.0183 (9)  
O1D 0.4937 (4) 0.6596 (2) 0.3678 (2) 0.0218 (7)  
O2D -0.2272 (4) 0.6985 (3) 0.2527 (3) 0.0263 (8)  
H2D -0.2835 0.7406 0.2806 0.039*  
O3D -0.0680 (4) 0.8445 (3) 0.1462 (2) 0.0218 (7)  
O4D 0.1140 (5) 0.7242 (3) 0.1216 (2) 0.0312 (9)  
O5D 0.0242 (4) 0.8640 (2) 0.3285 (2) 0.0186 (7)  
O6D 0.5610 (4) 0.8378 (3) 0.3219 (2) 0.0236 (7)  
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O7D 0.5989 (4) 1.0178 (3) 0.3022 (2) 0.0231 (7)  
H7D 0.6301 0.9611 0.3079 0.035*  
C1A 1.0019 (6) 0.1167 (4) 1.0952 (3) 0.0237 (10)  
H1AA 0.9355 0.1555 1.1378 0.036*  
H1AB 1.1176 0.1509 1.0922 0.036*  
H1AC 1.0225 0.0536 1.1185 0.036*  
C2A 0.7284 (6) 0.0669 (3) 0.9911 (3) 0.0172 (9)  
C3A 0.6326 (6) 0.0642 (4) 1.0758 (3) 0.0222 (10)  
H3AA 0.6136 0.1315 1.1007 0.027*  
H3AB 0.7099 0.0352 1.1253 0.027*  
C4A 0.4521 (6) 0.0066 (4) 1.0549 (3) 0.0214 (10)  
H4AA 0.4720 -0.0636 1.0506 0.026*  
H4AB 0.3821 0.0219 1.1071 0.026*  
C5A 0.3451 (6) 0.0296 (4) 0.9637 (3) 0.0216 (10)  
H5A 0.3206 0.1000 0.9694 0.026*  
C6A 0.4488 (6) 0.0074 (4) 0.8799 (3) 0.0180 (9)  
C7A 0.6471 (6) 0.0379 (3) 0.9023 (3) 0.0174 (9)  
C8A 0.4138 (5) -0.1009 (3) 0.8431 (3) 0.0157 (9)  
C9A 0.4802 (7) -0.2607 (4) 0.8718 (4) 0.0248 (10)  
H9AA 0.3512 -0.2791 0.8597 0.037*  
H9AB 0.5370 -0.2956 0.9224 0.037*  
H9AC 0.5339 -0.2774 0.8147 0.037*  
C10A 0.7401 (6) 0.0348 (3) 0.8194 (3) 0.0147 (9)  
C11A 0.6257 (6) 0.0370 (3) 0.7293 (3) 0.0156 (9)  
C12A 0.4421 (6) 0.0547 (3) 0.7265 (3) 0.0153 (9)  
C13A 0.3354 (6) 0.0679 (3) 0.6437 (3) 0.0179 (9)  
H13A 0.2126 0.0812 0.6432 0.022*  
C14A 0.4125 (6) 0.0613 (4) 0.5611 (3) 0.0193 (9)  
H14A 0.3402 0.0700 0.5038 0.023*  
C15A 0.5915 (6) 0.0424 (3) 0.5599 (3) 0.0178 (9)  
H15A 0.6399 0.0367 0.5024 0.021*  
C16A 0.6993 (6) 0.0319 (3) 0.6438 (3) 0.0158 (9)  
O1A 0.8990 (4) 0.1021 (3) 1.0028 (2) 0.0226 (7)  
O2A 0.1803 (4) -0.0261 (3) 0.9514 (2) 0.0256 (8)  
H2A 0.1042 -0.0008 0.9149 0.038*  
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O3A 0.5076 (4) -0.1560 (2) 0.8994 (2) 0.0211 (7)  
O4A 0.3150 (4) -0.1314 (3) 0.7729 (2) 0.0252 (7)  
O5A 0.3645 (4) 0.0612 (2) 0.8071 (2) 0.0172 (7)  
O6A 0.9060 (4) 0.0298 (2) 0.8217 (2) 0.0201 (7)  
O7A 0.8753 (4) 0.0177 (2) 0.6421 (2) 0.0188 (7)  
H7A 0.9274 0.0173 0.6973 0.028*  
 
  
X-ray crystallographic data for compound (+)-192: 
 
Crystals of compound (+)-192 suitable for X-ray analysis were obtained by slow 
evaporation from CH2Cl2/MeOH. Crystallographic data have been deposited with the 
Cambridge Cystallograhic Data Centre (CCDC# 961592). Copies of the data can be 
obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Data collection: APEX2 (Bruker, 2006); cell refinement: SAINT (Bruker, 2006); data 
reduction: SAINT (Bruker, 2006); program(s) used to refine structure: SHELX, G.M. 
Sheldrick, Acta Cryst. (2008). A64, 112-122; molecular graphics: O. V. Dolomanov, L. J. 
Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, OLEX2: a complete structure 
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solution, refinement and analysis program. J. Appl. Cryst. 2009, 42, 339-341.; software 
used to prepare material for publication: O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. 
A. K. Howard and H. Puschmann, OLEX2: a complete structure solution, refinement and 
analysis program. J. Appl. Cryst. 2009, 42, 339-341. 
Crystal data 
  C40H42O16 F(000) = 820 
Mr = 778.73 Dx = 1.415 Mg m-3 
Monoclinic, C2 Cu Ka radiation, l = 1.54178 Å 
Hall symbol:  C 2y Cell parameters from 9067 reflections 
a = 14.7105 (5) Å q = 5.4–66.5° 
b = 7.6108 (3) Å m = 0.93 mm-1 
c = 16.3778 (5) Å T = 100 K 
b = 94.668 (1)° Block, yellow 
V = 1827.55 (11)  Å3 0.12 × 0.09 × 0.08 mm 
Z = 2  
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
3173 independent reflections 
Radiation source: rotating anode 3166 reflections with I > 2s(I) 
multilayer Rint = 0.034 
w & f scans qmax = 66.6°, qmin = 2.7° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -17®17 
Tmin = 0.717, Tmax = 0.753 k = -8®9 
46030 measured reflections l = -19®19 
 
    
Refinement 
  Refinement on F2 Secondary atom site location: inferred from 
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neighbouring sites 
Least-squares matrix: full Hydrogen site location: mixed 
R[F2 > 2s(F2)] = 0.025 H atoms treated by a mixture of independent 
and constrained refinement 
wR(F2) = 0.085  w = 1/[s2(Fo2) + (0.0553P)2 + 0.3657P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.25 (D/s)max = 0.002 
3173 reflections Dñmax = 0.28 e Å-3 
260 parameters Dñmin = -0.33 e Å-3 
1 restraint Absolute structure:  Flack x determined using 
1426 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Parsons 
and Flack (2004), Acta Cryst. A60, s61). 
Primary atom site location: structure-invariant 
direct methods 
Flack parameter: 0.03 (3) 
 
     
Special details 
 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  
are estimated using the full covariance matrix.  The cell esds are taken  into account 
individually in the estimation of esds in distances, angles  and torsion angles; correlations 
between esds in cell parameters are only  used when they are defined by crystal 
symmetry.  An approximate (isotropic)  treatment of cell esds is used for estimating esds 
involving l.s. planes. 
 
Refinement. CheckCIF Alert and Discussion: 
 PLAT089_ALERT_3_C Poor Data / Parameter Ratio (Zmax < 18) .. 6.73 
 Discussion: 
 
 
      
Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
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 x y z Uiso*/Ueq  
O1 0.24591 (8) 0.3284 (2) 0.10722 (7) 0.0157 (3)  
O2 0.17302 (8) 0.47131 (19) 0.25419 (8) 0.0149 (3)  
O3 0.45263 (8) 0.4489 (2) 0.40019 (8) 0.0184 (3)  
O4 0.15792 (9) 0.3418 (2) 0.54045 (8) 0.0194 (3)  
O5 0.30708 (9) 0.3181 (2) 0.47298 (8) 0.0208 (3)  
O6 0.13743 (9) 0.1296 (2) 0.22556 (9) 0.0219 (3)  
O7 0.28237 (9) 0.0523 (2) 0.26256 (9) 0.0203 (3)  
O8 0.18022 (10) 0.5851 (2) 0.06538 (9) 0.0253 (4)  
C1 0.09083 (17) 0.4160 (3) -0.07583 (13) 0.0282 (5)  
H1A 0.1379 0.4774 -0.1038 0.042*  
H1B 0.0480 0.5019 -0.0563 0.042*  
H1C 0.0580 0.3346 -0.1141 0.042*  
C2 0.13537 (14) 0.3136 (3) -0.00324 (12) 0.0214 (5)  
H2A 0.0875 0.2500 0.0240 0.026*  
H2B 0.1774 0.2251 -0.0236 0.026*  
C3 0.18762 (13) 0.4287 (3) 0.05864 (12) 0.0171 (4)  
C4 0.29700 (13) 0.4106 (3) 0.17597 (11) 0.0145 (4)  
H4A 0.2944 0.5411 0.1692 0.017*  
C5 0.25174 (12) 0.3587 (3) 0.25375 (11) 0.0140 (4)  
C6 0.12662 (13) 0.4611 (3) 0.32366 (11) 0.0144 (4)  
C7 0.03663 (13) 0.5134 (3) 0.31714 (12) 0.0181 (4)  
H7 0.0079 0.5503 0.2659 0.022*  
C8 -0.01161 (13) 0.5112 (3) 0.38706 (12) 0.0183 (4)  
H8 -0.0733 0.5496 0.3825 0.022*  
C9 0.02670 (12) 0.4550 (3) 0.46333 (11) 0.0162 (4)  
C10 0.11853 (13) 0.4002 (3) 0.46859 (12) 0.0154 (4)  
C11 0.16966 (13) 0.4044 (3) 0.39897 (12) 0.0146 (4)  
C12 0.39583 (12) 0.3500 (3) 0.17799 (11) 0.0149 (4)  
H12 0.3975 0.2200 0.1870 0.018*  
C13 0.44894 (12) 0.4384 (3) 0.25071 (11) 0.0155 (4)  
H13A 0.5107 0.3860 0.2581 0.019*  
H13B 0.4561 0.5647 0.2383 0.019*  
C14 0.40392 (13) 0.4210 (3) 0.32927 (11) 0.0137 (4)  
C15 0.54787 (12) 0.4936 (3) 0.40078 (12) 0.0215 (5)  
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H15A 0.5711 0.5272 0.4564 0.032*  
H15B 0.5552 0.5921 0.3634 0.032*  
H15C 0.5820 0.3919 0.3830 0.032*  
C16 0.31381 (13) 0.3827 (3) 0.33106 (11) 0.0141 (4)  
C17 0.26768 (13) 0.3640 (3) 0.40634 (11) 0.0145 (4)  
C18 0.21525 (12) 0.1679 (3) 0.24524 (11) 0.0148 (4)  
C19 0.25591 (17) -0.1312 (3) 0.25702 (15) 0.0261 (5)  
H19A 0.3089 -0.2052 0.2730 0.039*  
H19B 0.2331 -0.1586 0.2006 0.039*  
H19C 0.2078 -0.1537 0.2937 0.039*  
C20 0.43957 (14) 0.3899 (3) 0.09859 (12) 0.0197 (5)  
H20A 0.5017 0.3424 0.1020 0.030*  
H20B 0.4417 0.5173 0.0904 0.030*  
H20C 0.4034 0.3355 0.0524 0.030*  
H4 0.209 (2) 0.318 (4) 0.5288 (17) 0.030*  
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Key HMQC data for secalonic acid D 
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Chapter 4 
 
Atropselective Syntheses of (-) and (+) Rugulotrosin A Utilizing Point-
to-Axial Chirality Transfer 
 
4.1 Introduction to Rugulotrosins and Related Axially Chiral Biaryl 
Tetrahydroxanthone Natural Products 
        Due to the hindered rotational barriers of highly substituted biaryls and related 
compounds, stereochemistry in the form of axial chirality is generated, often termed 
atropisomerism.83  Atropisomerism widely exists in nature and can lead to biological 
stereoselectivity for molecular targets.84 ,85 ,86   Moreover, in contrast to traditional sp3 
carbon-centered chirality, control of axial chirality and atropisomer selectivity is still 
highly challenging especially in the context of complex natural product synthesis.87,88,89 
During the last decade, tetrahydroxanthones containing biaryl axial chirality 
including the 2,2’-linked natural product10 rugulotrosin A (6) and the 2,4’-linked 
rugulotrosin B (7) (Figure 4.1) have been isolated and characterized. Related hybrid 
chromone lactones/ tetrahydroxanthones including the 2,4'-linked heterodimer gonytolide 
E (195)13 and the 4,4'-linked chromone lactone homodimer gonytolide A (9)12 have also 
been reported. Axially chiral dimers with a methyl or hydroxymethyl instead of a methyl 
ester at the C10a position such as phomalevone A (196),90 ascherxanthone B (197),91 and 
xanthonol (198)92 were also isolated.  
161 
Besides these tetra-substituted biaryl compounds, tri-substituted axially chiral 
compounds including such as bipolarinone (199) have also been discovered in nature.93 
Because of the additional axially chiral center, many of these natural products lack 
assignment of absolute stereochemistry (e.g. rugulotrosin A) or relative stereochemistry 
(e.g. ascherxanthone B, xanthonol). Recently, these interesting molecules have attracted 
Figure 4.1 Axially Chiral Dimeric Tetrahydroxanthone Natural Products 
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significant interest in the synthetic community as evidenced by reports of syntheses of 
both monomeric38-42 and dimeric natural products. However, syntheses of 
tetrahydroxanthones bearing axial chirality including rugulotrosin A (1) and related 
compounds have not yet been described.  
 
4.2 Synthetic Plan to Rugulotrosin A 
       Our plan toward rugulotrosin A (6) started with the synthesis of the protected dimer 
200 (Figure 4.2), which could be derived from the monomeric stannyl or boryl 
tetrahydroxanthone 201. We envisioned that the chiral iodide (-)-202 could be obtained 
by kinetic resolution as has been described in the syntheses of the secalonic acids 
(Chapter 3). The previously synthesized epi-blennolide C (50) may serve as a starting 
material for 202. 
       A key aspect is to establish axial chirality for rugulotrosin A. In order to achieve the 
Figure 4.2 Retrosynthetic Analysis for Rugulotrosin A 
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goal, we envisioned that a point-to-axial chirality transfer strategy94,95,96,97,98,99,100,101,102,103 
could be implemented. However, existing stereocenters in the monomeric 
tetrahydroxanthone system are remote from the emerged biaryl bond (Figure 4.2). In this 
case, we planned to employ transition metal catalysis to bring the two monomers in close 
proximity to maximize chirality transfer to an axially chiral center. 
 
4.3 Point-to-axial Chirality Transfer Strategy 
          In the past few decades, synthetic chemists have developed numerous 
methodologies to achieve atropselective synthesis. Among these different strategies, 
point-to-axial chiral transfer was appealing to us because it would not require any extra 
auxiliaries and the overall approach could be applied to several the tetrahydroxanthone 
natural product syntheses.  
       Evaluation of the literature indicates a number of examples of point-to-axial chirality 
Scheme 4.1 Chirality Transfer in the Synthesis of Calphostin A 
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transfer as a general template for this strategy. During the synthesis of calphostin A 
(Scheme 4.1), Coleman and coworkers97 found that under oxidative coupling reaction 
conditions, substrate 203 could generate an astonishing 8:1 ratio favoring atropisomer 
204.  Interestingly, the Broka group98 also reported that starting from a similar compound 
205, the other atropisomer 206 was favored.  Neither author provided a rationale for the 
observed selectivity.  
        The natural products korupensamine A (208) and B (209) are atropisomers (Scheme 
4.2).  Both compounds have proven to be ideal targets to study atropselectivity for 
synthetic chemists.  Lipshutz and coworkers95 found that if the diphenylphosphine group 
Scheme 4.2 Chirality Transfer in the Synthesis of Korupensamine 
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shown in Scheme 4.2 was linked to a primary alcohol to form monomer 210, Suzuki 
coupling with borate 211 could selectively provide the P atropisomer 212. They believed 
that the phosphine chelated to Pd was key to achieving an atropselective synthesis. Ten 
years later, they found that if a naphthyl group was attached to form monomer 214, the 
coupling product favored the M diastereomer.96 The authors thought the intramolecular 
p-stacking 216 between the naphthyl moiety of 214 and the tetrahydroisoquinoline could 
explain the observed atropselectivity (Scheme 4.2).   
         Atropisomers often have totally different biological profiles in many natural 
products, such as vancomycin.84-86 Therefore, diastereoselective synthesis of the correct 
atropisomer can be crucial. In Evans’ synthesis of vancomycin, they found that the 
benzylic stereocenter could transfer chirality to the biaryl center efficiently. Under 
Scheme 4.3 Chirality Transfer in the Synthesis of Vancomycin 
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treatment of VOF3, 217 was converted to the P diastereomer with more than 95 % de.  
Meanwhile, diastereomer 218 could only convert to the M diastereomer under the same 
conditions. The explanation of the fully controlled point-to-axial chirality transfer was 
that the 1,3 allylic strain dramatically changed the conformation of the starting material.        
       In 2010, Shaw and coworkers reported the asymmetric synthesis of viriditoxin (221) 
(Scheme 4.4).94 The key transformation was the oxidative coupling of 222 with 
VO(acac)2 and air. The resulting dimer had a 76:24 dr favoring atropisomer 223.  This 
selectivity could be improved to 89:11 with Gong’s binuclear vanadium catalyst (Scheme 
4.4). They proposed that the diastereoselectivity originated from interaction between the 
two monomers when vanadium brought the monomers closer together in space. 
 
 
4.4 Synthesis of Rugulotrosin A 
Scheme 4.4 Chirality Transfer in the Synthesis of Viriditoxin 
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Our synthesis was initiated with chromone 117 which was prepared in greater 
than 50 gram batches and purified by recrystallization (Scheme 4.5). Utilizing 
diisopropylsilyl ditriflate to activate chromone 117 to a siloxybenzopyrylium species 
(Chapter 2), vinylogous addition of 2-trimethylsiloxyfuran was achieved which was 
followed by hydrogenation to afford chromone lactone 138 on a decagram scale (89 % 
yield, dr > 10:1) after purification by trituration. Further treatment of 138 with NaH in 
THF led to the production of epi-blennolide C 50 through Dieckmann cyclization. Due to 
the lability of the vinylogous acid moiety of tetrahydroxanthone 50 by both epimerization 
and tetrahydroxanthone-to-chromone lactone rearrangement, we utilized the neutral 
methylating reagent trimethylsilyldiazomethane to obtain the desired O-methylated 
product 225 in 58 % yield along with isomer 224 (32 % yield). After phenol-directed 
ortho-iodination of 225, the derived aryl iodide 202 was subjected to kinetic resolution 
Scheme 4.5 Scalable Syntheses of Enantiopure Tetrahydroxanthone Monomers 
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using Birman's catalyst104 on a gram scale (s factor ˃200). Chiral monomer (-)-202 was 
isolated in 46 % yield (99 % ee) and the O-acylated product (+)-226 was obtained in 46 % 
yield (99 % ee) after recrystallization.  
       After obtaining the two enantiopure tetrahydroxanthone monomers, our initial plan 
was to employ our stannane dimerization strategy which successfully led to syntheses of 
secalonic acids A and D (Chapter 3). However, after evaluation of various conditions, we 
observed only trace stannylation of iodides 202 or 226 (Scheme 4.6) which may be due 
to steric hindrance of the aryl iodide. Subsequently, we considered that the less bulky 
borate may more readily undergo transmetallation. Gratifyingly, iodide (-)-202 was found 
to be stable under basic conditions and to produce bis(pinacolato) tetrahydroxanthone in 
~40 to 50 % conversion using an Pd(OAc)2/SPhos and two equivalent 
bis(pinacolato)diboron. More surprisingly, iodide (-)-202 generated an inseparable 
mixture of dimeric products (dr = 88: 12) under one-pot Suzuki coupling conditions using 
Pd(OAc)2/SPhos 105 and 0.6 equivalents of bis(pinacolato)diboron. We subsequently 
attempted to establish the stereochemistry of the major atropisomer by NMR studies or 
by acid-mediated deprotection of both atropisomers 227 and 228 to 6 and 232 (Scheme 
4.8)). However, both efforts failed as the axial chiral center is remote from existing 
stereocenters leading to almost identical 1H NMR spectra for both atropisomers of 
rugulotrosin A. Fortunately, single X-ray crystal structure analysis of the major 
atropisomer (-)-227 was obtained (Dr. Jeffery Bacon, BU CIC) which verified that the 
relative stereochemistry was identical to that found in natural rugulotrosin A.12 
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       During our evaluation of dimerization conditions, we found that water was essential 
and that the ratio of atropisomers was dependent on ligands for palladium rather than 
solvent, temperature, or reaction time. Therefore, we focused our efforts on the influence 
of ligands on atropisomeric selectivity (Scheme 4.6). After extensive ligand screening, 
Scheme 4.6 One-pot Suzuki Dimerization of (-)-202 
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we found that monophosphines were crucial for the success of the reaction, and that 
bidentate ligands such as XantPhos or DPEPhos (not shown) failed to provide the desired 
dimeric products. Noteworthy, ligand PPh3 gave a stable Pd complex 229 which was 
verified by both 1H NMR and MS. Besides SPhos (L1), the related ligand RuPhos (L2) 
provided dimeric products in even higher atropselectivity (93:7). Interestingly, we found 
that when the 2' position of the monophosphine ligand did not contain an oxygen atom 
(e.g. carbon atom in XPhos L2 or a nitrogen atom (DavePhos, L4), dimeric products 
were obtained in trace amounts. After experiments with the achiral ligand L5, which 
provided similar results to SPhos, we anticipated that related chiral ligands may achieve 
efficient control of atropselectivity. We began this investigation with (R) and (S)-BI-
DIME ligands L6,106,107 which recently have shown excellent atropselectivities in biaryl 
couplings. However, neither ligand was able to perform the one-pot dimerization of (-)-
202. Gratifyingly, chiral versions of the SPhos ligands, S-Cy-MOP (L7) and R-Cy-MOP 
(L8), 108 , 109 , 110  both successfully produced dimeric products. The R-Cy-MOP ligand 
provided a satisfactory dr of 95.5:4.5, and the mismatched ligand S-Cy-MOP gave a 
lower dr (81:19) still favoring the same major atropisomer. Even with the increased bulk 
of ligand L9, the dr did not improve. In order to enhance product yield, we prepared the 
Buchwald 3rd generation precatalysts 111  with SPhos, R-Cy-MOP, and S-Cy-MOP. 
Indeed, the precatalyst increased yields for these conditions and maintained 
atropselectivity. Use of bis(neopentyl glycolato)diboron or the more active 
tetrahydroxydiboron112,113 as boron transfer reagents led only to trace amounts of dimeric 
products.  
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         The acylated, enantiopure monomer (+)-226 was also investigated in the Suzuki 
dimerization which generated a separable, mixture of atropisomers in a 3:1 ratio and 36 % 
yield (Scheme 4.7). Fortunately, X-ray crystal structure analysis of the minor atropisomer 
(-)-231 was obtained to verify relative and absolute stereochemistry. Introduction of a 
bulky ester onto the secondary alcohol of the monomer (e.g. OCOPh) did not affect the 
ratio of atropisomers.   
       After obtaining and establishing stereochemistry for several protected dimers, we 
anticipated that we could access all atropisomers and enantiomers of rugulotrosin A. 
Dimer (-)-227 was treated with 3M HCl/MeOH for 10 min which afforded rugulotrosin A 
((-)-6) in 89 % yield (Scheme 4.8, a). In a similar manner, (+)-rugulotrosin A was 
obtained from acidic hydrolysis of (+)-239 (Scheme 4.8, b). With both enantiomers of 
rugulotrosin A in hand, natural rugulotrosin A was unambiguously assigned as (+)-6 
though comparison of rotation data. Similarly, atrop-rugulotrosin A (-)-232 and ent-
Scheme 4.7 One-pot Suzuki Dimerization of (+)-226 
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atrop-rugulotrosin A (+)-232 were synthesized using similar protocols from both 
protected (-)-231 and (+)-231 (Scheme 4.8, c and d). To study the thermolytic stability of 
the axially chiral biaryl, we heated rugulotrosin A (+)-6 in toluene (1 mg/mL) at 100 °C 
for 12 h and 150 °C for 3 h (Scheme 4.9). Under both conditions, we did not observe 
formation of atrop-rugulotrosin. This is supported by a high barrier for rotation of 
Scheme 4.8 Syntheses of (-) and (+)-rugulotrosin A and atrop-rugulotrosin A 
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rugulotrosin A, calculated (in collaboration with Prof. Richard Johnson and Ms. Sarah 
Joiner, UNH) as 47.7 kcal/mol for this process using the B3LYP/6-31G(d) level of theory 
(Scheme 4.9). 
 
4.5 Computational Studies 
In order to rationalize the axial chirality selectivity observed in the dimerization, 
we modeled the geometry of the expected intermediate diaryl palladium (II) complexes114 
using SPhos (L1) as the ligand (Figure 4.3). Conformational analysis was carried out by 
systematic six-fold rotation about the C-Pd bonds, followed by optimization of candidate 
structures at the B3LYP/LanL2DZ level of theory.115 The five lowest energy structures 
are represented in Figure 4.3.  From this analysis, the three lowest energy structures 233a 
– 233c all had dihedral angles (C1, C2, C2’,C1’) for the monomer fragments which 
would afford atropisomer (-)-227 (precursor to rugulotrosin) after stereospecific reductive 
Scheme 4.9 Thermal Stability of Rugulotrosin A 
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elimination (Figure 4.3,a).  The next two higher energy structures 234a and 234b 
displayed a reversed dihedral angle, which should lead to atropisomer 228. Relative 
Figure 4.3 Computational Studies for Atropselective Suzuki Dimerization 
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energies correlate with the steric fit of components.  Space filling models (Figure 4.3, c-
d) of structures 233a-c and 234a-b show a more crowded arrangement of the latter, in 
part because of steric interactions between the methyl ester and cyclohexyl group. The 
distance between proton on the methyl ester group to proton on the cyclohexyl is 2.4 and 
2.5 Å for conforms 234a and 234b.  Based on literature precedent,46 we assume that these 
catalyst-reactant complexes are under thermodynamic equilibrium and additional 
computational studies will be required to predict barriers to interconversion.  It thus 
appears that product stereochemistry is determined by reactant and catalyst assembly in 
the Pd complex; this provides a basis for prediction of stereochemistry in future 
atropselective couplings.   
 
4.6 UPLC Analysis of Fungal Extracts  
     After assigning the absolute configuration of rugulotrosin A (in collaboration with 
Prof Robert Capon, University of Queesland, Australia), we employed our library of 
synthetic rugulotrosins to determine whether Penicillium nov. sp. (MST-F8741) was 
capable of producing atrop-rugulotrosin A. To this end, separate 21 day fermentations of 
MST-F8741 were extracted with either MeCN (Figure 4.4a) or MeOH (Figure 4.4b), 
after which they were analyzed by an HPLC-DAD method optimized for the resolution of 
rugulotrosin A (Figure 4.4e-g) and atrop-rugulotrosin A (Figure 4.4h,i). To further 
enhance sensitivity, these analyses were also carried out using HPLC-DAD-ESIMS 
protocols augmented by single ion extraction (SIE) (Figure 4.4c,d). As these analytical 
studies failed to detect any trace of atrop-rugulotrosin in MST-F8741 extracts, we 
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conclude that the rugulotrosin biosynthetic pathway present in Penicillium nov. sp. 
Figure 4.4 HPLC-DAD analysis of the Penicillium nov. sp. Extract 
 
 
 
*light grey is the natural rugulotrosin A, dark grey is the synthetic/ent-rugulotrosin A, and blue are 
atrop/ent-atrop rugulotrosin A. 
HPLC-DAD (210 nm) (Zorbax C18column, gradient elution H2O/MeCN plus 0.05 % HCO2H) analysis of 
21 day Penicillium nov. sp. (MST-F8741) cultures extracted with (a) MeCN extract, (b) MeOH extract, (c) 
natural rugulotrosin A with polar minors, (d) natural rugulotrosin A with non-polar minors, (e) natural 
rugulotrosin A, (f) synthetic rugulotrosin A, (g) ent- rugulotrosin A, (h) atrop-rugulotrosin A, (i) ent-
atroprugulotrosin A, (j) mixture of synthetic rugulotrosin A, ent- rugulotrosin A, atrop-rugulotrosin A and 
ent-atroprugulotrosin A. 
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(MST-F8741) operates with high atropisomer fidelity. 
As natural rugulotrosin A had previously been reported to exhibit antibacterial 
activity, we also tested the synthetic rugulotrosins ((+)-6, (-)-6, (-)-232, and (+)-232) 
against several strains of Gram-positive and Gram-negative bacteria (Table 4.1). 
Consistent with earlier reports, (+)-6 exhibited antibacterial activity against Bacillus 
subtilis (ATCC 6633) (IC50 = 2.1 mM) and Staphylococcus aureus (ATCC 25923) (IC50 = 
6 mM). Of note, the enantiomer (-)-6 was also active against B. subtilis (ATCC 6633) 
(IC50 = 0.7 mM) and S. aureus (ATCC 25923) (IC50 = 18 mM), whereas the antibacterial 
activity of the atropisomer (-)-232 was weak and limited to B. subtilis (ATCC 6633) (IC50 
= 10 mM), and (+)-232 lacked any appreciable antibacterial activity. None of the 
rugulotrosins (+)-6, (-)-6, (-)-232, or (+)-232 exhibited activity against the Gram-negative 
bacteria Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853), 
nor did they exhibit cytotoxicity (IC50>30 mM) against human colon (SW620) and lung 
(NCI-H460) cancer cells. 
Table 4.1 Antibacterial Activities of Rugulotrosins 
 
 Escherichia 
coli ATCC 
25922 
Pseudomonas 
aeruginosa 
ATCC 27853 
Staphylococcus 
aureus ATCC 
25923 
Bacillus 
subtilis ATCC 
6633 
Candida 
albicans 
ATCC 90028 
Compounds MIC 
(mM) 
IC50 
(mM) 
MIC 
(mM) 
IC50 
(mM) 
MIC 
(mM) 
IC50 
(mM) 
MIC 
(mM) 
IC50 
(mM) 
MIC 
(mM) 
IC50 
(mM) 
Rugulotrosin 
A  
>30 >30 >30 >30 10 6 10 2.1 >30 >30 
ent-
rugulotrosin 
A  
>30 >30 >30 >30 30 18 1.1 0.7 >30 >30 
atrop-
rugulotrosin 
A  
>30 >30 >30 >30 >30 >30 30 10 >30 >30 
ent-atrop-
rugulotrosin 
A  
>30 >30 >30 >30 >30 >30 >30 >30 >30 >30 
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4.7 Synthetic Plan for Gonytolide A 
      In future studies, we have considered that the chromone lactone dimer gonytolide A 
(9) could be another target to approach using point-to-axial chirality transfer strategy. 
Additionally, gonytolide A is a 4,4’-linked dimer another dimeric pattern to investigate 
the chirality transfer process. 
        Our synthetic plan may entail use of parallel kinetic resolution to synthesize the 
chiral chromone lactone (+)-139 from 236. The para-iodide 235 could be selectively 
obtained under gold (III)-catalyzed bromination (Chapter 5). Using one-pot Suzuki 
dimerization conditions, we anticipate that gonytolide A (9) may be synthesized from 
(+)-235 through point-to-axial chirality transfer. 
 
 
 
Scheme 4.10 Retrosynthetic Plan for gonytolide A 
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4.8 Conclusion 
      In conclusion, we have developed a concise, atropselective approach to the synthesis 
of rugulotrosin A and stereoisomers through point-to-axial chirality transfer which has 
facilitated determination of the absolute configuration of rugulotrosin A. Initial 
computational studies have provided a rationale for the atropselectivity observed in 
Suzuki dimerization. Through HPLC analysis of fungal extracts and synthetic samples, 
we have determined that Penicillium nov. sp. (MST-F8741) generates rugulotrosin A in 
an atropselective manner. Moreover, the atropisomers and enantiomers of rugulotrosin A 
were found to have different activities against Gram-positive bacteria illustrating the 
importance of stereochemistry on target selectivity. 
 
4.9 Experimental Section 
General Information: 1H NMR spectra were recorded at 400 MHz at ambient 
temperature with CDCl3 (Cambridge Isotope Laboratories, Inc.) as the solvent unless 
otherwise stated. 13C NMR spectra were recorded at 100.0 MHz at ambient temperature 
with CDCl3 as the solvent unless otherwise stated. Chemical shifts are reported in parts 
per million relative to CDCl3 (1H, δ 7.26; 13C, δ 77.0). Data for 1H NMR are reported as 
follows: chemical shift, integration, multiplicity (app= apparent, br = broad, par obsc = 
partially obscure, ovrlp = overlapping, s = singlet, d =doublet, t = triplet, q = quartet, m = 
multiplet) and coupling constants. All 13C NMR spectra were recorded with complete 
proton decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
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Chemical Instrumentation Center using a Waters Q-TOF mass spectrometer. Melting 
points were recorded on a Mel-temp (Laboratory Devices). Analytical thin layer 
chromatography was performed using 0.25 mm silica gel 60-F plates. Flash 
chromatography was performed using 200-400 mesh silica gel (Sorbent Technologies, 
Inc.). Preparative TLC was conducted with glass-backed 1000μm silica gel 60-F plates 
(Silicycle, Inc.) Yields refer to chromatographically and spectroscopically pure 
compounds, unless otherwise stated. All other reactions were carried out in oven-dried 
glassware under an argon atmosphere unless otherwise noted. The ArthurTM Suite 
Reaction Planner (Symyx Technologies, Inc.) was used for experimental procedure 
planning. Analytical LC-MS experiments were performed using a Waters Acquity UPLC 
(Ultra Performance Liquid Chromatography) with a Binary solvent manager, SQ mass 
spectrometer, Water 2996 PDA (Photo Diode Array) detector, and Evaporative Light 
Scattering Detector (ELSD). An Acquity UPLC BEH C18 1.7 μm column was used for 
analytical UPLC-MS. Preparative HPLC purification was performed on a Gilson PLC 
2020 Personal Purification System. A Chiralcel®OD (Chiral Technologies Inc., 250 × 
4.6 mm I.D.) column was used for enantiomeric excess determination. Analytical high 
pressure liquid chromatography mass spectrometry (HPLC-DAD-ESIMS) was performed 
on an Agilent 1100 Series separation module equipped with a diode array and an Agilent 
1100 single quadrupole mass detector, the latter operating in both dual positive and 
negative ion modes. 
HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, toluene, and hexanes 
were purchased from Fisher and VWR and were purified and dried by passing through a 
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PURE SOLV®solvent purification system (Innovative Technology, Inc.). Methanol was 
purchased from Fisher and used without further purification. 1,1'-Bis(di-i-
propylphosphino)ferrocene (dippf) was purchased from Strem Chemical. All other 
reagents and relevant catalysts were purchased from Sigma-Aldrich, Acros, Alfa Aesar, 
and Strem Chemicals. 
 
 
Ortho-iodo Tetrahydroxanthone 202: O-Methyl-protected tetrahydroxanthone 225 (836 
mg, 2.50 mmol), CaCO3 (1.75 g, 17.50 mmol, 7.0 equiv), and Me3NBnICl2 (914 mg, 2.63 
mmol, 1.05 equiv) were added to a solution of 5:1 CH2Cl2: MeOH (25 mL). After stirring 
at room temperature for 12 h, the reaction mixture was directly filtered to remove the 
calcium carbonate. After concentration in vacuo, the crude product was purified by silica 
gel chromatography (CH2Cl2/EtOAc = 20: 1 to 3: 7) to afford product 202 (1.09 g, 95 %) 
as a yellow powder. 
 
202: Rf = 0.17 (dichloromethane/EtOAc = 5: 1); mp decomp 210 °C (racemic) (CH2Cl2); 
IR (thin film): νmax 3457, 2951, 1747, 1627, 1563, 1369, 1226, 1171, 732 cm-1; 1H NMR 
(CDCl3, 125 MHz): δ 13.68 (s, 1H), 6.56 (s, 1H), 4.27 (ddd, J = 12.5, 4.3, 2.7 Hz, 1H), 
3.95 (s, 3H), 3.69 (s, 3H), 2.80 (ddd, J = 18.6, 6.2, 1.1 Hz, 1H), 2.79 (s, OH, chemical 
shift and coupling varies with concentration), 2.66 (ddd, J = 18.1, 10.9, 6.8 Hz, 1H), 2.44 
(s, 3H), 2.22 (ddd, J = 24.0, 13.0, 6.2 Hz, 1H), 2.09 (m, 1H); 13C NMR (CDCl3, 125 
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MHz) : δ 183.9, 169.7, 169.5, 161.5, 158.3, 151.7, 108.8, 106.2, 104.8, 86.3, 82.5, 71.6, 
56.4, 53.3, 29.5, 24.9, 23.8; HRMS ESI (m/z): [M+H] + calcd for C17H18O7I, 461.0097; 
found, 461.0078. 
 
 
 
Chiral, Non-Racemic Tetrahydroxanthones (-)-202 and (+)-226: (±)-
Tetrahydroxanthone 202 (1.0 g, 2.17 mmol) and 100 mL of CDCl3 was added to a flame-
dried flask. The solution was gently warmed at 40 oC for 5 min until the substrate was 
fully dissolved. The solution was cooled to 0 oC. To a flame-dried tube was added (R)-
HBTM (58 mg, 0.22 mmol, 0.1 equiv), DIEA (168 mg, 227 µL, 1.30 mmol, 0.6 equiv) 
and (EtCO)2O (169 mg, 167 µL, 1.30 mmol, 0.6 equiv) in 2 mL of CDCl3 and the 
contents were mixed for 3 min. The latter solution was transferred dropwise to a cold 
solution of 202. After stirring at 0 oC for 11 h and monitoring by crude 1H NMR analysis, 
the reaction was quenched with 0.5 mL of MeOH and was warmed to room temperature. 
After concentrating in vacuo, the crude reaction product was subjected to 1H NMR 
analysis to monitor conversion (δ 6.56, 4-H for (-)-202; δ 6.51, 4-H for (+)-226).The 
crude product was readily purified by silica gel chromatography (CH2Cl2/EtOAc = 30: 1 
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to 10: 1) to afford (+)-226 (570 mg, 51 %) as a yellow solid and (-)-202 (463 mg, 46 %) 
as a yellow powder. 
 
(+)-226: Rf = 0.62 (hexanes/EtOAc = 1: 2); mp 189-191 °C (CH2Cl2, 99 % ee); IR (thin 
film): νmax 2983, 1748, 1631, 1567, 1370, 1233, 1172, 1086, 734 cm-1; 1H NMR (CDCl3, 
500 MHz): δ 13.55 (s, 1H), 6.51 (s, 1H), 5.43 (dd, J = 12.2, 4.5 Hz, 1H), 3.93 (s, 3H), 
3.68 (s, 3H), 2.78 (ddd, J = 18.3, 6.6, 2.8 Hz, 1H), 2.71 (ddd, J = 18.6, 10.3, 6.1 Hz, 1H), 
2.42 (s, 3H), 2.37 (q, J = 7.6 Hz, 2H), 2.32 (m, 1H), 2.10 (m, 1H), 1.17 (t, J = 7.6 Hz, 
3H); 13C NMR (CDCl3, 125 MHz) : δ 183.9, 173.2, 169.4, 168.5, 161.3, 158.5, 151.7, 
109.0, 106.2, 105.2, 84.0, 82.1, 71.8, 56.5, 53.2, 29.4, 27.7, 24.4, 22.6, 8.9; HRMS-ESI 
(m/z): [M+H]+ calcd for C20H22O8I, 517.0359; found, 517.0338.  
Enantiomers were separated using a Chiralcel®OD column (Chiral Technologies Inc., 
250 × 4.6 mm I.D.) using 10 % IPA in hexanes. The enantiomeric excess for (+)-226 
after kinetic resolution was determined to be 95 %. 
(±)-226: 
 
95 % ee (+)-226: 
Recrystallization of (+)-226: 
hexanes/CH2Cl2 (3:1, 10 mg/mL)
overnight in which case the racemate
solid, the solution was concentrated 
yellow solid (99 % ee). [α]D28= 
>99 % ee (+)-226: 
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450 mg 95 % ee (+)-226 was dissolved in 45
. The mixture was placed in a -40 °C refrigerator 
 precipitated from solution. After filtration of the 
in vacuo to afford (+)-226 (411 mg, 91 
30.8° (c= 1.0, CHCl3). 
 mL of 
%) as a 
(-)-202: 1H NMR, 13C NMR, IR, and HRMS for 
for (±)-202. mp >220 °C (CH
hexanes on a Chiralcel®OD column (Chiral T
enantiomeric excess for (-)-202
CHCl3). 
(±)-202: 
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(-)-202 were identical to data reported 
2Cl2); Enantiomers were separated using 10% IPA in 
echnologies Inc., 250 × 4.6 mm I.D.)
 after kinetic resolution was 99 %. [α]D29= -38.3°
 
. The 
 (c= 0.1, 
99 % ee (-)-202: 
 
Synthesis of R-Cy-MOP: 
OTf
OMe
237
R-Cy-MOP L7: BINOL triflate (
mmol, 0.05 equiv), 1,1'-Bis(di-
0.06 equiv) and HPCy2BF4 (688.5 mg, 2.4 mmol, 1.05 equiv) were placed in flame dried 
seal tube under a N2 atmosphere
and 11 mL of degassed DMSO (0.2 M). The seal
After cooling to room temperature, the reaction was quenched 
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PCy2
OMe
0.05 equiv Pd(OAc)2
0.06 equiv dippf
1.05 equiv HPCy2BF4
10.0 equiv DIEA
DMSO, 120 °C, 40 h
R-Cy-MOP L8  
R)-237116 (1.00 g, 2.3 mmol), Pd(OAc)2 (26.0 mg, 0.12 
i-propylphosphino)ferrocene (dippf, 57.7 mg, 0.14 mmol, 
, followed by DIEA (3.0 g, 4.0 mL, 23 mmol, 10 equiv) 
ed tube was heated at 120 oC 
with saturated NH
for 40 h. 
4Cl and 
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was extracted 3 times with 50 mL of ether. The combined organic layer was washed with 
brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by 
silica gel chromatography (hexanes/EtOAc = 30:1) to afford the crude R-Cy-MOP. The 
compound was further dissolved in minimum amount of dichloromethane which was 
followed by addition of 300 mL of MeOH and placed in a -40 °C refrigerator overnight 
in which case the pure R-Cy-MOP was precipitated (486 mg, 44 %) from the solution. 
The physical properties of R-Cy-MOP were identical to those reported in the literature.117 
The S-Cy-MOP was prepared following the same procedure. Both ligands were 
enantiopure and separable using 0.2% IPA in hexanes on a Chiralcel®OD column (Chiral 
Technologies Inc., 250 × 4.6 mm I.D.) (S-Cy-MOP, t =3.96 min; R-Cy-MOP, t = 4.18 
min). 
 
 
R-Cy-MOP-G3: A mixture of 238 (123 mg, 0.15 mmol, 0.5 equiv) and R-Cy-MOP L8 
(150 mg, 0.31 mmol, 1.0 equiv) were place in a flame dried flask under a N2 atmosphere. 
4 mL of THF was added into the flask and the reaction was stirred at room temperature 
for 30 min. After removal of 90 % of the solvent under vacuum, the crude product was 
triturated from pentane to afford R-Cy-MOP-G3 as a beige solid (213 mg, 78 %).  
R-Cy-MOP-G3: IR (thin film): νmax 3423, 3302, 3060, 2931, 2851, 1615, 1587, 1273, 
1217, 1153, 1089, 750 cm-1; 1H NMR (CD3OD, 500 MHz, δ 3.31): δ 8.89 (d, J = 9.2 Hz, 
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1H), 8.77 (d, J = 9.2 Hz, 1H), 8.35 (d, J = 8.1 Hz, 1H), 8.19 (m, 1H), 8.10 (t, J = 7.4 Hz, 
2H), 8.02 (d, J = 9.2 Hz, 1H), 7.91-7.99 (m, 4H), 7.55-7.61 (m, 4H), 6.93-7.49 (m, 20H), 
6.82 (dd, J = 7.8, 3.2 Hz, 1H), 6.78 (t, J = 7.7 Hz, 1H), 6.54 (d, J = 8.5 Hz, 1H), 5.50 (d, J 
= 7.9 Hz, 1H), 5.72 (d, J = 8.6 Hz, 1H), 5.62 (d, J = 8.6 Hz, 1H), 4.08 (s, 3H), 3.41 (s, 
3H), 2.69 (s, 6H), 2.16-2.58 (m, 8H), 1.76-2.05 (m, 8H), 0.53-1.53 (m, 30H), 0.12 (m, 
1H), -0.03 (m, 1H); 13C NMR (CD3OD, 125 MHz) : δ 161.36, 160.62, 144.68, 144.53, 
144.22, 144.07, 143.73, 143.72, 143.44, 141.67, 141.39, 141.03, 139.76, 139.32, 138.15, 
138.12, 137.37, 137.21, 136.93, 136.92, 136.91, 136.89, 136.83, 136.81, 136.71, 136.66, 
136.45, 136.33, 136.28, 135.25, 135.11, 134.92, 134.79, 133.48, 133.38, 133.33, 131.07, 
131.97, 130.83, 130.78, 130.75, 130.48, 130.43, 129.60, 129.56, 129.47, 129.39, 129.36, 
129.33, 129.24, 129.19, 129.18, 129.06, 128.80, 128.69, 128.65, 128.44, 128.09, 127.90, 
127.86, 127.85, 127.31, 127.21, 126.80, 126.71, 126.36, 126.04, 125.95, 125.78, 121.28, 
121.27, 116.16, 115.55, 108.59, 108.55, 107.54, 107.51, 57.17, 56.55, 39.52, 36.30, 36.05, 
35.65, 35.41, 32.79, 32.59, 32.53, 32.51, 32.35, 32.15, 31.84, 31.82, 30.70, 30.67, 30.62, 
30.59, 29.25, 29.19, 29.17, 29.11, 28.78, 28.75, 28.68, 28.66, 28.53, 28.47, 27.45, 27.40, 
27.34, 27.30, 27.23, 26.86, 26.85, 26.80, 26.74, 26.64, 26.63 (Observed complexity due 
to P-C splitting); 31P NMR (CDCl3, 161 MHz) :δ 41.61 (br, s); 31P NMR (CDOD, 161 
MHz) :δ 42.73 (s), 42.41 (s); [α]D26= -35.0° (c= 1.0, CH2Cl2). 
S-Cy-MOP-G3 was prepared following the same procedure and the NMR data were 
found to be identical with R-Cy-MOP-G3. [α]D27= 31.4°(c= 1.0, CH2Cl2). 
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General Procedure for one pot Suzuki dimerization: 
Tetrahydroxanthone (-)-202 (10 mg, 0.022 mmol), Pd(OAc)2 (1.0 mg, 0.004 mmol, 0.2 
equiv), ligand (0.009 mmol, 0.4 equiv), BPin2 (3.9 mg, 0.015 mmol, 0.7 equiv), and 
K3PO4 (14.0 mg, 0.066 mmol, 3 equiv) were placed in a flame dried sealed tube under a 
N2atmosphere, then degassed 0.2 mL THF/water (4:1) was added. The sealed tube was 
stirred at 70 oC for 5 h. After cooling to room temperature, the reaction was quenched 
with saturated NH4Cl and was extracted three times with 3 mL of EtOAc and the 
combined organic layer was washed with brine and dried over Na2SO4. After 
concentration in vacuo, an inseparable dimer mixture was obtained after preparative TLC 
separation (first EtOAc, then CH2Cl2/MeOH 25:1). The dr was determined by crude 1H 
NMR analysis and by examination of the separated dimer products (δ 3.90, 4-H for (-)-
227; δ 3.93, 4-H for 228). 
 
(-)-227: Rf = 0.09 (EtOAc); 0.23 (CH2Cl2/MeOH = 25: 1); mp >220 °C (CH2Cl2); IR 
(thin film): νmax 3445, 2926, 1734, 1628, 1571, 1403, 1226, 1170, 1088, 1018, 817, 757 
cm-1; 1H NMR (CDCl3, 500 MHz): δ 12.75 (s, 2H), 6.47 (s, 2H), 4.25 (d, J = 12.1 Hz, 
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2H), 3.90 (s, 6H), 3.71 (s, 3H), 2.82 (s, 2H, OH, chemical shift and coupling varies with 
concentration), 2.76 (dd, J = 18.4, 5.9 Hz, 2H), 2.63 (ddd, J = 18.3, 10.8, 7.0 Hz, 2H), 
2.20 (dddd, J = 24.4, 12.2, 6.7, 0.8, 2H), 2.07 (m, 2H), 2.02 (s, 6H); 13C NMR (CDCl3, 
125 MHz) : δ 184.8, 170.2, 168.1, 160.5, 157.6, 149.0, 116.8, 107.9, 106.3, 105.7, 86.1, 
71.9, 56.4, 53.0, 24.9, 23.8, 20.8; HRMS-ESI (m/z): [M+H]+ calcd for C34H35O14, 
667.2027; found, 667.2006. [α]D28= -64.1° (c= 0.1, CHCl3).  
 
 
 
 
General Procedure for one-pot Suzuki dimerization using a Pd pre-catalyst: 
Tetrahydroxanthone (-)-202 (50 mg, 0.109 mmol), R-Cy-MOP-G3 (18.5 mg, 0.022 mmol, 
0.2 equiv), BPin2 (16.6 mg, 0.065 mmol, 0.6 equiv), and K3PO4 (69.2 mg, 0.326 mmol, 3 
equiv) were placed in a flame dried sealed tube under a N2 atmosphere, then degassed 1.1 
mL THF/water (4:1) was added. The sealed tube was stirred at 70 oC for 5 h. After 
cooling to room temperature, the reaction was quenched with saturated NH4Cl and 
extracted three times with 3 mL of EtOAc, and the combined organic layer was washed 
with brine and dried over Na2SO4. After concentration in vacuo, 16 mg of dimer products 
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were obtained after preparative TLC separation (EtOAc followed by 25:1 
CH2Cl2/MeOH). The dr (95.5: 4.5) was determined by crude 1H NMR analysis and as 
well as by examination of the 1H NMR spectra of the purified dimeric products (δ 3.90, 
4-H for (-)-227; δ 3.93, 4-H for 228). 
 
Chiral, Dimeric Tetrahydroxanthones (+)-230 and (-)-231:  
Tetrahydroxanthone (+)-226 (30 mg, 0.058 mmol), Pd(OAc)2 (2.6 mg, 0.012 mmol, 0.2 
equiv), SPhos (10.0 mg, 0.024 mmol, 0.42 equiv), BPin2 (10.3 mg, 0.041 mmol, 0.7 
equiv) and K3PO4 (36.9 mg, 0.174 mmol, 3 equiv) were placed in a flame dried sealed 
tube under a N2 atmosphere, then degassed 0.6 mL THF/water (4:1) was added. The 
sealed tube was stirred at 70 oC for 5 h. After cooling to room temperature, the reaction 
was quenched with saturated NH4Cl and extracted three times with 3 mL EtOAc, and 
combined organic layer was washed with brine and dried over Na2SO4. After 
concentration in vacuo, the dimeric mixture was obtained after preparative TLC 
separation (EtOAc). The mixture was further separated by preparative TLC 
(ether/acetone = 3:1) to afford (+)-230 (6.0 mg, 27 %) and (-)-231 (2.1 mg, 9 %). 
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(+)-230: Rf = 0.44 (EtOAc); 0.30 (ether/acetone = 3: 1); mp >200 °C (EtOAc); IR (thin 
film): νmax 2951, 1750, 1631, 1574, 1403, 1228, 1169, 1085, 828, 735 cm-1; 1H NMR 
(CDCl3, 400 MHz): δ 12.57 (s, 2H), 6.43 (s, 2H), 5.41 (dd, J = 11.8, 4.3 Hz, 2H), 3.88 (s, 
6H), 3.70 (s, 3H), 2.71 (m, 4H), 2.44 (q, J = 5.2 Hz, 4H), 2.35 (m, 2H), 2.10 (m, 2H), 
1.99 (s, 6H), 1.17 (t, J = 7.5 Hz, 6H); 13C NMR (CDCl3, 125 MHz) : δ 184.3, 173.2, 
169.8, 166.9, 160.2, 157.8, 149.1, 116.5, 108.0, 106.3, 106.1, 83.8, 72.3, 56.5, 52.9, 27.7, 
24.3, 22.8, 20.7, 9.0; HRMS-ESI (m/z): [M+H]+ calcd for C40H43O16, 779.2551; found, 
779.2571. [α]D27= 165.4° (c = 0.1, CHCl3). 
 
 
(-)-231: Rf = 0.44 (EtOAc); 0.38 (ether/acetone = 3: 1); mp >200 °C (EtOAc); IR (thin 
film): νmax 2951, 1751, 1631, 1575, 1402, 1279, 1230, 1169, 1086, 830, 760 cm-1; 1H 
NMR (CDCl3, 500 MHz): δ 12.65 (s, 2H), 6.42 (s, 2H), 5.45 (dd, J = 11.9, 4.3 Hz, 2H), 
3.92 (s, 6H), 3.71 (s, 3H), 2.73 (m, 4H), 2.40 (q, J = 7.8 Hz, 4H), 2.35 (m, 2H), 2.10 (m, 
2H), 1.95 (s, 6H), 1.18 (t, J = 7.7 Hz, 6H); 13C NMR (CDCl3, 125 MHz) : δ 184.9, 173.3, 
169.6, 167.0, 160.2, 157.6, 149.6, 116.7, 108.2, 106.3, 106.2, 83.7, 72.1, 56.3, 53.2, 27.8, 
24.2, 22.7, 20.7, 9.0; HRMS-ESI (m/z): [M+H]+ calcd for C40H43O16, 779.2551; found, 
779.2543. [α]D27= -193.1° (c= 0.1, CHCl3).  
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Rugulotrosin A (+)-6: Dimeric tetrahydroxanthone (+)-230 (5.0 mg, 0.0064 mmol) was 
dissolved in 1 mL of methanol and 1 mL of 3M aqueous HCl solution was added. The 
reaction was warmed to 60 oC and was stirred under argon for 8 h. After cooling to room 
temperature, the solution was diluted with 5 mL of ethyl acetate and the organics were 
washed with 5 mL of water, brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo to afford a yellow residue which was purified by preparative HPLC (C18, 10-75% 
CH3CN/water).The fractions were extracted with EtOAc, washed with brine, dried over 
sodium sulfate, and concentrated in vacuo to afford rugulotrosin A (+)-6 (3.5 mg, 85%) 
as a yellow solid. (+)-6: mp: 189-191 oC (EtOAc) (lit: 189-190 oC); IR (thin film): νmax 
3421, 2953, 2926, 1739, 1609, 1585, 1453, 1358, 1282, 1171, 1080, 742 cm-1(lit:S7 νmax 
3009, 2936, 2858, 1732, 1611, 1583, 1460, 1437, 1238, 1194, 1175, 1115 cm-1); 1H NMR 
(CDCl3, 500 MHz): δ 13.88(s, 2H), 11.49 (s, 2H), 6.56 (s, 2H), 4.32(dd, J = 12.3, 5.0 Hz, 
2H), 3.75 (s, 6H), 2.82 (br, 2H, OH, chemical shift and coupling varies with 
concentration), 2.66 (m, 4H), 2.20 (m, 2H), 2.10 (m, 2H), 2.06 (s, 6H); 13C NMR (CDCl3, 
125 MHz) : δ 186.6, 177.6, 170.2, 159.4, 157.9, 150.2, 116.8, 109.2, 104.9, 101.1, 84.3, 
72.0, 53.1, 27.5, 23.8, 20.9; HRMS-ESI (m/z): [M+H]+ calcd for C32H31O16, 639.1714; 
found, 639.1716; [α]D26= 252.8° (c= 0.1, CHCl3) (lit: [α]D25= 260° (c= 1.30, CHCl3)). 
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Atrop-Rugulotrosin A (-)-232: Dimeric tetrahydroxanthone (-)-231 (3.0 mg, 0.0090 
mmol) was dissolved in 1 mL of methanol and 1 mL of 3M aqueous HCl solution was 
added. The reaction was warmed to 60 oC and was stirred under argon for 8 h. After 
cooling to room temperature, the solution was diluted with 5 mL of ethyl acetate and the 
organic layer was washed 5 mL of water, brine, dried over sodium sulfate, filtered, and 
concentrated in vacuo to afford a yellow residue which was purified by preparative 
HPLC (C18, 10-75% CH3CN/water).The fractions were extracted with EtOAc, washed 
with brine, dried over sodium sulfate, and concentrated in vacuo to afford atrop-
rugulotrosin A (-)-232 (2.1 mg, 85 %) as a yellow solid. (-)-232: IR (thin film): νmax 3480, 
2925, 1738, 1607, 1584, 1450, 1359, 1282, 1171, 1067, 759 cm-1;1H NMR (CDCl3, 500 
MHz): δ 13.95 (s, 2H), 11.51 (s, 2H), 6.55 (s, 2H), 4.32 (dd, J = 12.1, 5.1 Hz, 2H), 3.76 
(s, 6H), 2.82 (br, 2H, OH, chemical shift and coupling varies with concentration), 2.66 (m, 
4H), 2.18 (m, 2H), 2.11 (m, 2H), 2.01 (s, 6H); 13C NMR (CDCl3, 125 MHz) : δ 186.7, 
177.7, 170.1, 159.4, 157.7, 150.1, 117.0, 109.2, 105.0, 101.1, 84.2, 72.1, 53.3, 27.6, 23.8, 
20.9; HRMS-ESI (m/z): [M+H]+ calcd for C32H31O16, 639.1714; found, 639.1707; [α]D28 
= -145.2° (c= 0.1, CHCl3). 
 
4.10 NMR Data and UPLC Comparisons for Rugulotrosin A and Atrop-
Rugulotrosin A 
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A) 1H NMR spectra of synthetic rugulotrosin A and atrop-rugulotrosin A in comparison 
with literature data (CDCl3, 7.26 ppm): 
 
 
 
 
 
 
Position 
δ (JH-H in Hz) 
Natural Product 
(Isolation Paper) 
(ref unknown)10 
Natural Products 
(another set) (400 
MHz, CDCl3) 
Natural 
Product (this 
work)118 
( 500 MHz, 
CDCl3) 
Synthetic Natural 
Product 
( 500 MHz, 
CDCl3) 
Synthetic 
Atrop-
rugulotrosin 
A (500 MHz, 
CDCl3) 
4/4' 6.53 (s, 2H) 6.56 (s, 2H) 6.56 (s, 2H) 6.56 (s, 2H) 6.55 (s, 2H) 
5/5' 4.23 (dd, J = 4.7, 
4.7) 
4.27 (dd, J = 12.4, 
5.2, 2H) 
4.32 (dd, J = 
12.3, 5.0, 2H) 
4.32 (dd, J = 
12.3, 5.0, 2H) 
4.32 (dd, J = 
12.1, 5.1, 2H) 
6β/6β' 2.20 (m, 4H) 2.17 (m, 2H) 2.20 (m, 2H) 2.20 (m, 2H) 2.18 (m, 2H) 
6α/6α' 2.09 (m, 2H) 2.10 (m, 2H) 2.10 (m, 2H) 2.11 (m, 2H) 
7α/7α' 2.63 (m, 4H) 2.66 (m, 4H) 2.66 (m, 4H) 2.66 (m, 4H) 2.66 (m, 4H) 
11/11' 2.03 (s, 6H) 2.05 (s, 6H) 2.06 (s, 6H) 2.06 (s, 6H) 2.01 (s, 6H) 
13/13' 3.73 (s, 6H) 3.75 (s, 6H) 3.75 (s, 6H) 3.75 (s, 6H) 3.76 (s, 6H) 
1-OH/1'-
OH 
11.52 (s, 2H) 11.51 (s, 2H) 11.49 (s, 2H) 11.49 (s, 2H) 11.51 (s, 2H) 
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5-OH/5'-
OH* 
-- -- 2.82 (br, 2H) 2.83 (br, 2H) 2.83 (br, 2H) 
8-OH/8'-
OH 
13.86 (s, 2H) 13.88 (s, 2H) 13.88 (s, 2H) 13.88 (s, 2H) 13.95 (s, 2H) 
*The chemical shift of the 5-OH peak was found to vary with concentration. 
 
 
B) 13C NMR spectrum of synthetic rugulotrosin A and atrop-rugulotrosin A in 
comparison with literature data (CDCl3, 77.0 ppm): 
 
 
 
Position 
δ 
Natural Product 
(Isolation paper) 
(unkown)10 
Natural 
Product 
(another set) 
(100 MHz, 
CDCl3) 
Natural Product 
(this work) 
( 125 MHz, 
CDCl3) 
Synthetic 
Rugulotrosin 
A  
( 125 MHz, 
CDCl3) 
Synthetic 
Atrop-
rugulotrosin A 
( 125 MHz, 
CDCl3) 
1 159.3 159.3 159.4 159.4 159.4 
2 116.7 116.7 116.8 116.8 117.0 
3 150.2 150.2 150.2 150.2 150.1 
4 109.2 109.2 109.2 109.2 109.2 
4a 157.9 157.9 157.9 157.9 157.7 
5 71.9 71.9 72.0 72.0 72.1 
6 23.8 23.8 23.8 23.8 23.8 
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7 27.5 27.5 27.5 27.5 27.6 
8 177.5 177.5 177.6 177.6 177.7 
8a 101.0 101.0 101.1 101.1 101.1 
9 186.6 186.6 186.6 186.6 186.7 
9a 104.8 104.8 104.9 104.9 105.0 
10a 84.3 84.3 84.3 84.3 84.2 
11 20.9 20.9 20.9 20.9 20.9 
12 170.2 170.2 170.2 170.2 170.1 
13 53.1 53.1 53.1 53.1 53.3 
 
 
4.11 X-ray Crystallographic Data 
X-ray crystallographic data for compound (-)-227: 
 
 
Crystals of compound (-)-227 suitable for X-ray analysis were obtained by slow 
evaporation from CH2Cl2. Crystallographic data have been deposited with the Cambridge 
Cystallograhic Data Centre (CCDC#1022610). Copies of the data can be obtained free of 
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charge on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: 
(+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Data collection: APEX2 (Bruker, 2006); Cell refinement: SAINT v8.34A (Bruker, 2013); 
data reduction: SAINT v8.34A (Bruker, 2013); program(s) used to refine structure: XL 
(Sheldrick, 2008); molecular graphics: Olex2 (Dolomanov et al., 2009); software used to 
prepare material for publication: Olex2 (Dolomanov et al., 2009). 
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Crystal data 
  C34H34O14·0.48(CH2Cl2) Dx = 1.358 Mg m-3 
Mr = 707.21 Cu Ka radiation, l = 1.54178 Å 
Orthorhombic, C2221 Cell parameters from 9192 reflections 
a = 9.8002 (8) Å q = 2.9–66.6° 
b = 11.4061 (10) Å m = 1.54 mm-1 
c = 30.952 (3) Å T = 100 K 
V = 3459.9 (5)  Å3 Block, colorless 
Z = 4 0.17 × 0.15 × 0.11 mm 
F(000) = 1480.3  
 
 
Data collection 
  Bruker Proteum-R  
diffractometer 
2986 independent reflections 
Radiation source: rotating anode 2960 reflections with I> 2s(I) 
Montel Rint = 0.033 
w&f scans qmax = 66.6°, qmin = 2.9° 
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Absorption correction: multi-scan  
SADABS2012/1 (Bruker,2012) was used for 
absorption correction. wR2(int) was 0.1138 
before and 0.0516 after correction. The Ratio of 
minimum to maximum transmission is 0.9220. 
The l/2 correction factor is 0.0015. 
h = -11®11 
Tmin = 0.694, Tmax = 0.753 k = -10®13 
37641 measured reflections l = -36®36 
 
 
Refinement 
  Refinement on F2 Secondary atom site location: difference Fourier 
map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2> 2s(F2)] = 0.039 H-atom parameters constrained 
wR(F2) = 0.126 w = 1/[s2(Fo2) + (0.0628P)2 + 4.8498P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.22 (D/s)max< 0.001 
2986 reflections Dñmax = 0.44 e Å-3 
243 parameters Dñmin = -0.35 e Å-3 
244 restraints Absolute structure:  Flack x determined using 
1277 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Parsons 
and Flack (2004), Acta Cryst. A60, s61). 
1 constraint Flack parameter: 0.039 (10) 
Primary atom site location: structure-invariant 
direct methods 
 
 
 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  are 
estimated using the full covariance matrix.  The cell esds are taken  into account 
individually in the estimation of esds in distances, angles  and torsion angles; correlations 
between esds in cell parameters are only  used when they are defined by crystal 
symmetry.  An approximate (isotropic)  treatment of cell esds is used for estimating esds 
involving l.s. planes. 
200 
 
Refinement. CheckCIF Alerts and Discussion: 
 PLAT077_ALERT_4_C Unitcell contains non-integer number of atoms .. Please 
Check 
 Discussion:  The dichloro­methane solvent model, which is disordered on a  twofold 
axis, is also partially absent, resulting in the noninteger number of  atoms. 
 PLAT089_ALERT_3_C Poor Data / Parameter Ratio (Zmax < 18) .. 7.12 Note  
PLAT340_ALERT_3_C Low Bond Precision on  C-C Bonds .. 0.0049 Ang. 
 Discussion:  Due to the presence of one or more small satellite crystals, some  of the 
low angle data were rejected, resulting in a slightly low completeness  of 0.986 at theta 
full (and 96% from infinity to 1.809 Angstroms).  The  missing data lead to a low data to 
parameter ratio and low C-C bond precision  for this disordered structure, which none the 
less unambiguously achieves the  goals of the present study. 
 PLAT213_ALERT_2_C Atom C1A has ADP max/min Ratio .. 3.5 prolat  
PLAT213_ALERT_2_C Atom C1B has ADP max/min Ratio .. 3.5 prolat  
PLAT220_ALERT_2_C Large Non-Solvent C Ueq(max)/Ueq(min) Range 3.1 Ratio  
 Discussion:  It was necessary to use a SHELX EADP constraint on C1A and C1B to  
prevent C1B from becoming non-positive definite during refinement of this  disordered 
methyl group.  The constraint resulted in a prolate ellipsoid shape. 
 
 
 
Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O1 0.1684 (3) 0.7447 (3) 0.28747 (8) 0.0287 (6)  
O2 0.2166 (3) 0.8286 (2) 0.39773 (7) 0.0203 (6)  
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O3 0.3406 (3) 0.7130 (3) 0.33401 (10) 0.0314 (7)  
O4 0.0492 (3) 0.4547 (2) 0.44736 (8) 0.0248 (6)  
H4 -0.0031 0.4639 0.4261 0.037*  
O5 -0.0676 (3) 0.5646 (2) 0.38507 (8) 0.0254 (6)  
O6 -0.2297 (2) 0.7463 (3) 0.36335 (9) 0.0289 (6)  
O7 0.2441 (3) 0.9918 (2) 0.32463 (8) 0.0233 (6)  
H7 0.2928 1.0238 0.3436 0.035*  
Cl1S 0.6383 (5) 0.6378 (4) 0.45668 (13) 0.0368 (11) 0.239 (4) 
C1S 0.756 (2) 0.540 (2) 0.4777 (6) 0.0368 (11) 0.239 (4) 
H1SA 0.7737 0.4791 0.4557 0.044* 0.239 (4) 
H1SB 0.8425 0.5829 0.4825 0.044* 0.239 (4) 
Cl2S 0.7116 (5) 0.4711 (5) 0.52533 (15) 0.0368 (11) 0.239 (4) 
C17 0.2476 (6) 0.6850 (4) 0.25443 (14) 0.0433 (12)  
H17A 0.2632 0.6035 0.2632 0.065*  
H17B 0.3355 0.7248 0.2508 0.065*  
H17C 0.1975 0.6865 0.2270 0.065*  
C16 0.2305 (3) 0.7534 (3) 0.32577 (10) 0.0198 (7)  
C15 0.1401 (3) 0.8205 (3) 0.35823 (10) 0.0167 (7)  
C6 0.2211 (3) 0.7323 (3) 0.42383 (10) 0.0184 (7)  
C5 0.1288 (3) 0.6390 (3) 0.41925 (10) 0.0158 (7)  
C4 0.1361 (3) 0.5462 (3) 0.44987 (11) 0.0170 (7)  
C3 0.2290 (4) 0.5485 (3) 0.48375 (10) 0.0181 (7)  
C7 0.3156 (4) 0.7339 (4) 0.45688 (12) 0.0298 (9)  
H7A 0.3795 0.7963 0.4588 0.036*  
C2 0.3175 (4) 0.6440 (4) 0.48739 (12) 0.0281 (9)  
C8 0.0166 (3) 0.6470 (3) 0.38873 (10) 0.0164 (7)  
C9 0.0062 (3) 0.7572 (3) 0.36487 (10) 0.0157 (7)  
C11 -0.1156 (4) 0.8057 (3) 0.35324 (11) 0.0200 (7)  
C18 -0.3626 (4) 0.7967 (4) 0.35610 (14) 0.0343 (10)  
H18A -0.4320 0.7485 0.3704 0.051*  
H18B -0.3810 0.7996 0.3250 0.051*  
H18C -0.3650 0.8763 0.3680 0.051*  
C12 -0.1278 (4) 0.9223 (3) 0.33186 (12) 0.0240 (8)  
H12A -0.1586 0.9807 0.3534 0.029*  
H12B -0.1981 0.9177 0.3089 0.029*  
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C13 0.0060 (4) 0.9633 (3) 0.31203 (11) 0.0224 (8)  
H13A 0.0253 0.9170 0.2857 0.027*  
H13B -0.0020 1.0467 0.3036 0.027*  
C14 0.1227 (4) 0.9489 (3) 0.34388 (10) 0.0185 (7)  
H14 0.1024 0.9975 0.3700 0.022*  
C1A 0.408 (2) 0.652 (2) 0.5265 (5) 0.049 (3) 0.75 (6) 
H1AA 0.3525 0.6647 0.5523 0.073* 0.75 (6) 
H1AB 0.4719 0.7178 0.5230 0.073* 0.75 (6) 
H1AC 0.4601 0.5791 0.5296 0.073* 0.75 (6) 
C1B 0.433 (6) 0.662 (6) 0.5205 (18) 0.049 (3) 0.25 (6) 
H1BA 0.4264 0.7409 0.5329 0.073* 0.25 (6) 
H1BB 0.5217 0.6533 0.5061 0.073* 0.25 (6) 
H1BC 0.4252 0.6036 0.5436 0.073* 0.25 (6) 
 
 
X-ray crystallographic data for compound (-)-231: 
 
Crystals of compound (-)-231 suitable for X-ray analysis were obtained by slow 
evaporation from CH2Cl2/MeOH. Crystallographic data have been deposited with the 
Cambridge Cystallograhic Data Centre (CCDC#1022611). Copies of the data can be 
obtained free of charge on application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
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Crystal data 
C40H42O16 V = 1935.80 (11)  Å3 
Mr = 778.73 Z = 2 
Monoclinic, P21 Cu Ka radiation, l = 1.54178 Å 
a = 11.3036 (4) Å m = 0.88 mm-1 
b = 15.8950 (5) Å T = 100 K 
c = 11.5465 (4) Å 0.37 × 0.18 × 0.09 mm 
b = 111.075 (1)°  
 
 
Data collection 
Bruker Proteum-R  
diffractometer 
6886 independent reflections 
Absorption correction: multi-scan  
SADABS2012/1 (Bruker,2012) was used for 
absorption correction. wR2(int) was 0.0977 
before and 0.0417 after correction. The Ratio of 
minimum to maximum transmission is 0.8632. 
The l/2 correction factor is 0.0015. 
6839 reflections with I> 2s(I) 
Tmin = 0.650, Tmax = 0.753 Rint = 0.030 
48580 measured reflections  
 
 
Refinement 
R[F2> 2s(F2)] = 0.027 H-atom parameters constrained 
wR(F2) = 0.074 Dñmax = 0.25 e Å-3 
S = 1.05 Dñmin = -0.18 e Å-3 
6886 reflections Absolute structure:  Flack x determined using 
3263 quotients [(I+)-(I-)]/[(I+)+(I-)]  (Parsons 
and Flack (2004), Acta Cryst. A60, s61). 
529 parameters Flack parameter: 0.03 (5) 
1 restraint  
 
Data collection: APEX2 (Bruker, 2013); cell refinement: SAINT v8.34A (Bruker, 2013); data 
reduction: SAINT v8.34A (Bruker, 2013); program(s) used to solve structure: SHELXS (Sheldrick, 
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2008); program(s) used to refine structure: SHELXL (Sheldrick, 2008); molecular graphics: Olex2 
(Dolomanov et al., 2009); software used to prepare material for publication: Olex2 (Dolomanov 
et al., 2009). 
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O1 0.76066 (15) 0.37252 (10) 0.48477 (16) 0.0429 (4)  
O2 0.12116 (12) 0.97223 (8) -0.15227 (12) 0.0275 (3)  
O3 -0.05887 (14) 1.10944 (9) -0.24489 (14) 0.0329 (3)  
O4 0.17272 (14) 0.68398 (9) -0.01696 (13) 0.0328 (3)  
H4 0.1025 0.6801 -0.0756 0.049*  
O5 0.33739 (13) 0.74050 (9) 0.32112 (12) 0.0293 (3)  
H5 0.3560 0.7303 0.3970 0.044*  
O6 0.44864 (13) 0.66645 (10) 0.53063 (12) 0.0334 (3)  
O7 0.66271 (13) 0.53292 (9) 0.37205 (13) 0.0310 (3)  
C40 0.4875 (3) 0.68280 (19) -0.0167 (2) 0.0505 (6)  
H40A 0.4015 0.6726 -0.0759 0.076*  
H40B 0.5469 0.6448 -0.0349 0.076*  
H40C 0.5115 0.7413 -0.0239 0.076*  
O9A 0.9770 (2) 0.37156 (18) 0.5619 (2) 0.0440 (6) 0.794 (3) 
O10 0.65284 (16) 0.63766 (11) 0.74221 (14) 0.0426 (4)  
O11 0.50437 (14) 0.40892 (9) 0.31964 (14) 0.0354 (3)  
O12 0.49092 (14) 0.40264 (10) 0.50839 (15) 0.0394 (4)  
O13 -0.01681 (15) 0.73050 (9) -0.20296 (14) 0.0364 (3)  
O14 -0.16185 (13) 0.78455 (9) -0.42372 (13) 0.0327 (3)  
205 
O15 -0.00991 (14) 1.00366 (10) -0.00533 (14) 0.0374 (3)  
O16 -0.19463 (13) 0.96640 (9) -0.15116 (13) 0.0324 (3)  
O17 0.11451 (18) 1.16010 (12) -0.2708 (2) 0.0555 (5)  
C1A 0.7496 (4) 0.2437 (2) 0.3246 (4) 0.0447 (7) 0.794 (3) 
H1AA 0.7491 0.2892 0.2672 0.067* 0.794 (3) 
H1AB 0.6714 0.2459 0.3429 0.067* 0.794 (3) 
H1AC 0.7549 0.1894 0.2866 0.067* 0.794 (3) 
C2A 0.8628 (3) 0.2539 (2) 0.4439 (3) 0.0447 (8) 0.794 (3) 
H2AA 0.8570 0.2111 0.5040 0.054* 0.794 (3) 
H2AB 0.9407 0.2419 0.4263 0.054* 0.794 (3) 
C3A 0.8763 (3) 0.3385 (2) 0.5035 (3) 0.0354 (7) 0.794 (3) 
C4 0.7673 (2) 0.45128 (15) 0.5487 (2) 0.0376 (5)  
H4A 0.8405 0.4848 0.5445 0.045*  
C5 0.64312 (19) 0.49825 (13) 0.47871 (19) 0.0312 (4)  
C6 0.61344 (19) 0.56601 (14) 0.55563 (19) 0.0309 (4)  
C7 0.51217 (18) 0.62415 (12) 0.48370 (18) 0.0280 (4)  
C8 0.49514 (17) 0.63307 (12) 0.35231 (17) 0.0253 (4)  
C9 0.41318 (17) 0.69547 (12) 0.27738 (17) 0.0246 (4)  
C10 0.41179 (18) 0.71338 (12) 0.15830 (18) 0.0272 (4)  
C11 0.33114 (18) 0.78271 (12) 0.08252 (17) 0.0263 (4)  
C12 0.21214 (18) 0.76457 (12) -0.00537 (17) 0.0256 (4)  
C13 0.13557 (18) 0.82752 (12) -0.08433 (18) 0.0246 (4)  
C14 0.18527 (17) 0.90925 (12) -0.07414 (16) 0.0242 (4)  
C15 -0.01412 (18) 0.96175 (12) -0.20991 (17) 0.0267 (4)  
C16 -0.05517 (19) 1.03195 (12) -0.30780 (18) 0.0296 (4)  
H16 0.0075 1.0368 -0.3504 0.036*  
C17 0.03244 (19) 1.16733 (13) -0.22946 (19) 0.0327 (4)  
C18 0.0144 (2) 1.23909 (14) -0.1532 (2) 0.0382 (5)  
H18A 0.0201 1.2175 -0.0709 0.046*  
H18B -0.0717 1.2626 -0.1942 0.046*  
C19 0.1104 (3) 1.30874 (16) -0.1348 (3) 0.0494 (6)  
H19A 0.0989 1.3349 -0.2150 0.074*  
H19B 0.1962 1.2853 -0.0992 0.074*  
H19C 0.0985 1.3511 -0.0784 0.074*  
C20 0.57486 (18) 0.58999 (12) 0.30341 (19) 0.0271 (4)  
206 
C21 0.57294 (19) 0.60586 (14) 0.1855 (2) 0.0311 (4)  
H21 0.6269 0.5753 0.1539 0.037*  
C22 0.49136 (19) 0.66704 (14) 0.11270 (19) 0.0320 (4)  
C23 0.7851 (2) 0.43572 (16) 0.6832 (2) 0.0420 (5)  
H23A 0.7140 0.4014 0.6881 0.050*  
H23B 0.8649 0.4043 0.7244 0.050*  
C24 0.7900 (2) 0.51865 (17) 0.7481 (2) 0.0429 (5)  
H24A 0.7886 0.5080 0.8321 0.051*  
H24B 0.8706 0.5475 0.7578 0.051*  
C25 0.6817 (2) 0.57490 (15) 0.6790 (2) 0.0358 (5)  
C26 0.7446 (2) 0.66055 (18) 0.8611 (2) 0.0454 (6)  
H26A 0.8261 0.6724 0.8525 0.068*  
H26B 0.7548 0.6141 0.9197 0.068*  
H26C 0.7154 0.7108 0.8922 0.068*  
C27 0.53581 (19) 0.43154 (13) 0.43739 (19) 0.0315 (4)  
C28 0.4206 (2) 0.33716 (15) 0.2820 (2) 0.0407 (5)  
H28A 0.4074 0.3228 0.1957 0.061*  
H28B 0.3389 0.3509 0.2890 0.061*  
H28C 0.4586 0.2891 0.3357 0.061*  
C29 0.37714 (18) 0.86566 (12) 0.09002 (18) 0.0271 (4)  
C30 0.30412 (18) 0.92793 (12) 0.01078 (18) 0.0272 (4)  
H30 0.3365 0.9835 0.0154 0.033*  
C31 0.5056 (2) 0.88810 (14) 0.1834 (2) 0.0373 (5)  
H31A 0.5038 0.8837 0.2674 0.056*  
H31B 0.5272 0.9458 0.1687 0.056*  
H31C 0.5694 0.8493 0.1748 0.056*  
C32 0.01791 (19) 0.80584 (12) -0.18563 (18) 0.0265 (4)  
C33 -0.04890 (18) 0.87474 (12) -0.26549 (18) 0.0264 (4)  
C34 -0.13438 (18) 0.86292 (13) -0.38338 (18) 0.0282 (4)  
C35 -0.2400 (2) 0.76831 (16) -0.55127 (19) 0.0398 (5)  
H35A -0.2069 0.7996 -0.6062 0.060*  
H35B -0.3271 0.7863 -0.5660 0.060*  
H35C -0.2390 0.7080 -0.5683 0.060*  
C36 -0.1943 (2) 0.93395 (14) -0.46971 (19) 0.0346 (5)  
H36A -0.2844 0.9201 -0.5161 0.042*  
207 
H36B -0.1517 0.9397 -0.5307 0.042*  
C37 -0.1872 (2) 1.01775 (14) -0.4035 (2) 0.0358 (5)  
H37A -0.2085 1.0640 -0.4650 0.043*  
H37B -0.2500 1.0183 -0.3619 0.043*  
C38 -0.07003 (18) 0.98006 (12) -0.10768 (17) 0.0278 (4)  
C39 -0.2623 (2) 0.99339 (13) -0.0720 (2) 0.0340 (4)  
H39A -0.3535 0.9851 -0.1154 0.051*  
H39B -0.2451 1.0531 -0.0517 0.051*  
H39C -0.2338 0.9602 0.0047 0.051*  
O9B 0.9479 (12) 0.3356 (8) 0.5236 (10) 0.0440 (6) 0.206 (3) 
C3B 0.8419 (13) 0.3135 (10) 0.4623 (13) 0.0354 (7) 0.206 (3) 
C2B 0.8051 (19) 0.2377 (9) 0.3871 (19) 0.0447 (8) 0.206 (3) 
H2BA 0.7777 0.2541 0.2986 0.054* 0.206 (3) 
H2BB 0.7309 0.2127 0.4005 0.054* 0.206 (3) 
C1B 0.9034 (11) 0.1730 (8) 0.4112 (11) 0.0447 (7) 0.206 (3) 
H1BA 0.8650 0.1204 0.3706 0.067* 0.206 (3) 
H1BB 0.9430 0.1638 0.5008 0.067* 0.206 (3) 
H1BC 0.9678 0.1915 0.3783 0.067* 0.206 (3) 
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Chapter 5 
 
Syntheses of 2,4’- and 4,4’-linked Secalonic Acids and Their 
Isomerization Chemistry 
 
5.1 Introduction to 2,4’- and 4,4’-Linked Secalonic Acids and Related 
Natural Products 
        Besides the previously discussed 2,2’-linked dimeric natural products, nature has 
dramatically increased the structural complexity through additional 2,4’ and 4,4’ linkages. 
For example, secalonic acid A (ent-5) is a 2,2’-linked dimer. Its 2,4’-linked isomer 
penicillixanthone A (16)119 is also found in nature (Figure 5.1). Similarly, the 4,4’-linked 
secalonic acid E (talaroxanthone, 239)120 was recently isolated and characterized. Based 
on our previous discussions, the different secalonic acids possessing different linkages 
was converted to each other under certain conditions. 
        Recently, another related sub-class of tetrahydroxanthone compounds, 
phomoxanthones, have been isolated in the last decade. Phomoxanthone A (240) is a 
4,4’-linked dimer. Its absolute stereochemistry was recently established by X-ray 
crystallography and TDDFT (Time-dependent density functional theory)-ECD 
calculations.121 The corresponding 2,4’-linked dimer phomoxanthone B (241) and the 
2,2’-linked dimer dicerandrol C (242)122 are also been found in nature.  
223 
         Due to the presence of different linkages, the shape of molecule changes 
dramatically which also has an substantial influence on biological properties. For 
example, the 4,4’-linked compound phomoxanthone A exhibits a strong cytotoxicity to 
cancer cells L5178Y (IC50 = 0.3 µM), whereas 2,2’-linked dicerandrol C was found to be 
less potent (IC50 = 2.8 µM).121c 
        Since these molecules could undergo interesting isomerizations, we considered that 
the chemical synthesis of 2,4’-linked and 4,4-linked secalonic acids could provide us with 
a tool to study “shapeshifting” transformations.123 Moreover, the 2,4’-linked and 4,4’-
Figure 5.1 2,2’-, 2,4’- and 4,4’-Linked Dimeric Tetrahydroxanthone Natural Products 
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linked dimers also exhibit interesting biological activities. Along with the 2,2’-linked 
compounds, these compounds can be used to eventually construct a complete 
tetrahydroxanthone library. 
 
5.2 Synthesis of 4,4’-linked Chromone Lactone Dimers 
Based on our strategy for the synthesis of 2,2’-linked chromone lactones, we 
anticipated that if we could prefunctionalize the para-position of the chromone lactone, 
then the 4,4’-linked dimers may be synthesized using our previously developed copper-
mediated stannane coupling approach. However, after investigating various iodination 
and bromination conditions on monomer 114, we found that the ortho-halogenated 
chromone lactone 243 was generally the major product (Scheme 5.1, a)). Our explanation 
is that the free phenol is directing halogenations or that the para position is more 
hindered. 
     During our screening of additives, we found that a catalytic amount of the Lewis acid 
AuCl3124 dramatically changed the outcome of the bromination (Scheme 5.1, b)). In the 
presence of 0.05 equivalent AuCl3, the para-brominated chromone lactone 244 was 
favored. This phenomenon was also observed in other related chromone lactones. For 
138, the para-bromide 245 was obtained in 65 % yield. Additionally, the para-bromide 
246 was isolated in 81 % yield from 140. We considered that the Au (III) catalyst may 
might chelate with the butenolide ring to direct the bromination. This hypothesis is 
supported by the fact that AuCl3 can not enhance the yield of the para product on 
225 
tetrahydroxanthone substrates. This result highlights the importance of the butenolide 
moiety in this gold-catalyzed reaction. 
 
 
     With the para-bromide 244 in hand, we converted it to the corresponding para-
stannane 247 in 79 % yield (Scheme 5.2). We next initiated studies towards the stannane 
coupling with several different metals and oxidants. Surprisingly, the free phenol 
Scheme 5.1 Para-Activation of Chromone Lactone 
 
 
Scheme 5.2 Attempted Synthesis of 4,4’-Linked Chromone Lactone 
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stannane 247 did not generate the desired 4,4’-linked dimers 248/249 under these 
conditions; the main side reaction generally observed was protodestannylation.  
          We considered that the phenol may have a low enough pka to favor the 
protodestannylation process. Thus we changed our strategy and compound 114 was 
protected with Me2SO4 (Scheme 5.3). After methyl protection, we found that the 
chromonane became less nucleophilic and the para-position became less hindered. 
Treatment of 166 with NIS in presence of catalytic In(OTf)3 or with nBu4NBr3 led to the 
corresponding para-iodide 251 or bromide 250, respectively. Sequential stannylation 
provided stannane 252 in 61 % yield along with the elimination product 253. When we 
applied the previously developed CuCl/air mediated coupling conditions, stannane 250 
Scheme 5.3 Synthesis of 4,4’-linked Chromone Lactones 
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was only coverted to dimers in trace amounts and a large amount of the starting material 
was intact. We thought that the amount of oxidant in air was difficult to accurately 
control and that this could be the problem for the conversion of this reaction. Fortunately, 
after we changed the oxidant to CuCl2, the C2 dimer 254 and Cs dimer 255 were each 
isolated in 23 % reproducible yield. 
 
5.3 Synthesis of 4,4’-linked Secalonic Acids 
      The successful synthesis of 4,4’-linked chromone lactones encouraged us to further 
investigate the synthesis of 4,4’-linked dimeric tetrahydroxanthones. We envisioned that 
the synthesis of an enantiopure para-functionalized tetrahydroxanthone was the key 
intermediate. Our initial thought was that the para-brominated tetrahydroxanthone could 
be obtained from a para-brominated chromone lactone through Dieckmann cyclization 
Scheme 5.4 Dieckmann Cyclization on Brominated Chromone Lactone 
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(Scheme 5.4). However, the potential rearrangement of tetrahydroxanthones could still 
be problematic. Thus, we started by treating the ortho-brominated chromone lactone 256 
with 10 equivalents of NaH in THF for 3 h. In this case, the corresponding 
tetrahydroxanthone 257 was isolated in 43 % yield as a single diastereomer. Surprisingly, 
when we treated the para-bromide 244 with 10 equivalents of NaH, we obtained three 
different tetrahydroxanthones. The desired para-brominated tetrahydroxanthone 258 was 
only obtained in 10 % yield. The main byproduct was the ortho-bromide 259 with a syn-
configuration. Even when we shortened the reaction time or lowered the reaction 
temperature, the undesired tetrahydroxanthones 259 were still observed. Thus, we 
considered that under Dieckmann cyclization conditions, para-bromide 244 generated 
intermediate 260 in situ. If 260 was cyclized through 1-OH, the anti-configuation 259 
was generated. The ortho-bromo tetrahydroxanthone 257 was observed through a retro-
oxa-Michael/oxa-Michael reaction pathway during longer reaction times.  
      From these results, we hypothesized that the para-bromide tetrahydroxanthone was 
not favored under NaH/THF conditions. Therefore, we changed our strategy to 
prefunctionalize the tetrahydroxanthone moiety. However, when tetrahydroxanthone 130 
was treated with halogenation reagents such as NCS, the enol-chlorinated derivative 261 
was isolated in near quantitative yield as a single diastereomer (Scheme 5.5). The anti-
configuration between chlorine and the methyl ester was confirmed by X-ray crystal 
structure analysis. The high diastereomeric selectivity is likely due to steric repulsion 
between the electrophile and the methyl ester. Since the free enol should be the most 
nucleophilic position in the tetrahydroxanthone substrate, we thought that the enol-
229 
protected compound 173 would avoid this problem. After screening different iodination 
and bromination conditions, the ortho-halogenated product was found to be dominant.  
       We reasoned that the vinylogous acid group in the tetrahydroxanthone could be 
stabilized under acid conditions. After forming protonated tetrahydroxanthone 263, the 
phenol may be the more nucleophilic site. Indeed, when 130 was treated with NIS in 
TFA/CH2Cl2 (Scheme 5.5), the para-iodo and ortho-iodo tetrahydroxanthones were 
generated in a 1:1 ratio by crude 1H NMR analysis. The mixture was further methylated 
using trimethylsilydiazomethane to afford para-iodide 262 and ortho-iodide 174 were 
separated in 31 % and 32 % yields (two steps). 
  
 
Scheme 5.5 Synthesis of the para-Iodo Tetrahydroxanthone 
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      With compound 262 in hand, we followed our previous sequence to MOM protect the 
free phenol. However, in this case MOM protection was found to be low yielding and 
irreproducible. Fortunately, stannylation could be cleanly performed on the unprotected 
substrate 262 (Scheme 5.6). Remarkably, the para-iodide 262 was not transformed to a 
dimeric product under our previous one-pot Suzuki dimerization conditions (Pd-SPhos-II, 
BPin2, K3PO4) (cf. Chapter 4).  
     Since there are no literature reports of stannane dimerizations with substrates 
containing a free phenol, we worried that a free phenol could jeopardize the dimerization 
step. Nevertheless, the resulting stannane 264 was subjected to dimerization conditions.  
Applying our previously developed CuCl/air condition to the stannane 264 cleanly 
produced a protodestannylation product. After further screening of oxidants (e.g. 
Cu(ethylhexanoate)2, Cu(OAc)2, FeCl3, Mn(acac)3), we found that CuCl2 and ferroceium 
tetrafluoroborate could provide the corresponding 4,4’-linked dimers in 40~50 % 
Scheme 5.6 Synthesis of Model 4,4’-Tetrahydroxanthone Dimer 
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conversion (Scheme 5.6). However, the yield/conversion was remained inconsistent over 
several experimental trials. After further screening of additives (e.g. Na2SO4, CaCO3, 
NaHCO3), we found that a trace amount of water decreased the yield dramatically. Thus, 
using either freshly-prepared stannane 264 or the additive Drierite could afford the 
corresponding separable Cs symmetric dimer 266 and C2 symmetric dimer 265 each in 22 
% yield.  
      After successfully establishing a model 4,4’-linked dimeric tetrahydroxanthone 
synthesis, we considered that the racemic 4,4’-secalonic acids A/D could be synthesized 
in a similar manner (Scheme 5.7). Blennolide B (2) was iodinated with NIS in 
TFA/CH2Cl2. The resulting para- and ortho-iodides were O-methylated to afford 267 in 
Scheme 5.7 Synthesis of 4,4’-Tetrahydroxanthone Dimers 
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32 % (para-iodide). Stannylation proceeded smoothly following the protocol to generate 
268. The C2 dimer 269 and Cs dimer 270 were successfully synthesized by treating 
freshly-dried stannane 268 with CuCl/CuCl2. The presence of a 4,4’-linkage was further 
verified through a key HMBC correlation between C2 and 1-OH. Interestingly, the 3H 1H 
NMR signal of 269 became a broad peak which indicated that the 4,4’-biaryl rotation was 
likely restricted. 
      In order to asymmetrically synthesize 4,4’-linked secalonic acid, synthesis of an 
enantioenriched or enantiopure monomeric tetrahydroxanthone became essential. Relying 
on our developed kinetic resolution on the tetrahydroxanthone moiety using HBTM 
catalyst, we anticipated that an enantiopure para-iodide could be obtained similarly. 
However, contrary to the excellent kinetic resolution observed on the ortho-iodide 174, 
the HBTM catalyst 184 did not successfully catalyze acetylation on para-iodide 262 
using propionic anhydride. When we changed to the less hindered acetic anhydride, the 
resulting acetylated tetrahydroxanthone 271 only had a moderate ee (Scheme 5.8). This 
unpredicted result indicated that the substitution on the para-position of the 
tetrahydroxanthone jeopardized its reactivity with HBTM catalyst. 
Scheme 5.8 Unsecessful Kinetic Resolution of a para-Iodide Substrate 
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      After the unsuccessful kinetic resolution attempts on the para-iodide 
tetrahydroxanthone, we considered that the kinetic resolution could proceed on the 
unprotected tetrahydroxanthones. Indeed, the HBTM catalyst 184 could convert 130 to 
the acylated product. However, even with a substoichiometric amount of the base DIEA, 
the tetrahydroxanthone still underwent syn/anti and retro-Dieckmann rearrangement 
(Scheme 5.9). Since tetrahydroxanthone substrates were found to be stable in acidic 
conditions, we wondered whether base was necessary for the acylation. Gratifyingly, 
without any base, kinetic resolution proceeded smoothly on tetrahydroxanthone 130 to 
generate (-)-130 and (+)-272 in excellent yield and in excellent enantiomeric excess 
(Scheme 5.9). The s factor for this reaction was above 200. For the real system, 
blennolide B (2), we were concerned that the additional methyl on C ring could 
Scheme 5.9 Kinetic Resolution on an Unprotected Tetrahydroxanthone Moiety 
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dramatically decrease the secondary alcohol acylation reactivity. For this case, 
enantioselectivities using propionic anhydride never exceeded 40 % conversion after 
screening various conditions. Fortunately, after switching to the less hindered acetic 
anhydride, (-)-2 and the acylated tetrahydroxanthone (+)-273 were obtained in high yield 
and ee. Notably, the s factor for the unprotected blennolide B (s=159) was even higher 
than for the enol protected 189 shown previously (s=93).  
      With the enantioenriched monomers in hand, the chiral 4,4’-linked dimers were 
synthesized using similar conditions. Chiral 4,4’-linked secalonic acids (-)-265 and (-)-
269 were obtained by treating with CuCl2/CuCl from monomers (-)-264 and (-)-268, 
respectively (Scheme 5.10). 
 
5.4 Synthesis of 2,4’-linked Dimers 
Scheme 5.10 Synthesis of Chiral 4,4’-Tetrahydroxanthone Dimers 
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     Tetrahydroxanthones with 2,4’-linkage are also widely found in dimeric natural 
products. Since the ortho- and para- functionalized chromone lactones and 
tetrahydroxanthones were already prepared, we could utilize the copper-mediated 
dimerization to generate 2,4’-linked dimers and heterodimers. 
     We initially used the racemic ortho-stannane 164 and para-stannane 250 to perform 
this heterocoupling (Scheme 5.11). Theoretically, the heterocoupling product should be 
the major isomer in a ratio of 2:1:1 to other two homodimers based on statistics. The 
stannane mixture was treated with CuCl2/CuCl for 12 h. Indeed, the heterocoupled 2,4’-
linked dimer 274/275 was the major diastereomer and isolated in 35 % yield. However, 
the relatively low yield of 4,4’-linked dimers indicates that the para position is more 
hindered in comparison to the ortho position. 
Scheme 5.11 Synthesis of 2,4’-Chromone Lactone Dimers 
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       After successfully preparing the 2,4’-linked chromone lactone dimers, we envisioned 
that the chiral 2,4’ secalonic acid could be synthesized in a similar manner. Starting from 
enantioenriched monomers (+)-176 and (-)-264, the resulting 2,4’-linked dimer 276 was 
obtained in 35 % yield under similar dimerization conditions (Scheme 5.12). 
 
5.5 Future Plans: Isomerization Studies 
     
       Based on previous discussion, we have synthesized the 2,2’- (Chapter 3), 2,4’- and 
4,4’- linked secalonic acids (Figure 5.2). Our future plan will be to evaluate the 
Scheme 5.12 Synthesis of Chiral 2,4’ Tetrahydroxanthone Dimers 
 
 
Figure 5.2 Equilibration Studies between 2,2’, 2,4’ and 4,4’ Secalonic acid A 
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isomerization process24 using UPLC methods. Specifically, we will evaluate 
isomerization of the secalonic acid A in DMSO, DMSO/pyridine mixtures, as well as 
other solvent. This study should allow us to further understand the mechanism of this 
intriguing isomerization and the conditions to promote linkage isomerization. 
  
5.6 Conclusion 
      In summary, the bioactive 2,4’- and 4,4’- linked chromone lactones/ 
tetrahydroxanthone dimers have been synthesized for the first time. Birman's 
homobenzotetramisole (HBTM) catalysts were found to be highly effective for kinetic 
resolution of unprotected tetrahydroxanthone monomers. In addition, modified copper-
mediated stannane dimerization conditions allowed us to successfully access various 
heterocoupling products.  
 
5.7 Experimental Section 
General Information: 1H NMR spectra were recorded at 400 MHz at ambient 
temperature with CDCl3 (Cambridge Isotope Laboratories, Inc.) as the solvent unless 
otherwise stated. 13C NMR spectra were recorded at 100.0 MHz at ambient temperature 
with CDCl3 as the solvent unless otherwise stated. Chemical shifts are reported in parts 
per million relative to CDCl3 (1H, δ 7.26; 13C, δ 77.0). Data for 1H NMR are reported as 
follows: chemical shift, integration, multiplicity (app = apparent, br = broad, par obsc = 
partially obscure, ovrlp = overlapping, s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet) and coupling constants. All 13C NMR spectra were recorded with complete 
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proton decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
Chemical Instrumentation Center using a Waters Q-TOF mass spectrometer. Melting 
points were recorded on a Mel-temp (Laboratory Devices). Analytical thin layer 
chromatography was performed using 0.25 mm silica gel 60-F plates. Flash 
chromatography was performed using 200-400 mesh silica gel (Sorbent Technologies, 
Inc.). Preparative TLC was conducted with glass backed 1000μm silica gel 60-F plates 
(Silicycle, Inc.) Yields refer to chromatographically and spectroscopically pure 
compounds, unless otherwise stated.  All other reactions were carried out in oven-dried 
glassware under an argon atmosphere unless otherwise noted. The ArthurTM Suite 
Reaction Planner (Symyx Technologies, Inc.) was used for experimental procedure 
planning. Analytical LC-MS experiments were performed using a Waters Acquity UPLC 
(Ultra Performance Liquid Chromatography) with a Binary solvent manager, SQ mass 
spectrometer, Water 2996 PDA (PhotoDiode Array) detector, and Evaporative Light 
Scattering Detector (ELSD). An Acquity UPLC BEH C18 1.7 μm column was used for 
analytical UPLC-MS analysis. Preparative HPLC purification was performed on a Gilson 
PLC 2020 Personal Purification System. A Chiralcel®OD (Chiral Technologies Inc., 250 
× 4.6 mm I.D.) column was used for enantiomeric excess determination. HPLC grade 
tetrahydrofuran, methylene chloride, diethyl ether, toluene and hexanes were purchased 
from Fisher and VWR and were purified and dried by passing through a PURE SOLV® 
solvent purification system (Innovative Technology, Inc.). Methanol was purchased from 
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Fisher and used without further purification. Other ACS grade solvents were purchased 
from Clean Harbors. 
 
 
para-Bromide Chromone Lactone 244: To a flame-dried flask containing 500 mg 
chromone lactone 114 (1.63 mmol), 291 mg NBS (1.63 mmol, 1 equiv), and 25 mg 
AuCl3 (0.082 mmol, 0.05 equiv) added 16 mL DCE. The solution was stirred at rt for 12 
h. The reaction was then concentrated in vacuo. The crude product was purified by 
column chromatography (hexanes/ether = 1: 2) which afforded 244 (455 mg, 71 %) as a 
white solid and along with 256 (127 mg, 20 %) as a pale yellow solid. 
244: Rf = 0.74 (ether); mp 137-139 °C (CH2Cl2); IR (thin film): νmax 1788, 1757, 1655, 
1621, 1464, 1346, 1229, 1162, 840, 762 cm-1; 1H NMR (CDCl3, 500 MHz): δ 11.45 (s, 
1H), 7.57 (d, J = 9.0 Hz, 1H), 6.49 (d, J = 8.9 Hz, 1H), 4.80 (dd, J = 9.1, 2.9 Hz, 1H), 
3.72 (s, 3H), 3.53 (d, J = 17.5 Hz, 1H), 3.12 (m, 1H), 3.11 (d, J = 17.4 Hz, 1H), 2.54 (m, 
2H), 2.38 (m, 1H); 13C NMR (CDCl3, 125 MHz) : δ 194.6, 176.3, 168.3, 161.1, 155.2, 
141.3, 111.9, 108.1, 99.0, 85.9, 79.2, 53.8, 40.3, 27.4, 21.9; HRMS ESI (m/z): [M+H]+ 
calcd for C15H14BrO7, 384.9923; found, 384.9907.  
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256: Rf = 0.61 (ether); mp 141-143 °C (CH2Cl2); IR (thin film): νmax 1786, 1755, 1652, 
1620, 1432, 1352, 1282, 1201, 1161, 1121, 1057, 1009, 752 cm-1; 1H NMR (CDCl3, 500 
MHz): δ 12.10 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 6.49 (d, J = 8.8 Hz, 1H), 4.79 (dd, J = 
8.5, 4.5 Hz, 1H), 3.75 (s, 3H), 3.51 (d, J = 17.3 Hz, 1H), 3.14 (d, J = 17.3 Hz, 1H), 2.79 
(ddd, J = 18.1, 10.2, 7.9 Hz, 1H), 2.59 (ddd, J = 17.7, 10.6, 5.3 Hz, 1H), 2.50 (ddd, J = 
18.2, 10.3, 5.0 Hz, 1H), 2.35 (m, 1H); 13C NMR (CDCl3, 125 MHz) : δ 194.7, 175.7, 
168.6, 158.5, 158.0, 141.4, 108.9, 108.0, 102.4, 84.9, 79.4, 53.8, 40.3, 27.7, 21.6; HRMS 
ESI (m/z): [M+H]+ calcd for C15H14BrO7, 384.9923; found, 384.9910.  
 
Compounds 245 and 246 were prepared following the same procedure. 
 
245: colorless solid; Rf = 0.56 (hexanes/EtOAc = 1:1); mp 155-157 °C (CH2Cl2); IR (thin 
film): νmax 1791, 1758, 1654, 1622, 1462, 1347, 1227, 1156, 1018, 840, 758 cm-1; 1H 
NMR (CDCl3, 500 MHz): δ 11.41 (s, 1H), 6.53 (s, 1H), 4.81 (dd, J = 9.0, 2.9 Hz, 1H), 
3.74 (s, 3H), 3.52 (d, J = 17.4 Hz, 1H), 3.20 (dd, J = 20.3, 11.2, 11.2 Hz, 1H), 3.43 (d, J = 
17.4 Hz, 1H), 2.58 (m, 2H), 2.40 (s, 3H), 2.39 (m, 1H); 13C NMR (CDCl3, 125 MHz) : δ 
194.1, 176.3, 168.6, 160.3, 155.2, 150.3, 112.5, 106.4, 102.2, 86.0, 79.3, 53.8, 40.1, 27.5, 
24.3, 22.0; HRMS ESI (m/z): [M+H]+ calcd for C16H16BrO7, 399.0079; found, 399.0080. 
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246: colorless solid; Rf = 0.61 (hexanes/EtOAc = 1:1); mp 148-149 °C (CH2Cl2); IR (thin 
film): νmax 1785, 1756, 1652, 1628, 1461, 1363, 1288, 1190, 1162, 1124, 1030, 758 cm-1; 
1H NMR (CDCl3, 500 MHz): δ 11.44 (s, 1H), 7.59 (d, J = 9.0 Hz, 1H), 6.50 (d, J = 9.0 
Hz, 1H), 4.88 (d, J = 7.3 Hz, 1H), 3.74 (s, 3H), 3.70 (d, J = 17.6 Hz, 1H), 3.10 (dd, J = 
13.1, 12.4 Hz, 1H), 3.05 (m, 1H), 2.92 (d, J = 17.6 Hz, 1H), 2.56 (dd, J = 15.9, 7.4 Hz, 
1H), 1.32 (d, J = 6.5 Hz, 1H); 13C NMR (CDCl3, 125 MHz) : δ 194.3, 175.7, 169.1, 161.0, 
155.9, 141.4, 111.8, 108.2, 98.6, 85.4, 81.7, 53.5, 41.3, 34.9, 33.6, 12.9; HRMS-ESI 
(m/z): [M+H]+ calcd for C16H16BrO7, 399.0079; found, 399.0072.  
 
 
Para-Stannane Chromone Lactone 247: para-Bromide chromone lactone 244 (100 mg, 
0.26 mmol), nBu4NI (96 mg, 0.26 mmol, 1 equiv), Pd2(dba)3 (24 mg, 0.026 mmol, 0.1 
equiv), PtBu3 (21 mg, 0.104 mmol, 0.4 equiv) and bis(tributyltin) (261 µL, 0.52 mmol, 
2.0 equiv) were added to a flame-dried flask. Under a N2 atmosphere, 2.5 mL of 
anhydrous dioxane was added. The flask was warmed to 50 oC and stirred for 4 h. After 
cooling to room temperature, the solvent was removed in vacuo. The crude mixture was 
directly purified by silica gel chromatography (hexanes/EtOAc = 6: 1) to afford the 
tetrahydroxanthone stannane 247 (121 mg, 78 %) as a colorless oil. 
247: Rf = 0.52 (hexanes/EtOAc = 3:1); IR (thin film): νmax 2955, 2924, 2871, 2853, 1793, 
1742, 1648, 1614, 1566, 1460, 1403, 1345, 1234, 1196, 1053, 1017, 838 cm-1; 1H NMR 
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(CDCl3, 500 MHz): δ 11.61 (s, 1H), 7.44 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 
4.78 (dd, J = 7.7, 7.7 Hz, 1H), 3.70 (s, 3H), 3.35 (d, J = 17.0 Hz, 1H), 3.21 (d, J = 17.0 
Hz, 1H), 2.66 (m, 2H), 2.56 (m, 1H), 2.27 (ddd, J = 20.7, 6.9, 6.9 Hz, 1H); 13C NMR 
(CDCl3, 125 MHz) : δ 195.4, 174.7, 168.9, 163.3, 162.5, 146.4, 117.3, 111.1, 107.3, 83.2, 
80.2, 53.5, 40.4, 29.0, 28.2, 27.3, 21.4, 13.7, 9.7; HRMS ESI (m/z): [M+H]+ calcd for 
C27H41SnO7, 597.1880; found, 597.1876.  
 
 
O-Methyl Chromone Lactone 166: Chromone lactone 114 (1g, 3.27 mmol) and Cs2CO3 
(2.12 g, 6.53 mmol, 2 equiv) were added to a flame-dried flask. Under a N2 atmosphere, 
32 mL of anhydrous acetone and Me2SO4 (0.62 mL, 6.53 mmol, 2 equiv) was added. The 
flask was warmed to 60 oC and stirred for 2 h. After cooling to room temperature, the 
crude mixture was filtered, and solvent was removed in vacuo. The crude mixture was 
directly purified by silica gel chromatography (hexanes/EtOAc = 1: 1) to afford the 
chromone lactone 166 (856 mg, 82 %) as a colorless oil which could become solid after 
cooling. 
166: Rf = 0.19 (hexanes/EtOAc = 1:1); mp 141-143 °C (CH2Cl2); IR (thin film): νmax 
3018, 2956, 1783, 1752, 1687, 1602, 1577, 1472, 1438, 1258, 1164, 1081, 1016, 791, 752 
cm-1; 1H NMR (CDCl3, 400 MHz): δ 7.37 (t, J = 8.4 Hz, 1H), 6.58 (d, J = 8.3 Hz, 1H), 
6.50 (d, J = 8.3 Hz, 1H), 4.75 (dd, J = 8.5, 4.4 Hz, 1H), 3.83 (s, 3H), 3.64 (s, 3H), 3.32 (d, 
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J = 16.3 Hz, 1H), 2.94 (d, J = 16.3 Hz, 1H), 2.74 (ddd, J = 18.1, 10.2, 7.9 Hz, 1H), 2.51 
(ddd, J = 17.8, 10.5, 5.2 Hz, 1H), 2.41 (ddd, J = 15.0, 10.0, 4.7 Hz, 1H), 2.29 (m, 1H); 
13C NMR (CDCl3, 100 MHz) : δ 187.3, 176.1, 168.9, 160.8, 160.1, 136.4, 110.4, 109.7, 
104.6, 84.3, 79.6, 56.0, 53.3, 42.2, 27.6, 21.5; HRMS ESI (m/z): [M+Na]+ calcd for 
C16H16O7Na, 321.0974; found, 343.0806. 
 
 
para-Bromide 250: chromone lactone 166 (340 mg, 1.06 mmol) and nBu4NBr3 (502 mg, 
1.04 mmol, 0.98 equiv) were added to a flask. Under a N2 atmosphere, 6 mL of 
THF/water (1:1) was added. The flask was stirred at rt for 1d. The crude mixture was 
extracted with EtOAc 40 mL twice, washed with brine, dried over sodium sulfate. The 
organic phase was concentrated in vacuo and purified by silica gel chromatography 
(hexanes/EtOAc = 1: 1) to afford the para-bromide chromone lactone 250 (395 mg, 93 
%) as a white solid. 
250: Rf = 0.28 (hexanes/EtOAc = 1:1); mp 191-192 °C (hexanes/CH2Cl2); IR (thin film): 
νmax 3019, 2956, 1783, 1753, 1692, 1589, 1565, 1473, 1438, 1253, 1118, 1061, 755 cm-1; 
1H NMR (CDCl3, 400 MHz): δ 7.62 (d, J = 9.0 Hz, 1H), 6.49 (d, J = 9.0 Hz, 1H), 4.82 
(dd, J = 8.9, 3.0 Hz, 1H), 3.87 (s, 3H), 3.70 (s, 3H), 3.43 (d, J = 16.5 Hz, 1H), 3.17 (ddd, 
J = 19.1, 10.1, 8.6 Hz, 1H), 3.00 (d, J = 16.5 Hz, 1H), 2.53 (m, 2H), 2.37 (m, 1H); 13C 
NMR (CDCl3, 125 MHz) : δ 186.9, 176.5, 168.5, 159.6, 157.0, 139.2, 111.7, 106.1, 102.0, 
244 
85.8, 79.3, 56.3, 53.6, 42.2, 27.4, 21.8; HRMS ESI (m/z): [M+H]+ calcd for C16H16O7Br, 
399.0079; found, 399.0083. 
 
 
 
Para-Stannane Chromone Lactone 252: para-Bromide chromone lactone 250 (238 mg, 
0.60 mmol), nBu4NI (220 mg, 0.60 mmol, 1 equiv), Pd2(dba)3 (55 mg, 0.06 mmol, 0.1 
equiv), PtBu3 (48 mg, 0.24 mmol, 0.4 equiv) and bis(tributyltin) (597 µL, 1.19 mmol, 2.0 
equiv) were added to a flame-dried flask. Under a N2 atmosphere, 6 mL of anhydrous 
dioxane was added. The flask was warmed to 40 oC and stirred for 6 h. After cooling to 
room temperature, the solvent was removed in vacuo. The crude mixture was directly 
purified by silica gel chromatography (hexanes/EtOAc = 3: 1) to afford the 
tetrahydroxanthone stannane 252 (256 mg, 70 %) as a colorless oil. 
252: Rf = 0.51 (hexanes/EtOAc = 1: 1); IR (thin film): νmax 3373, 2956, 2924, 2871, 2852, 
1791, 1756, 1691, 1579, 1470, 1260, 1097, 1024 cm-1; 1H NMR (CDCl3, 400 MHz): δ 
7.47 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 4.77 (dd, J = 7.9, 7.9 Hz, 1H), 3.89 (s, 
3H), 3.67 (s, 3H), 3.25 (d, J = 16.1 Hz, 1H), 3.04 (d, J = 16.1 Hz, 1H), 2.64 (m, 2H), 2.53 
(m, 1H), 2.24 (ddd, J = 19.9, 13.6, 6.3 Hz, 1H), 1.53 (m, 6H), 1.32 (m, 6H), 1.09 (m, 6H), 
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0.88 (t, J = 7.3 Hz, 9H); 13C NMR (CDCl3, 100 MHz) : δ 188.1, 174.9, 169.0, 165.1, 
161.0, 144.3, 120.2, 110.3, 105.5, 83.0, 80.6, 56.1, 53.3, 42.4, 29.0, 28.3, 27.3, 21.4, 13.7, 
9.7; HRMS-ESI (m/z): [M+H]+ calcd for C28H43O7Sn, 611.2037; found, 611.2020. 
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Dimeric Chromone Lactones 254 and 255: Chromanone stannane 252 (60 mg, 0.082 
mmol), freshly prepared CuCl (41 mg, 0.41 mmol, 5 equiv) and anhydrous CuCl2 (11 mg, 
0.082 mmol, 1 equiv) were placed in a flame-dried tube. Under N2 atmosphere, 0.8 mL of 
DMA was added into the tube and the reaction mixture was stirred at room temperature 
for 12 h. The mixture was quenched with 3 mL of saturated NH4Cl solution and was 
extracted 5 times with 5 mL of EtOAc After concentrating the reaction mixture at 40 oC 
in vacuo, the crude product was directly purified by column chromatography (EtOAc) to 
afford the Cs symmetric dimeric chromone lactones 255 (6 mg, 23 %) and C2 symmetric 
dimer 254 (6 mg, 23 %) as a colorless gel.  
246 
254 (C2 dimer): Rf = 0.25 (EtOAc); IR (thin film): νmax 2960, 1785, 1752, 1689, 1595, 
1476, 1292, 1258, 1118, 758 cm-1; 1H NMR (acetone-D6, 500 MHz): δ 7.69 (br, 2H, due 
to restrict rotation), 6.81 (d, J = 8.6 Hz, 2H), 4.78 (dd, J = 8.5, 3.0 Hz, 2H), 3.89 (s, 6H), 
3.74 (s, 3H), 3.35 (d, J = 16.1 Hz, 2H), 2.82 (d, J = 16.1 Hz, 2H), 2.28 (m, 2H), 2.15 (m, 
4H), 1.68 (m, 2H); 13C NMR (acetone-D6, 125 MHz) : δ 188.1, 177.5, 171.1, 161.9, 
160.2, 139.9, 119.7, 112.7, 106.3, 87.2, 81.2, 57.4, 54.7, 44.1, 28.3, 23.4; HRMS-ESI 
(m/z): [M+H]+ calcd for C32H31O14, 639.1714; found, 639.1714. 
255 (Cs dimer): Rf = 0.34 (EtOAc); IR (thin film): νmax 3017, 2960, 1784, 1751, 1687, 
1595, 1570, 1476, 1297, 1258, 1165, 1117, 1060, 1018, 756 cm-1; 1H NMR (acetone-D6, 
500 MHz): δ 7.71 (br, 2H, due to restrict rotation), 6.82 (d, J = 8.6 Hz, 2H), 4.82 (dd, J = 
7.9, 4.4 Hz, 2H), 3.89 (s, 6H), 3.72 (br, 6H), 3.32 (d, J = 16.3 Hz, 2H), 2.97 (d, J = 16.3 
Hz, 2H), 2.27 (m, 4H), 2.11 (m, 4H); 13C NMR (acetone-D6, 125 MHz) : δ 188.0, 177.6, 
171.1, 161.8, 159.9, 140.5, 119.5, 112.8, 106.2, 86.9 (br), 81.6, 57.4, 54.9, 44.4, 28.8, 
23.1; HRMS-ESI (m/z): [M+H]+ calcd for C32H31O14, 639.1714; found, 639.1705. 
 
 
Ortho-Bromide Tetrahydroxanthone 257: Chromone lactone 256 (20 mg, 0.05 mmol) 
and NaH (20.8 mg, 0.52 mmol, 10 equiv) were placed into a flask under a N2 atmosphere. 
0.5 mL of THF was next added to the flask which was warmed up to 60 oC and stirred for 
3 h. After cooling to room temperature, 2M HCl aqueous solution was used to quench the 
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reaction which was further extracted twice with 10 mL of EtOAc. The organic phase was 
combined, washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo. Purification by silica gel column chromatography (CH2Cl2/EtOAc = 20: 1) 
afforded tetrahydroxanthone 257 (8.9 mg, 44 %) as a white powder. 
257: Rf = 0.43 (CH2Cl2/EtOAc= 5:1); mp 203-205 °C (hexanes/CH2Cl2); IR (thin film): 
νmax 3455, 2954, 1737, 1612, 1584, 1436, 1354, 1278, 1219, 1061, 816 cm-1; 1H NMR 
(CDCl3, 500 MHz): δ 13.79 (s, 1H), 11.92 (s, 1H), 7.59 (d, J = 8.8 Hz, 1H), 6.52 (d, J = 
8.8 Hz, 1H), 4.32 (dd, J = 11.9, 3.3 Hz, 1H), 3.71 (s, 3H), 2.78 (s, 1H, OH chemical shift 
and coupling varies with concentration), 2.69 (m, 2H), 2.21 (m, 1H), 2.10 (m, 1H); 13C 
NMR (CDCl3, 125 MHz) : δ 186.5, 179.3, 169.8, 158.1, 158.0, 140.6, 109.3, 107.7, 102.6, 
101.1, 84.7, 71.8, 53.3, 27.7, 23.8; HRMS-ESI (m/z): [M+H]+ calcd for C15H14O7Br, 
384.9923; found, 384.9912. 
O
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Ortho-Bromide Tetrahydroxanthone 259 and para-Bromide Tetrahydroxanthone 
258: para-Chromone lactone 244 (20 mg, 0.05 mmol) and NaH (20.8 mg, 0.52 mmol, 10 
equiv) were placed into a flask under a N2 atmosphere. 0.5 mL of THF was next added to 
the flask which was warmed up to 60 oC and stirred for 3 h. After cooling to room 
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temperature, 2M HCl aqueous solution was used to quench the reaction which was 
further extracted twice with 10 mL of EtOAc. The organic phase was combined, washed 
with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by 
silica gel column chromatography (CH2Cl2/EtOAc = 20: 1) afforded tetrahydroxanthone 
258 (2.1 mg, 10 %) as a white solid and mixture of 259/257. The mixture was further 
separated by preparative TLC (benzene/EtOAc = 3:1) afforded ortho-bromide 
tetrahydroxanthone 259 (5.5 mg, 27 %) and para-bromide tetrahydroxanthone 257 (1.0 
mg, 5 %).  
258: Rf = 0.54 (CH2Cl2/EtOAc= 1:1); mp 156-158 °C (hexanes/CH2Cl2); IR (thin film): 
νmax 3531, 2954, 1739, 1617, 1582, 1465, 1353, 1284, 1221, 1065, 736 cm-1; 1H NMR 
(CDCl3, 500 MHz): δ 13.81 (s, 1H), 11.26 (s, 1H), 7.55 (d, J = 8.9 Hz, 1H), 6.49 (d, J = 
8.9 Hz, 1H), 4.38 (dd, J = 12.2, 4.5 Hz, 1H), 3.71 (s, 3H), 2.90 (br, 1H, OH chemical 
shift and coupling varies with concentration), 2.70 (m, 2H), 2.25 (m, 1H), 2.13 (m, 1H); 
13C NMR (CDCl3, 125 MHz) : δ 186.6, 179.2, 169.6, 161.4, 154.6, 140.6, 112.2, 110.0, 
108.0, 101.3, 99.8, 71.7, 53.4, 27.7, 23.6; HRMS-ESI (m/z): [M+H]+ calcd for 
C15H14O7Br, 384.9923; found, 384.9912. 
 
259: Rf = 0.54 (CH2Cl2/EtOAc= 5:1); IR (thin film): νmax 3438, 2957, 1738, 1614, 1583, 
1436, 1360, 1280, 1240, 1210, 1066, 2032, 996 cm-1; 1H NMR (CDCl3, 500 MHz): δ 
13.92 (s, 1H), 12.04 (s, 1H), 7.57 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 8.8 Hz, 1H), 4.34 (s, 
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1H), 3.70 (s, 3H), 2.85 (ddd, J = 18.7, 11.0, 6.6 Hz, 1H), 2.65 (br, 1H, OH chemical shift 
and coupling varies with concentration), 2.42 (dd, J = 19.4, 11.0, 6.9 Hz, 1H), 2.16 (m, 
1H), 1.98 (m, 1H); 13C NMR (CDCl3, 125 MHz) : δ 186.7, 180.8, 170.1, 158.0, 157.1, 
140.2, 109.2, 107.7, 103.1, 100.1, 84.2, 66.8, 53.5, 24.5, 23.0; HRMS-ESI (m/z): 
[M+H]+ calcd for C15H14O7Br, 384.9923; found, 384.9935. 
 
 
 
anti-Chloride 261: Tetrahydroxanthone 130 (49 mg, 0.16 mmol) and NCS (30 mg, 0.16 
mmol, 1.02 equiv) were added to a flask. Under a N2 atmosphere, 1.6 mL of CH2Cl2 was 
added. The flask was stirred at rt for 2h. The crude mixture was extracted with EtOAc 
40mL twice, washed with water and brine, dried over sodium sulfate. The organic phase 
was concentrated in vacuo and purified by silica gel chromatography (hexanes/EtOAc = 
1: 1) to afford the anti-chloride tetrahydroxanthone 261 (52 mg, 95 %) as a yellow solid. 
261: Rf = 0.38 (hexanes/EtOAc= 1:1); mp 198-199 °C (CH2Cl2); IR (thin film): νmax 3493, 
1749, 1628, 1650, 1581, 1337, 1221, 1052, 761 cm-1; 1H NMR (CDCl3, 500 MHz): δ 
11.23 (s, 1H), 7.78 (t, J = 8.3 Hz, 1H), 6.64 (d, J = 5.9, 0.7 Hz, 1H), 6.63 (d, J = 5.7, 0.7 
Hz, 1H), 4.92 (ddd, J = 11.9, 5.6, 2.7 Hz, 1H), 3.68 (s, 3H), 3.26 (ddd, J = 21.0, 13.6, 8.9 
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Hz, 1H), 2.75 (d, J = 2.9 Hz, 2H, OH), 2.60 (ddd, J = 16.2, 5.8, 1.6 Hz, 1H), 2.28 (dddd, 
J = 15.1, 7.3, 5.6, 1.7 Hz, 1H), 1.88 (dddd, J = 25.6, 12.1, 5.9, 1.6 Hz, 1H); 13C NMR 
(CDCl3, 125 MHz) : δ 192.3, 186.3, 167.5, 163.5, 157.2, 139.2, 111.8, 107.4, 105.9, 88.3, 
68.8, 59.2, 53.9, 34.0, 25.7; HRMS-ESI (m/z): [M+H]+ calcd for C15H14O7Cl, 341.0428; 
found, 341.0421. 
 
 
Tetrahydroxanthone para-iodide 262: Tetrahydoxanthone 130 (159 mg, 0.50 mmol) 
and NIS (112 mg, 0.50 mmol, 1 equiv) were placed in a flame-dried flask. Next, 4.5 mL 
CH2Cl2 and 0.5 mL TFA was added into the flask. The reaction was stirred at rt for 3 h. 
Then the solution was diluted with 150 mL EtOAc, and washed with 1M NaHCO3 
aqueous solution, followed by 2M aqueous HCl solution and brine, dried over Na2SO4. 
After filtration, the solution was concentrated in vacuo. 15 mL of CH2Cl2/MeOH (1:1) 
was added into the residue, then SiMe3CHN2 (1.24 mL 2M ether solution, 2.48 mmol, 5 
equiv) solution was added into the flask dropwise. The reaction was stirring at rt for 30 
min, and monitored by TLC. Then 10 mL 10% AcOH aqueous solution was added 
dropwise to quench the reaction. The mixture was further extract twice with 50 mL of 
EtOAc. The organic phase was combined, washed with brine, dried over sodium sulfate, 
filtered, and concentrated in vacuo. Purification by silica gel column chromatography 
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(hexanes/EtOAc = 1: 1) afforded para-iodide tetrahydroxanthone 262 (71 mg, 31 %) as a 
yellow oil and ortho-iodide tetrahydroxanthone 174 (73 mg, 32 %). 
262: Rf = 0.44 (hexanes/EtOAc = 1: 2); IR (thin film): νmax 3449, 2952, 1747, 1631, 1564, 
1458, 1343, 1276, 1217, 1067, 758 cm-1; 1H NMR (CDCl3, 400 MHz): δ 12.71 (s, 1H), 
7.67 (d, J = 8.8 Hz, 1H), 6.39 (d, J = 8.8 Hz, 1H), 4.34 (ddd, J = 12.7, 4.6, 1.9 Hz, 1H), 
3.96 (s, 3H), 3.68 (s, 3H), 2.91 (d, J = 2.1 Hz, 1H, OH, chemical shift and coupling varies 
with concentration), 2.83 (ddd, J = 18.9, 6.4, 1.6 Hz, 1H), 2.67 (ddd, J = 17.9, 10.8, 6.9 
Hz, 1H), 2.23 (dddd, J = 24.2, 10.9, 6.5, 2.3 Hz, 1H), 2.12 (dddd, J = 13.3, 6.6, 4.7, 1.6 
Hz, 1H); 13C NMR (CDCl3, 125 MHz) : δ 184.4, 170.2, 169.5, 163.4, 156.7, 145.1, 113.0, 
108.8, 104.9, 87.2, 71.6, 70.3, 56.4, 53.3, 24.9, 23.2; HRMS-ESI (m/z): [M+H]+ calcd 
for C16H16O7I, 446.9941; found, 446.9960. 
 
 
Para-Stannane Tetrahydroxanthone 264: para-Iodide tetrahydroxanthone 262 (70 mg, 
0.15 mmol), nBu4NI (29 mg, 0.08 mmol, 0.5 equiv), Pd2(dba)3 (14 mg, 0.015 mmol, 0.1 
equiv), PtBu3 (12.7 mg, 0.063 mmol, 0.4 equiv) and bis(tributyltin) (157 µL, 0.31 mmol, 
2.0 equiv) were added to a flame-dried flask. Under a N2 atmosphere, 1.6 mL of 
anhydrous dioxane was added. The flask was warmed to 50 oC and stirred for 4 h. After 
cooling to room temperature, the solvent was removed in vacuo. The crude mixture was 
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directly purified by silica gel chromatography (hexanes/EtOAc = 2: 1) to afford the 
tetrahydroxanthone stannane 264 (71 mg, 74 %) as a yellow oil. 
264: Rf = 0.77 (hexanes/EtOAc = 1: 2); IR (thin film): νmax 3458, 2954, 2924, 2852, 1741, 
1633, 1569, 1463, 1221, 1043, 823 cm-1; 1H NMR (CDCl3, 500 MHz): δ 12.67 (s, 1H), 
7.35 (d, J = 7.9 Hz, 1H), 6.52 (d, J = 7.9 Hz, 1H), 4.23 (d, J = 11.8 Hz, 1H), 3.93 (s, 3H), 
3.65 (s, 3H), 2.78 (dd, J = 18.5, 5.5 Hz, 1H), 2.64 (m, 1H), 2.63 (s, 1H, OH, chemical 
shift and coupling varies with concentration), 2.21 (m, 1H), 2.09 (m, 1H),  1.54 (m, 6H), 
1.33 (m, 6H), 1.10 (m, 6H), 0.89 (t, J = 7.1 Hz, 9H); 13C NMR (CDCl3, 125 MHz) : δ 
185.8, 170.0, 168.3, 163.7, 162.5, 144.7, 116.3, 111.0, 107.9, 105.5, 85.9, 71.8, 56.3, 29.1, 
27.4, 24.7, 24.0, 13.7, 9.9; HRMS-ESI (m/z): [M+H]+ calcd for C28H43O7Sn, 611.2037; 
found, 611.2054. 
 
 
4,4’-Linked Dimeric Tetrahydroxanthone 265 and 266: Freshly dried para-stannane 
264 (10 mg, 0.016 mmol), freshly prepared CuCl (8.1 mg, 0.083 mmol, 5 equiv) and 
anhydrous CuCl2 (2.2 mg, 0.016 mmol, 1 equiv) were placed in a flame-dried tube. 
Under N2 atmosphere, 0.2 mL of DMA was added into the tube and the reaction mixture 
was stirred at room temperature for 12 h. The mixture was quenched with 3 mL of 
saturated NH4Cl solution and was extracted 5 times with 5 mL of EtOAc After 
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concentrating the reaction mixture at 40 oC in vacuo, the crude product was directly 
purified by preparative TLC (developed by EtOAc multiple times) to afford the C2 
symmetric dimeric tetrahydroxanthone 265 (1.0 mg, 20 %) and Cs symmetric dimer 266 
(1.0 mg, 20 %) as a yellow gel.  
265 (C2 dimer): Rf = 0.11 (EtOAc); IR (thin film): νmax 3417, 2953, 1746, 1633, 1557, 
1469, 1348, 1227, 1067 cm-1; 1H NMR (CDCl3, 500 MHz): δ 12.73 (s, 2H), 7.55 (br, 2H, 
due to restricted rotation), 6.54 (d, J = 8.5 Hz, 2H), 4.16 (d, J = 10.7 Hz, 2H), 3.92 (s, 
6H), 3.73 (s, 6H), 2.79 (dd, J = 18.5, 5.5 Hz, 2H), 2.60 (ddd, J = 18.1, 11.2, 6.4 Hz, 2H), 
2.22 (ddd, J = 24.5, 12.6, 5.8 Hz, 2H), 2.06 (m, 2H); 13C NMR (CDCl3, 125 MHz) : δ 
185.5, 169.7, 168.5, 162.7, 156.1 (br), 140.2, 115.2 (br), 109.7, 108.5, 105.3, 86.9 (br), 
71.2, 56.4, 53.3, 24.9, 24.1; HRMS-ESI (m/z): [M+H]+ calcd for C32H30O14, 639.1714; 
found, 639.1709. 
266 (Cs dimer): Rf = 0.09 (EtOAc); IR (thin film): νmax 3450, 2927, 2854, 1748, 1634, 
1559, 1467, 1348, 1225 cm-1; 1H NMR (CDCl3, 500 MHz): δ 12.78 (s, 2H), 7.51 (br d, J 
= 9.0 Hz , 2H, due to restricted rotation), 6.57 (d, J = 8.6 Hz, 2H), 4.15 (dd, J = 13.9, 4.0 
Hz, 2H), 3.95 (s, 6H), 3.68 (s, 6H), 2.92 (br, OH, 2H), 2.79 (dd, J = 18.6, 6.2 Hz, 2H), 
2.63 (ddd, J = 18.0, 10.0, 6.7 Hz, 2H), 2.23 (m, 2H), 2.03 (m, 2H); HRMS-ESI (m/z): 
[M+H]+ calcd for C32H30O14, 639.1714; found, 639.1700. 
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Tetrahydroxanthone para-iodide 267: Blennolide B (2) (150 mg, 0.46 mmol) and NIS 
(103 mg, 0.46 mmol, 1 equiv) were placed in a flame-dried flask. Next, 4.0 mL CH2Cl2 
and 0.4 mL TFA was added into the flask. The reaction was stirred at rt for 3 h. Then the 
solution was diluted with 150 mL EtOAc, and washed with 1M NaHCO3 aqueous 
solution, followed by 2M aqueous HCl solution and brine, dried over Na2SO4. After 
filtration, the solution was concentrated in vacuo. 15 mL of CH2Cl2/MeOH (1:1) was 
added into the residue, then SiMe3CHN2 (1.15 mL 2M ether solution, 2.3 mmol, 5 equiv) 
solution was added into the flask dropwise. The reaction was stirring at rt for 30 min, and 
monitored by TLC. Then 10 mL 10% AcOH aqueous solution was added dropwise to 
quench the reaction. The mixture was further extract twice with 50 mL of EtOAc. The 
organic phase was combined, washed with brine, dried over sodium sulfate, filtered, and 
concentrated in vacuo. Purification by silica gel column chromatography (hexanes/EtOAc 
= 2: 1) afforded para-iodide tetrahydroxanthone 267 (70 mg, 32 %) as a yellow oil and 
ortho-iodide tetrahydroxanthone 189 (70 mg, 32 %). 
267: Rf = 0.29 (hexanes/EtOAc = 1: 2); IR (thin film): νmax 3464, 2954, 1751, 1633, 1567, 
1459, 1343, 1219, 1049, 820 cm-1; 1H NMR (CDCl3, 400 MHz): δ 12.69 (s, 1H), 7.67 (d, 
J = 8.8 Hz, 1H), 6.39 (d, J = 8.8 Hz, 1H), 3.97 (dd, J = 11.0, 1.6 Hz, 1H), 3.96 (s, 3H), 
3.67 (s, 3H), 2.87 (dd, J = 18.6, 5.9 Hz, 1H), 2.86 (s, 1H, OH, chemical shift and 
coupling varies with concentration), 2.45 (m, 1H), 2.25 (dd, J = 18.6, 10.5 Hz, 1H), 1.20 
(d, J = 6.5 Hz, 1H); 13C NMR (CDCl3, 125 MHz): δ 184.4, 169.6, 169.4, 163.5, 156.7, 
145.1, 113.0, 108.8, 105.1, 87.6, 76.5, 70.3, 56.4, 53.3, 33.6, 28.6, 17.7; HRMS-ESI 
(m/z): [M+H]+ calcd for C17H18O7I, 461.0097 ; found, 461.0112. 
255 
 
 
 
Para-Stannane Tetrahydroxanthone 268: para-Iodide tetrahydroxanthone 267 (90 mg, 
0.20 mmol), nBu4NI (36 mg, 0.10 mmol, 0.5 equiv), Pd2(dba)3 (19 mg, 0.02 mmol, 0.1 
equiv), PtBu3 (16.2 mg, 0.08 mmol, 0.4 equiv) and bis(tributyltin) (174 µL, 0.40 mmol, 
2.0 equiv) were added to a flame-dried flask. Under a N2 atmosphere, 2.0 mL of 
anhydrous dioxane was added. The flask was warmed to 50 oC and stirred for 4 h. After 
cooling to room temperature, the solvent was removed in vacuo. The crude mixture was 
directly purified by silica gel chromatography (hexanes/EtOAc = 3: 1) to afford the 
tetrahydroxanthone stannane 268 (81 mg, 66 %) as a yellow oil. 
268: Rf = 0.67 (hexanes/EtOAc = 1: 2); IR (thin film): νmax 3474, 2956, 2926, 2871, 2853, 
1737, 1634, 1569, 1464, 1343, 1220, 1071, 1048, 823 cm-1; 1H NMR (CDCl3, 400 MHz): 
δ 12.68 (s, 1H), 7.35 (d, J = 8.0 Hz, 1H), 6.51 (d, J = 8.0 Hz, 1H), 3.92 (s, 3H), 3.83 (d, J 
= 11.5 Hz, 1H), 3.63 (s, 3H), 2.82 (dd, J = 18.5, 5.5 Hz, 1H), 2.63 (br, 1H, OH, chemical 
shift and coupling varies with concentration), 2.39 (m, 1H), 2.23 (dd, J = 18.3, 10.6 Hz, 
1H),  1.56 (m, 6H), 1.34 (m, 6H), 1.17 (d, J = 5.1 Hz, 1H), 1.09 (m, 6H), 0.89 (t, J = 7.2 
Hz, 9H); 13C NMR (CDCl3, 125 MHz) : δ 185.7, 170.1, 167.6, 163.6, 162.5, 144.7, 116.3, 
110.9, 107.8, 105.7, 86.3, 76.7, 56.3, 52.9, 33.5, 29.1(0), 29.0(8), 27.4, 17.7, 13.7, 9.9; 
HRMS-ESI (m/z): [M+H]+ calcd for C29H45O7Sn, 625.2194; found, 625.2222. 
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4,4’-Linked Dimeric Tetrahydroxanthone 269 and 270: Freshly dried para-stannane 
268 (30 mg, 0.048 mmol), freshly prepared CuCl (23.8 mg, 0.24 mmol, 5 equiv) and 
anhydrous CuCl2 (6.5 mg, 0.048 mmol, 1 equiv) were placed in a flame-dried tube. 
Under N2 atmosphere, 0.5 mL of DMA was added into the tube and the reaction mixture 
was stirred at room temperature for 12 h. The mixture was quenched with 3 mL of 
saturated NH4Cl solution and was extracted 5 times with 5 mL of EtOAc After 
concentrating the reaction mixture at 40 oC in vacuo, the crude product was directly 
purified by preparative TLC (EtOAc) to afford the C2 symmetric dimeric 
tetrahydroxanthone 269 (3.3 mg, 21 %) and Cs symmetric dimer 270 (3.3 mg, 21 %) as a 
yellow solid.  
270 (Cs dimer): Rf = 0.27 (EtOAc); IR (thin film): νmax 3518, 2954, 1748, 1634, 1558, 
1468, 1346, 1221, 1047, 820, 732 cm-1; 1H NMR (CDCl3, 500 MHz): δ 12.76 (s, 2H), 
7.53 (d, J = 8.2 Hz, 2H), 6.55 (d, J = 8.6 Hz, 2H), 3.95 (s, 6H), 3.75 (d, J = 11.8 Hz, 2H), 
3.66 (s, 6H), 2.83 (dd, J = 18.4, 5.8 Hz, 2H), 2.74 (br, 2H, OH, chemical shift and 
coupling varies with concentration), 2.43 (m, 2H), 2.21 (dd, J = 18.6, 10.7 Hz, 2H),  1.12 
(d, J = 6.3 Hz, 1H); 13C NMR (CDCl3, 125 MHz) : δ 185.3, 169.9, 168.2, 162.6, 155.5, 
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139.7, 115.4, 109.9, 108.3, 105.7, 86.9, 76.4, 56.3, 53.1, 33.6, 28.7, 17.8; HRMS-ESI 
(m/z): [M+H]+ calcd for C34H35O14, 667.2027; found, 667.2035. 
 
 
269 (C2 dimer): Rf = 0.45 (EtOAc); 1H NMR (CDCl3, 500 MHz): δ 12.72 (s, 2H), 7.66 
(br, 2H, due to restricted rotation), 6.54 (d, J = 8.6 Hz, 2H), 3.92 (s, 6H), 3.77 (d, J = 11.8 
Hz, 2H), 3.73 (s, 6H), 2.80 (dd, J = 18.5, 5.5 Hz, 2H), 2.41 (m, 2H), 2.19 (dd, J = 18.5, 
10.7 Hz, 2H),  1.12 (d, J = 6.4 Hz, 1H); HRMS-ESI (m/z): [M+H]+ calcd for C34H35O14, 
667.2027; found, 667.2017. 
 
 
 
 
Chiral, Non-Racemic Tetrahydroxanthones (+)-272 and (-)-130: (±)-
Tetrahydroxanthone 130 (1 g, 3.26 mmol) and 100 mL of CDCl3 were added to a flame-
dried flask. The solution was gently warmed at 40 oC for 5 min until the substrate was 
fully dissolved. The solution was cooled to -5 oC. To a flame-dried tube was added R-
HBTM 184 (87 mg, 0.33 mmol, 0.1 equiv), and (EtCO)2O (255 mg, 251 µL, 1.96 mmol, 
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0.6 equiv) with 2 mL of CDCl3 and the contents were mixed for 3 min. The latter solution 
was transferred dropwise to a solution of 130. After stirring at -5 oC for 12 h, the reaction 
was quenched by 0.2 mL of MeOH, and was warmed to room temperature. After 
concentrating in vacuo, the crude reaction product was subjected to 1H NMR analysis to 
monitor conversion (δ 4.31, 5-H for (-)-130; δ 5.49 5-H for (+)-272). The crude product 
was purified by silica gel chromatography (CH2Cl2/EtOAc = 30: 1 to 10: 1) to afford 
product (+)-272 (575 mg, 49 %) as a pale yellow solid and (-)-130 (466 mg, 48 %) as a 
pale yellow solid. 
(+)-272: Rf = 0.65 (CH2Cl2); mp 149-151 °C (CH2Cl2); IR (thin film): νmax 2953, 1737, 
1612, 1583, 1464, 1357, 1217, 1170, 1076, 1038, 814, 733 cm-1; 1H NMR (CDCl3, 400 
MHz): δ 13.99 (s, 1H), 11.16 (s, 1H), 7.35 (d, J = 8.3 Hz, 1H), 6.51 (dd, J = 8.3, 0.9 Hz, 
1H), 6.49 (dd, J = 8.3, 0.9 Hz, 1H), 5.49 (dd, J = 12.4, 5.2 Hz, 1H), 3.71 (s, 3H), 2.76 
(ddd, J = 19.4, 11.1, 7.0 Hz, 1H), 2.65 (ddd, J = 19.4, 7.0, 1.6 Hz, 1H), 2.43 (q, J = 7.6 
Hz, 1H), 2.39 (q, J = 7.6 Hz, 1H), 2.30 (m, 2H), 2.11 (dddd, J = 13.6, 6.9, 5.3, 1.7 Hz, 
1H), 1.19 (t, J = 7.6 Hz, 1H); 13C NMR (CDCl3, 100 MHz) : δ 187.0, 177.7, 173.2, 169.9, 
161.9, 159.0, 138.0, 110.4, 108.1, 106.9, 101.6, 82.1, 72.0, 53.1, 27.7, 27.4, 22.5, 9.0; 
HRMS-ESI (m/z): [M+H]+ calcd for C18H19O8, 363.1080; found, 363.1094; [α]D26= 124.2 
° (c= 1.0, CHCl3).  
Enantiomers were separated using a 0.2% hexanes/IPA Chiralcel®OD (Chiral 
Technologies Inc., 250 × 4.6 mm I.D.) column. The enantiomeric excess for (+)-272 after 
kinetic resolution was 98 %. 
(±)-272: 
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98 % ee (+)-272: 
 
(-)-130: 1H NMR, 13C NMR, IR, and HRMS for (-)-130 were identical to data reported 
for (±)-130. Enantiomers were separated by 5% hexanes/IPA Chiralcel®OD (Chiral 
Technologies Inc., 250 × 4.6 mm I.D.) column. The enantiomeric excess for (-)-130 after 
kinetic resolution was 97 %. mp 148-151 °C (CH2Cl2); [α]D24= -133.5 ° (c= 1.0, CH2Cl2).  
(±)-130: 
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97 % ee (-)-130: 
 
 
 
Chiral, Non-Racemic Tetrahydroxanthones (+)-273 and (-)-2: (±)-Blennolide B 2 
(300 mg, 0.94 mmol) and 15 mL of CDCl3 were added to a flame-dried flask. The 
solution was gently warmed at 40 oC for 5 min until the substrate was fully dissolved. 
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The solution was cooled to -5 oC. To a flame-dried tube was added R-HBTM 184 (25 mg, 
0.094 mmol, 0.1 equiv), and acetic anhydride (53.02 µL, 0.56 mmol, 0.6 equiv) with 2 
mL of CDCl3 and the contents were mixed for 3 min. The latter solution was transferred 
dropwise to a solution of 2. After stirring at -5 oC for 12 h, the reaction was quenched by 
0.2 mL of MeOH, and was warmed to room temperature. After concentrating in vacuo, 
the crude reaction product was subjected to 1H NMR analysis to monitor conversion. The 
crude product was purified by silica gel chromatography (CH2Cl2/EtOAc = 30: 1 to 10: 
1) to afford product (+)-273 (159 mg, 47 %) as a pale yellow solid and (-)-2 (139 mg, 46 
%) as a pale yellow solid.  
(+)-273: Rf = 0.63 (CH2Cl2); mp 88-89 °C (CH2Cl2); IR (thin film): νmax 2954, 1750, 
1616, 1584, 1464, 1371, 1211, 1042, 751 cm-1; 1H NMR (CDCl3, 400 MHz): δ 13.81 (s, 
1H), 11.14 (s, 1H), 7.33 (t, J = 8.3 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.48 (d, J = 8.3 Hz, 
1H), 5.38 (d, J = 11.7 Hz, 1H), 3.69 (s, 3H), 2.74 (dd, J = 18.9, 6.2 Hz, 1H), 2.61 (m, 
1H), 2.40 (dd, J = 18.8, 10.7 Hz, 1H), 2.16 (s, 3H), 1.01 (t, J = 6.5 Hz, 1H); 13C NMR 
(CDCl3, 100 MHz) : δ 186.9, 176.8, 170.0, 169.0, 161.8, 158.9, 138.1, 110.3, 108.2, 
106.8, 101.7, 82.9, 76.0, 53.1, 36.0, 28.6, 20.8, 17.3; HRMS ESI (m/z): [M+H]+ calcd for 
C18H19O8, 363.1080; found, 363.1075; [α]D28= 174.3 ° (c= 1.0, CH2Cl2).  
After treated with 3M aqueous HCl/MeOH 60 °C for 8 h, 273 was hydrolyzed to 2. Then 
enantiomers were separated using a 1% hexanes/IPA Chiralcel®OD (Chiral Technologies 
Inc., 250 × 4.6 mm I.D.) column. The enantiomeric excess for (+)-273 after kinetic 
resolution was 96 %. 
(±)-2: 
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(+)-2 from (+)-273 
 
(-)-2: 1H NMR, 13C NMR, IR, and HRMS for (-)-2 were identical to data reported for 
(±)-2. Enantiomers were separated by 1% hexanes/IPA Chiralcel®OD (Chiral 
Technologies Inc., 250 × 4.6 mm I.D.) column. The enantiomeric excess for (-)-2 after 
kinetic resolution was 96 %. mp 188-189 °C (MeCN); [α]D27= -143.3 ° (c= 1.0, CH2Cl2).  
(-)-2: 
 
263 
 
1.0 equiv NIS
TFA/CH2Cl2, rt, 2 h I
ortho: para 1:1
SiMe3CHN2
31 %(-)-130 (-)-262
O
OH O OH
MeO2C OH
O
OH O OH
MeO2C OH
O
OH O OMe
MeO2C OHI
 
para-iodide (-)-262: (-)-262 was prepared following the previous described procedure 
from (-)-130. 1H NMR, 13C NMR, IR, and HRMS for (-)-262 were identical to data 
reported for (±)-262. [α]D27= -20.2 ° (c= 1.0, CH2Cl2).  
 
 
Para-Stannane Tetrahydroxanthone (-)-264: (-)-264 was prepared following the 
previous described procedure from (-)-262. 1H NMR, 13C NMR, IR, and HRMS for (-)-
264 were identical to data reported for (±)-264. [α]D27= -35.6 ° (c= 1.0, CH2Cl2).  
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4,4’-Linked Dimeric Tetrahydroxanthone (-)-265: (-)-265 was prepared following the 
previous described procedure from (-)-264. 1H NMR, 13C NMR, IR, and HRMS for (-)-
265 were identical to data reported for (±)-265. [α]D28= -22.3 ° (c= 0.5, CH2Cl2).  
 
 
Tetrahydroxanthone para-iodide (-)-267: (-)-267 was prepared following the previous 
described procedure from (-)-2. 1H NMR, 13C NMR, IR, and HRMS for (-)-267 were 
identical to data reported for (±)-267. [α]D28= -34.2 ° (c= 1.0, CH2Cl2).  
 
 
Para-Stannane Tetrahydroxanthone (-)-268: (-)-268 was prepared following the 
previous described procedure from (-)-267. 1H NMR, 13C NMR, IR, and HRMS for (-)-
268 were identical to data reported for (±)-268. [α]D29= -84.6 ° (c= 1.0, CH2Cl2).  
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4,4’-Linked Dimeric Tetrahydroxanthone (-)-269: (-)-269 was prepared following the 
previous described procedure from (-)-268. 1H NMR, 13C NMR, IR, and HRMS for (-)-
269 were identical to data reported for (±)-269.  
 
5.8 X-ray Crystallographic Data 
X-ray crystallographic data for compound 261: 
 
 
Crystals of compound 261 suitable for X-ray analysis were obtained by slow evaporation 
from hexanes/IPA.  
 
Crystal data 
 C15H13ClO7 V = 1406.7 (5)  Å3 
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Mr = 340.70 Z = 4 
?, ? F(000) = 704 
a = 8.963 (2) Å Dx = 1.609 Mg m-3 
b = 11.510 (3) Å Cu Ka radiation, l = 1.54178 Å 
c = 14.197 (3) Å m = 2.77 mm-1 
a = 90° T = 100 K 
b = 106.158 (8)° 0.13 × 0.08 × 0.04 mm 
g = 90°  
 
    
Data collection 
  Radiation source: fine-focus sealed tube Rint = 0.039 
graphite qmax = 66.3°, qmin = 5.0° 
22074 measured reflections h = -10®9 
2457 independent reflections k = -13®13 
2360 reflections with I > 2s(I) l = -16®16 
 
    
Refinement 
  Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference Fourier 
map 
R[F2 > 2s(F2)] = 0.031 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.086 H atoms treated by a mixture of independent 
and constrained refinement 
S = 1.07 w = 1/[s2(Fo2) + (0.0493P)2 + 0.8417P]   
where P = (Fo2 + 2Fc2)/3 
2457 reflections (D/s)max = 0.001 
211 parameters Dñmax = 0.34 e Å-3 
0 restraints Dñmin = -0.22 e Å-3 
 
     
Special details 
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 Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)   
are estimated using the full covariance matrix.  The cell esds are taken   into account 
individually in the estimation of esds in distances, angles   and torsion angles; 
correlations between esds in cell parameters are only   used when they are defined by 
crystal symmetry.  An approximate (isotropic)   treatment of cell esds is used for 
estimating esds involving l.s. planes. 
 
Refinement. Refinement of F2 against ALL reflections.  The weighted R-factor wR 
and   goodness of fit S are based on F2, conventional R-factors R are based   on F, with F 
set to zero for negative F2. The threshold expression of   F2 > 2sigma(F2) is used only for 
calculating R-factors(gt) etc. and is   not relevant to the choice of reflections for 
refinement.  R-factors based   on F2 are statistically about twice as large as those based on 
F, and R-   factors based on ALL data will be even larger. 
 
 
      
Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
 x y z Uiso*/Ueq  
Cl1 0.47072 (4) 0.61900 (3) 0.09853 (3) 0.01866 (13)  
O1 0.25764 (13) 0.97262 (10) 0.08588 (9) 0.0239 (3)  
O2 0.25504 (12) 0.70570 (9) 0.20756 (7) 0.0170 (2)  
O3 -0.08412 (13) 0.66442 (10) -0.12145 (8) 0.0231 (3)  
H3 -0.0046 0.6883 -0.1358 0.035*  
O4 0.47549 (14) 0.85928 (11) -0.03887 (8) 0.0250 (3)  
268 
O5 0.43981 (14) 0.86911 (10) 0.33781 (8) 0.0238 (3)  
H5 0.3892 0.8185 0.3585 0.036*  
O6 0.12353 (14) 0.92048 (10) 0.19196 (9) 0.0257 (3)  
O7 0.20251 (13) 0.73474 (10) -0.08818 (8) 0.0232 (3)  
C1 0.1800 (2) 1.08500 (16) 0.07247 (17) 0.0369 (5)  
H1A 0.0673 1.0734 0.0541 0.055*  
H1B 0.2084 1.1281 0.0204 0.055*  
H1C 0.2122 1.1292 0.1338 0.055*  
C2 0.22275 (18) 0.90293 (14) 0.15200 (11) 0.0173 (3)  
C3 0.33235 (17) 0.79637 (13) 0.17190 (10) 0.0158 (3)  
C4 0.11901 (18) 0.66978 (13) 0.14227 (11) 0.0170 (3)  
C5 0.01084 (19) 0.61504 (13) 0.17978 (12) 0.0208 (4)  
H5A 0.0319 0.6007 0.2481 0.025*  
C6 -0.12977 (19) 0.58144 (14) 0.11503 (13) 0.0235 (4)  
H6 -0.2047 0.5434 0.1402 0.028*  
C7 -0.16399 (19) 0.60174 (14) 0.01487 (13) 0.0223 (4)  
H7 -0.2631 0.5820 -0.0272 0.027*  
C8 -0.05171 (19) 0.65128 (14) -0.02307 (12) 0.0192 (3)  
C9 0.09308 (18) 0.68727 (13) 0.04038 (11) 0.0170 (3)  
C10 0.21662 (18) 0.72869 (13) 0.00033 (11) 0.0167 (3)  
C11 0.37030 (17) 0.75733 (13) 0.07694 (11) 0.0160 (3)  
C12 0.47976 (18) 0.82584 (14) 0.25500 (11) 0.0180 (3)  
H12 0.5429 0.7536 0.2741 0.022*  
C13 0.57776 (18) 0.91680 (14) 0.22188 (11) 0.0194 (3)  
H13A 0.6738 0.9308 0.2754 0.023*  
H13B 0.5192 0.9907 0.2088 0.023*  
C14 0.62173 (19) 0.87985 (14) 0.12937 (12) 0.0209 (4)  
H14A 0.6718 0.9464 0.1061 0.025*  
H14B 0.6993 0.8165 0.1469 0.025*  
C15 0.48667 (18) 0.83871 (13) 0.04595 (11) 0.0175 (3)  
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REFERENCES 
· Professor John A. Porco, Jr. 
Department of Chemistry, Boston University. Tel: 617-353-2493. Fax: 617-358-2847 
E-mail: porco@bu.edu 
· Professor James S. Panek 
Department of Chemistry, Boston University. Tel: 617-353-2484. Fax: 617-353-6466 
E-mail: panek@bu.edu 
· Professor Corey R. J. Stephenson 
Department of Chemistry, University of Michigan.  
E-mail: crjsteph@umich.edu 
 
 
 
 
 
